
    
<!DOCTYPE html>




<html lang="en" >
<head >
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">

    <!-- Mobile properties -->
    <meta name="HandheldFriendly" content="True">
    <meta name="MobileOptimized" content="320">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">

  
    <!-- Stylesheets -->
    <link rel="stylesheet" href="/pmc/static/CACHE/css/output.cc84172e9e16.css" type="text/css">
  
  <link rel="stylesheet" href="/pmc/static/CACHE/css/output.b634933a977d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.913c7dcab8ff.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.3766d7ad0d2d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.e3c3c2c84eb3.css" type="text/css">

  
    <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/font-awesome/4.7.0/css/font-awesome.min.css"/>
  
<link type="text/css" href="/pmc/static/bundles/base/base.a2ef7ca69e4b20dff539.css" rel="stylesheet" />


    <link rel="stylesheet" href="/corehtml/pmc/css/fonts/stix/stixfonts.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/3.18/pmcrefs1.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/pmc2020_1.1/ncbi_web.min.css?_=a" type="text/css" /><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-manuscript.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style>

    <link type="text/css" href="/pmc/static/bundles/article/article.3c5d12ff2e4beea20136.css" rel="stylesheet" />
    <link type="text/css" href="/pmc/static/django_pmc_cite_box/lib/cite-box.css" rel="stylesheet" />


    <title>Integrated Molecular Analysis of Tamoxifen-Resistant Invasive Lobular Breast Cancer Cells Identifies MAPK and GRM/mGluR Signaling as Therapeutic Vulnerabilities - PMC</title>

  
  <!-- Favicons -->
  <link rel="shortcut icon" type="image/ico" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.ico" />
  <link rel="icon" type="image/png" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.png" />

  <!-- 192x192, as recommended for Android
  http://updates.html5rocks.com/2014/11/Support-for-theme-color-in-Chrome-39-for-Android
  -->
  <link rel="icon" type="image/png" sizes="192x192" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-192.png" />

  <!-- 57x57 (precomposed) for iPhone 3GS, pre-2011 iPod Touch and older Android devices -->
  <link rel="apple-touch-icon-precomposed" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-57.png">
  <!-- 72x72 (precomposed) for 1st generation iPad, iPad 2 and iPad mini -->
  <link rel="apple-touch-icon-precomposed" sizes="72x72" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-72.png">
  <!-- 114x114 (precomposed) for iPhone 4, 4S, 5 and post-2011 iPod Touch -->
  <link rel="apple-touch-icon-precomposed" sizes="114x114" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-114.png">
  <!-- 144x144 (precomposed) for iPad 3rd and 4th generation -->
  <link rel="apple-touch-icon-precomposed" sizes="144x144" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-144.png">



    
        <!-- Logging params: Pinger defaults -->

<meta name="ncbi_app" content="pmc-frontend" />

<meta name="ncbi_db" content="pmc" />

<meta name="ncbi_phid" content="939BE807DB0F4BC50000277110018218.1.m_2" />


        <!-- Logging params: Pinger custom -->

<meta name="ncbi_pdid" content="article" />

<meta name="ncbi_op" content="retrieved" />

<meta name="ncbi_app_version" content="0.0" />

<meta name="ncbi_domain" content="nihpa" />

<meta name="ncbi_type" content="fulltext" />

<meta name="ncbi_pcid" content="/articles/PMC5858970/" />


    


    <script>
        
            var ncbiBaseUrl = "https://www.ncbi.nlm.nih.gov";
        
        var useOfficialGovtHeader = true;
    </script>


    <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5858970/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="citation_journal_title" content="Molecular and cellular endocrinology" /><meta name="citation_title" content="Integrated Molecular Analysis of Tamoxifen-Resistant Invasive Lobular Breast Cancer Cells Identifies MAPK and GRM/mGluR Signaling as Therapeutic Vulnerabilities" /><meta name="citation_author" content="Hillary Stires" /><meta name="citation_author_institution" content="Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA" /><meta name="citation_author" content="Mary M. Heckler" /><meta name="citation_author_institution" content="Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA" /><meta name="citation_author" content="Xiaoyong Fu" /><meta name="citation_author_institution" content="Lester and Sue Smith Breast Center, Dan L. Duncan Cancer Center, and Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA" /><meta name="citation_author" content="Li Zhao" /><meta name="citation_author_institution" content="Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA" /><meta name="citation_author" content="Catherine S. Grasso" /><meta name="citation_author_institution" content="University of California Los Angeles (UCLA), Los Angeles, CA, USA" /><meta name="citation_author" content="Michael J. Quist" /><meta name="citation_author_institution" content="Fred Hutchinson Cancer Research Center, Seattle, WA, USA" /><meta name="citation_author" content="Joseph A. Lewis" /><meta name="citation_author_institution" content="Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA" /><meta name="citation_author" content="Uwe Klimach" /><meta name="citation_author_institution" content="Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA" /><meta name="citation_author" content="Alan Zwart" /><meta name="citation_author_institution" content="Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA" /><meta name="citation_author" content="Akanksha Mahajan" /><meta name="citation_author_institution" content="Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA" /><meta name="citation_author" content="Bal&#x000e1;zs Gy&#x00151;rffy" /><meta name="citation_author_institution" content="MTA TTK Lend&#x000fc;let Cancer Biomarker Research Group, and 2nd Department of Pediatrics, Semmelweis University, Budapest, Hungary" /><meta name="citation_author" content="Luciane R. Cavalli" /><meta name="citation_author_institution" content="Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA" /><meta name="citation_author" content="Rebecca B. Riggins" /><meta name="citation_author_institution" content="Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA" /><meta name="citation_publication_date" content="2018/08/08" /><meta name="citation_volume" content="471" /><meta name="citation_firstpage" content="105" /><meta name="citation_doi" content="10.1016/j.mce.2017.09.024" /><meta name="citation_abstract_html_url" content="/pmc/articles/PMC5858970/?report=abstract" /><meta name="citation_fulltext_html_url" content="/pmc/articles/PMC5858970/" /><meta name="citation_pmid" content="28935545" /><meta name="DC.Title" content="Integrated Molecular Analysis of Tamoxifen-Resistant Invasive Lobular Breast Cancer Cells Identifies MAPK and GRM/mGluR Signaling as Therapeutic Vulnerabilities" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="NIH Public Access" /><meta name="DC.Contributor" content="Hillary Stires" /><meta name="DC.Contributor" content="Mary M. Heckler" /><meta name="DC.Contributor" content="Xiaoyong Fu" /><meta name="DC.Contributor" content="Li Zhao" /><meta name="DC.Contributor" content="Catherine S. Grasso" /><meta name="DC.Contributor" content="Michael J. Quist" /><meta name="DC.Contributor" content="Joseph A. Lewis" /><meta name="DC.Contributor" content="Uwe Klimach" /><meta name="DC.Contributor" content="Alan Zwart" /><meta name="DC.Contributor" content="Akanksha Mahajan" /><meta name="DC.Contributor" content="Bal&#x000e1;zs Gy&#x00151;rffy" /><meta name="DC.Contributor" content="Luciane R. Cavalli" /><meta name="DC.Contributor" content="Rebecca B. Riggins" /><meta name="DC.Date" content="2018 Aug 15" /><meta name="DC.Identifier" content="10.1016/j.mce.2017.09.024" /><meta name="DC.Language" content="en" /><meta property="og:title" content="Integrated Molecular Analysis of Tamoxifen-Resistant Invasive Lobular Breast Cancer Cells Identifies MAPK and GRM/mGluR Signaling as Therapeutic Vulnerabilities" /><meta property="og:type" content="article" /><meta property="og:description" content="Invasive lobular breast cancer (ILC) is an understudied malignancy with distinct clinical, pathological, and molecular features that distinguish it from the more common invasive ductal carcinoma (IDC). Mounting evidence suggests that estrogen receptor-alpha ..." /><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5858970/" /><meta property="og:site_name" content="PubMed Central (PMC)" /><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-card-share.jpg?_=0" /><meta name="twitter:card" content="summary_large_image" /><meta name="twitter:site" content="@ncbi" /><meta name="ncbi_feature" content="associated_data" />


</head>
<body >

   
    
        <button
          class="back-to-top back-to-top--bottom"
          data-ga-category="pagination"
          data-ga-action="back_to_top">
          Back to Top
        </button>
    

    <a class="usa-skipnav" href="#main-content">Skip to main content</a>
    <!-- ========== BEGIN HEADER ========== -->
<section class="usa-banner" style="display: none;">
  <div class="usa-accordion">
    <header class="usa-banner-header">
      <div class="usa-grid usa-banner-inner">
        <img src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png" alt="U.S. flag" />
        <p>An official website of the United States government</p>
        <button
          class="usa-accordion-button usa-banner-button"
          aria-expanded="false"
          aria-controls="gov-banner-top"
        >
          <span class="usa-banner-button-text">Here's how you know</span>
        </button>
      </div>
    </header>
    <div
      class="usa-banner-content usa-grid usa-accordion-content"
      id="gov-banner-top"
    >
      <div class="usa-banner-guidance-gov usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg"
          alt="Dot gov"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The .gov means it’s official.</strong>
            <br />
            Federal government websites often end in .gov or .mil. Before
            sharing sensitive information, make sure you’re on a federal
            government site.
          </p>
        </div>
      </div>
      <div class="usa-banner-guidance-ssl usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg"
          alt="Https"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The site is secure.</strong>
            <br />
            The <strong>https://</strong> ensures that you are connecting to the
            official website and that any information you provide is encrypted
            and transmitted securely.
          </p>
        </div>
      </div>
    </div>
  </div>
</section>
<div class="usa-overlay"></div>
<header class="ncbi-header" role="banner" data-section="Header">

	<div class="usa-grid">
		<div class="usa-width-one-whole">

            <div class="ncbi-header__logo">
                <a href="https://www.ncbi.nlm.nih.gov/" class="logo" aria-label="NCBI Logo" data-ga-action="click_image" data-ga-label="NIH NLM Logo">
                  <img src="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg" alt="NIH NLM Logo" />
                </a>
            </div>

			<div class="ncbi-header__account">
				<a id="account_login" href="https://account.ncbi.nlm.nih.gov" class="usa-button header-button" style="display:none" data-ga-action="open_menu" data-ga-label="account_menu">Log in</a>
				<button id="account_info" class="header-button" style="display:none"
						aria-controls="account_popup">
					<span class="fa fa-user" aria-hidden="true"></span>
					<span class="username desktop-only" aria-hidden="true" id="uname_short"></span>
					<span class="sr-only">Show account info</span>
				</button>
			</div>

			<div class="ncbi-popup-anchor">
				<div class="ncbi-popup account-popup" id="account_popup" aria-hidden="true">
					<div class="ncbi-popup-head">
						<button class="ncbi-close-button" data-ga-action="close_menu" data-ga-label="account_menu"><span class="fa fa-times"></span><span class="usa-sr-only">Close</span></button>
						<h4>Account</h4>
					</div>
					<div class="account-user-info">
						Logged in as:<br/>
						<b><span class="username" id="uname_long">username</span></b>
					</div>
					<div class="account-links">
						<ul class="usa-unstyled-list">
							<li><a id="account_myncbi" href="/myncbi/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_myncbi">Dashboard</a></li>
							<li><a id="account_pubs" href="/myncbi/collections/bibliography/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_pubs">Publications</a></li>
							<li><a id="account_settings" href="/account/settings/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_settings">Account settings</a></li>
							<li><a id="account_logout" href="/account/signout/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_logout">Log out</a></li>
						</ul>
					</div>
				</div>
			</div>

		</div>
	</div>
</header>
<div role="navigation" aria-label="access keys">
<a id="nws_header_accesskey_0" href="https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys" class="usa-sr-only" accesskey="0" tabindex="-1">Access keys</a>
<a id="nws_header_accesskey_1" href="https://www.ncbi.nlm.nih.gov" class="usa-sr-only" accesskey="1" tabindex="-1">NCBI Homepage</a>
<a id="nws_header_accesskey_2" href="/myncbi/" class="set-base-url usa-sr-only" accesskey="2" tabindex="-1">MyNCBI Homepage</a>
<a id="nws_header_accesskey_3" href="#maincontent" class="usa-sr-only" accesskey="3" tabindex="-1">Main Content</a>
<a id="nws_header_accesskey_4" href="#" class="usa-sr-only" accesskey="4" tabindex="-1">Main Navigation</a>
</div>
<section data-section="Alerts">
	<div class="ncbi-alerts-placeholder"></div>
</section>
<!-- ========== END HEADER ========== -->

    
    


    
        

<section class="pmc-alerts">
    
    <div role="alert" class="pmc-alert pmc-alert--info" role="region" aria-label="Alert" aria-hidden="false"  data-key="pmc-alert-welcome">
        <div class="pmc-alert__body pmc-alert--ncbi-icon">
            <div class="pmc-alert__content">
                <p>
                    <strong>
                        Preview improvements coming to the PMC website in October 2024.
                        <a href="https://ncbiinsights.ncbi.nlm.nih.gov/2024/03/14/preview-pmc-improvements/" data-ga-category="cloud_beta_banner" data-ga-label="learn_more" data-ga-action="on_pmc2020">Learn More</a> or
                        <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5858970/" data-ga-category="cloud_beta_banner" data-ga-action="on_pmc2020" data-ga-label="go_to_cloud">Try it out now</a>.
                    </strong>
                </p>
            </div>
        </div>
    </div>
    
</section>
    

    
    
        
        <header class="pmc-header usa-header-extended" role="banner">
    <div class="pmc-header__bar">
        <div class="pmc-header__control usa-accordion">
            
                <button class="usa-menu-btn pmc-header--button pmc-header--left">
                    <i class="fa fa-ellipsis-v" aria-hidden="true"></i>
                </button>
            

            <div class="usa-logo pmc-header__logo pmc-header--stretch
                
               " id="extended-mega-logo">
                <div class="usa-logo-text">
                    <a href="/pmc/" title="Home" aria-label="Home" ></a>
                </div>
            </div>
            <button class="usa-accordion-button pmc-header--right pmc-header--button pmc-header__search--control pmc-header--right" aria-expanded="false" aria-controls="a1">
                <i class="fa fa-search" aria-hidden="true"></i>
                <i class="fa fa-times" aria-hidden="true"></i>
            </button>
        </div>
        <div class="pmc-header__search usa-accordion-content" id="a1">
            <div role="search"  class="pmc-header--stretch"  >
    <form class="usa-search " autocomplete="off">
        <div>
              <label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
              <span class="clearable">
                <input
                  required="required"
                  autocomplete-url="/pmc/autocomplete/pmc/"
                  placeholder="Search PMC Full-Text Archive"
                  id="pmc-search" type="search" name="term"/>
                  <i class="clear-btn" ></i>
              </span>
              <button type="submit" formaction="/pmc/">
                <span class="usa-search-submit-text">Search in PMC</span>
              </button>
        </div>
    </form>
</div>


            <ul class="usa-unstyled-list usa-nav-secondary-links pmc-header--offset-two">
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/advanced" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        <a  href="/pmc/about/userguide/" data-ga-action="featured_link"
                        data-ga-label="user guide">
                            User Guide
                        </a>
                    </li>
            </ul>
        </div>
    </div>
     <nav role="navigation" class="usa-nav ">
        <button class="usa-nav-close">
            <i class="fa fa-times" aria-hidden="true"></i>
        </button>
        <div class="usa-breadcrumb usa-breadcrumb--wrap usa-breadcrumb--hack">
             
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/?term=hhs%20author%20manuscript[filter]" class="navlink">HHS Author Manuscripts</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC5858970
                </li>
            
    </ul>
 

        </div>
        
        
            <div class="pmc-sidebar pmc-sidebar-hack">
                

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pdf-link other_item"><a href="/pmc/articles/PMC5858970/pdf/nihms909796.pdf" class="int-view">PDF (1.5M)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/5858970/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/5858970/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<link type="text/css" href="ncbi-overlay-block/src/overlay-block.css">
<div class="collections-button-container" data-article-id="5858970" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5858970%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="yUtKyB8j6JGOdXlc9jYzZlM9d3SslBfbGWNEKN3ApvpR2WAedMjtCse0fmEBQblj">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-header "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-header ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-header "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-header ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5858970%2F&amp;text=Integrated%20Molecular%20Analysis%20of%20Tamoxifen-Resistant%20Invasive%20Lobular%20Breast%20Cancer%20Cells%20Identifies%20MAPK%20and%20GRM%2FmGluR%20..." alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5858970%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5858970/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC5858970/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/28935545/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-header" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC5858970/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/28935545/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-header"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC5858970/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/5858970/" class="usa-accordion-content" id="links-accordion-header" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>
            </div>
        

    </nav>

</header>

    
    

    <div class="usa-overlay"></div>
    
<main id="main-content" class="usa-grid usa-layout-docs pmc-main">
    <article class="usa-width-three-fourths usa-layout-docs-main_content pmc-article">
        <section class="usa-breadcrumb usa-breadcrumb--wrap">
         
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/?term=hhs%20author%20manuscript[filter]" class="navlink">HHS Author Manuscripts</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC5858970
                </li>
            
    </ul>
 

        </section>
        
  <div class="pmc-article__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/pmc/about/disclaimer/">PMC Disclaimer</a>
    |
    <a data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/pmc/about/copyright/">
        PMC Copyright Notice
    </a>
</div>

        <section class="pmc-page-banner" role="banner">
            
                
                    <div><img src="/corehtml/pmc/pmcgifs/logo-nihpa.png" alt="Logo of nihpa" usemap="#logo-imagemap" /><map id="logo-imagemap" name="logo-imagemap"><area alt="Link to Publisher's site" title="Link to Publisher's site" shape="default" coords="0,0,499,74" href="https://www.hhs.gov/open/public-access-guiding-principles/index.html" target="_blank" rel="noopener noreferrer" ref="reftype=publisher&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" /></map></div> 
                
            
        </section>
        <section  role="document">
            
                <div id="mc" class=" article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden,.nomenu'"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-flexbox"><div class="fm-citation"><div><span id="pmcmata">Mol Cell Endocrinol.</span> Author manuscript; available in PMC 2019 Aug 15.</div><div></div><div class="final-form"><em>Published in final edited form as:</em></div><div class="final-citation"><div class="fm-vol-iss-date"><a href="/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;retmode=ref&amp;cmd=prlinks&amp;id=28935545" target="_blank" rel="noopener noreferrer" ref="reftype=publisher&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CArticle%7CFree%20Access">Mol Cell Endocrinol. 2018 Aug 15; 471: 105–117. </a></div><span class="fm-vol-iss-date">Published online 2017 Sep 19. </span> <span class="doi"><span>doi: </span><a href="//doi.org/10.1016%2Fj.mce.2017.09.024" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1016/j.mce.2017.09.024</a></span></div></div><div class="fm-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC5858970</span></div><div class="fm-citation-manuscriptid"><span class="fm-citation-ids-label">NIHMSID: </span><span>NIHMS909796</span></div><div class="fm-citation-pmid">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/28935545">28935545</a></div></div></div><h1 class="content-title">Integrated Molecular Analysis of Tamoxifen-Resistant Invasive Lobular Breast Cancer Cells Identifies MAPK and GRM/mGluR Signaling as Therapeutic Vulnerabilities</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=Stires%20H%5BAuthor%5D" class="affpopup" co-rid="_co_idm139947096001472" co-class="co-affbox">Hillary Stires</a>,<sup>1</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Heckler%20MM%5BAuthor%5D" class="affpopup" co-rid="_co_idm139947102159488" co-class="co-affbox">Mary M. Heckler</a>,<sup>1</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Fu%20X%5BAuthor%5D" class="affpopup" co-rid="_co_idm139947098093184" co-class="co-affbox">Xiaoyong Fu</a>,<sup>2</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Zhao%20L%5BAuthor%5D" class="affpopup" co-rid="_co_idm139947109617744" co-class="co-affbox">Li Zhao</a>,<sup>3</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Grasso%20CS%5BAuthor%5D" class="affpopup" co-rid="_co_idm139947097983056" co-class="co-affbox">Catherine S. Grasso</a>,<sup>4</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Quist%20MJ%5BAuthor%5D" class="affpopup" co-rid="_co_idm139947105561296" co-class="co-affbox">Michael J. Quist</a>,<sup>5</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Lewis%20JA%5BAuthor%5D" class="affpopup" co-rid="_co_idm139947199620928" co-class="co-affbox">Joseph A. Lewis</a>,<sup>1</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Klimach%20U%5BAuthor%5D" class="affpopup" co-rid="_co_idm139947241438464" co-class="co-affbox">Uwe Klimach</a>,<sup>1</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Zwart%20A%5BAuthor%5D" class="affpopup" co-rid="_co_idm139947106417056" co-class="co-affbox">Alan Zwart</a>,<sup>1</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Mahajan%20A%5BAuthor%5D" class="affpopup" co-rid="_co_idm139947101576128" co-class="co-affbox">Akanksha Mahajan</a>,<sup>1</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Gy&#x00151;rffy%20B%5BAuthor%5D" class="affpopup" co-rid="_co_idm139947097574000" co-class="co-affbox">Bal&#x000e1;zs Gy&#x00151;rffy</a>,<sup>6</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Cavalli%20LR%5BAuthor%5D" class="affpopup" co-rid="_co_idm139947100685248" co-class="co-affbox">Luciane R. Cavalli</a>,<sup>1</sup> and  <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Riggins%20RB%5BAuthor%5D" class="affpopup" co-rid="_co_idm139947103522064" co-class="co-affbox">Rebecca B. Riggins</a><sup>1,</sup><sup>*</sup></div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm139947096001472"><h3 class="no_margin">Hillary Stires</h3><p>
<sup>1</sup>Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Stires%20H%5BAuthor%5D">Hillary Stires</a></div></div><div id="_co_idm139947102159488"><h3 class="no_margin">Mary M. Heckler</h3><p>
<sup>1</sup>Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Heckler%20MM%5BAuthor%5D">Mary M. Heckler</a></div></div><div id="_co_idm139947098093184"><h3 class="no_margin">Xiaoyong Fu</h3><p>
<sup>2</sup>Lester and Sue Smith Breast Center, Dan L. Duncan Cancer Center, and Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Fu%20X%5BAuthor%5D">Xiaoyong Fu</a></div></div><div id="_co_idm139947109617744"><h3 class="no_margin">Li Zhao</h3><p>
<sup>3</sup>Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Zhao%20L%5BAuthor%5D">Li Zhao</a></div></div><div id="_co_idm139947097983056"><h3 class="no_margin">Catherine S. Grasso</h3><p>
<sup>4</sup>University of California Los Angeles (UCLA), Los Angeles, CA, USA</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Grasso%20CS%5BAuthor%5D">Catherine S. Grasso</a></div></div><div id="_co_idm139947105561296"><h3 class="no_margin">Michael J. Quist</h3><p>
<sup>5</sup>Fred Hutchinson Cancer Research Center, Seattle, WA, USA</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Quist%20MJ%5BAuthor%5D">Michael J. Quist</a></div></div><div id="_co_idm139947199620928"><h3 class="no_margin">Joseph A. Lewis</h3><p>
<sup>1</sup>Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Lewis%20JA%5BAuthor%5D">Joseph A. Lewis</a></div></div><div id="_co_idm139947241438464"><h3 class="no_margin">Uwe Klimach</h3><p>
<sup>1</sup>Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Klimach%20U%5BAuthor%5D">Uwe Klimach</a></div></div><div id="_co_idm139947106417056"><h3 class="no_margin">Alan Zwart</h3><p>
<sup>1</sup>Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Zwart%20A%5BAuthor%5D">Alan Zwart</a></div></div><div id="_co_idm139947101576128"><h3 class="no_margin">Akanksha Mahajan</h3><p>
<sup>1</sup>Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Mahajan%20A%5BAuthor%5D">Akanksha Mahajan</a></div></div><div id="_co_idm139947097574000"><h3 class="no_margin">Bal&#x000e1;zs Gy&#x00151;rffy</h3><p>
<sup>6</sup>MTA TTK Lend&#x000fc;let Cancer Biomarker Research Group, and 2<sup>nd</sup> Department of Pediatrics, Semmelweis University, Budapest, Hungary</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Gy&#x00151;rffy%20B%5BAuthor%5D">Bal&#x000e1;zs Gy&#x00151;rffy</a></div></div><div id="_co_idm139947100685248"><h3 class="no_margin">Luciane R. Cavalli</h3><p>
<sup>1</sup>Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Cavalli%20LR%5BAuthor%5D">Luciane R. Cavalli</a></div></div><div id="_co_idm139947103522064"><h3 class="no_margin">Rebecca B. Riggins</h3><p>
<sup>1</sup>Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Riggins%20RB%5BAuthor%5D">Rebecca B. Riggins</a></div></div></div></div><div class="half_rhythm"><div class="togglers fm-copyright-license"><a href="#" class="pmctoggle" rid="idm139947108665504_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm139947108665504_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/" style="margin-left: 1em">PMC Disclaimer</a></div><div class="fm-authors-info hide half_rhythm" id="idm139947108665504_ai" style="display:none"><div class="fm-affl" id="A1">
<sup>1</sup>Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA</div><div class="fm-affl" id="A2">
<sup>2</sup>Lester and Sue Smith Breast Center, Dan L. Duncan Cancer Center, and Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA</div><div class="fm-affl" id="A3">
<sup>3</sup>Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA</div><div class="fm-affl" id="A4">
<sup>4</sup>University of California Los Angeles (UCLA), Los Angeles, CA, USA</div><div class="fm-affl" id="A5">
<sup>5</sup>Fred Hutchinson Cancer Research Center, Seattle, WA, USA</div><div class="fm-affl" id="A6">
<sup>6</sup>MTA TTK Lend&#x000fc;let Cancer Biomarker Research Group, and 2<sup>nd</sup> Department of Pediatrics, Semmelweis University, Budapest, Hungary</div><div id="FN1"><sup>*</sup>To whom correspondence should be addressed: 3970 Reservoir Rd NW, E412 Research Bldg., Washington, DC 20057, phone: (202) 687-1260, <a href="mailto:dev@null" data-email="ude.nwotegroeg@sniggir.acceber" class="oemail">ude.nwotegroeg@sniggir.acceber</a></div></div><div class="fm-article-notes half_rhythm"></div><div class="permissions half_rhythm hide" id="idm139947108665504_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">PMC Copyright notice</a> </div><div><a href="#FN2">Publisher's Disclaimer</a></div></div></div><div id="pmclinksbox" class="links-box whole_rhythm" role="complementary" aria-label="Related or updated information about this article."><div>The publisher's final edited version of this article is available free at <a href="/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;retmode=ref&amp;cmd=prlinks&amp;id=28935545" target="_blank" rel="noopener noreferrer" ref="reftype=publisher&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CArticle%7CFree%20Access">Mol Cell Endocrinol</a></div></div></div><div class="sec"></div><div id="ass-data" class="tsec fm-sec whole_rhythm" data-section="Featured_PMC_Datacitation"><h2 class="nomenu">Associated Data</h2><dl data-count="11" class="box-data-suppmats whole_rhythm no_bottom_margin"><dt><a href="#" rid="data-suppmats" data-ga-action="click_feat_toggler" data-ga-label="Supplementary Materials" class="pmctoggle">Supplementary Materials</a></dt><dd id="data-suppmats" style="display: none;"><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>1.</strong></div><div><a href="/pmc/articles/PMC5858970/bin/NIHMS909796-supplement-1.xlsx" data-ga-action="click_feat_suppl">NIHMS909796-supplement-1.xlsx</a><span style="color:gray"> (14K)</span></div><div class="small guid">GUID: B9D84D7C-633D-45F7-AAD9-55CCA05D83F4</div></div><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>10.</strong></div><div><a href="/pmc/articles/PMC5858970/bin/NIHMS909796-supplement-10.xlsx" data-ga-action="click_feat_suppl">NIHMS909796-supplement-10.xlsx</a><span style="color:gray"> (35K)</span></div><div class="small guid">GUID: A4ECDC8A-BBD2-4282-BF86-B84EA251993F</div></div><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>11.</strong></div><div><a href="/pmc/articles/PMC5858970/bin/NIHMS909796-supplement-11.xlsx" data-ga-action="click_feat_suppl">NIHMS909796-supplement-11.xlsx</a><span style="color:gray"> (9.4K)</span></div><div class="small guid">GUID: E3130BEB-A3A8-444F-9C53-E46D17DE0F21</div></div><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>2.</strong></div><div><a href="/pmc/articles/PMC5858970/bin/NIHMS909796-supplement-2.tif" data-ga-action="click_feat_suppl">NIHMS909796-supplement-2.tif</a><span style="color:gray"> (16M)</span></div><div class="small guid">GUID: B223E328-4D92-472D-B36F-F0558E04D710</div></div><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>3.</strong></div><div><a href="/pmc/articles/PMC5858970/bin/NIHMS909796-supplement-3.tif" data-ga-action="click_feat_suppl">NIHMS909796-supplement-3.tif</a><span style="color:gray"> (19M)</span></div><div class="small guid">GUID: 866D05C4-1827-4316-AA64-08CE52667C3C</div></div><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>4.</strong></div><div><a href="/pmc/articles/PMC5858970/bin/NIHMS909796-supplement-4.pdf" data-ga-action="click_feat_suppl">NIHMS909796-supplement-4.pdf</a><span style="color:gray"> (153K)</span></div><div class="small guid">GUID: EE6A1833-8297-4260-9DC8-1390D9EA7CD4</div></div><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>5.</strong></div><div><a href="/pmc/articles/PMC5858970/bin/NIHMS909796-supplement-5.docx" data-ga-action="click_feat_suppl">NIHMS909796-supplement-5.docx</a><span style="color:gray"> (74K)</span></div><div class="small guid">GUID: D7E5A214-E97D-4289-9AAB-26A1144A8F96</div></div><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>6.</strong></div><div><a href="/pmc/articles/PMC5858970/bin/NIHMS909796-supplement-6.tif" data-ga-action="click_feat_suppl">NIHMS909796-supplement-6.tif</a><span style="color:gray"> (16M)</span></div><div class="small guid">GUID: 6690F048-70E4-4851-A70F-25BFC64181CA</div></div><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>7.</strong></div><div><a href="/pmc/articles/PMC5858970/bin/NIHMS909796-supplement-7.tif" data-ga-action="click_feat_suppl">NIHMS909796-supplement-7.tif</a><span style="color:gray"> (16M)</span></div><div class="small guid">GUID: C7D36928-998F-4689-BA21-6E15A8AF3BCD</div></div><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>8.</strong></div><div><a href="/pmc/articles/PMC5858970/bin/NIHMS909796-supplement-8.xlsx" data-ga-action="click_feat_suppl">NIHMS909796-supplement-8.xlsx</a><span style="color:gray"> (61K)</span></div><div class="small guid">GUID: BB57A5A0-AEFE-41CE-A6D7-63FDAA10A7E4</div></div><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>9.</strong></div><div><a href="/pmc/articles/PMC5858970/bin/NIHMS909796-supplement-9.xlsx" data-ga-action="click_feat_suppl">NIHMS909796-supplement-9.xlsx</a><span style="color:gray"> (36K)</span></div><div class="small guid">GUID: B85A2A0E-538B-4672-AAF7-45B3FBEC3360</div></div></dd></dl></div><div id="abstract-a.t.b.u" lang="en" class="tsec sec"><h2 class="head no_bottom_margin" id="abstract-a.t.b.utitle">Abstract</h2><!--article-meta--><div><p id="P2" class="p p-first-last">Invasive lobular breast cancer (ILC) is an understudied malignancy with distinct clinical, pathological, and molecular features that distinguish it from the more common invasive ductal carcinoma (IDC). Mounting evidence suggests that estrogen receptor-alpha positive (ER+) ILC has a poor response to Tamoxifen (TAM), but the mechanistic drivers of this are undefined. In the current work, we comprehensively characterize the SUM44/LCCTam ILC cell model system through integrated analysis of gene expression, copy number, and mutation, with the goal of identifying actionable alterations relevant to clinical ILC that can be co-targeted along with ER to improve treatment outcomes. We show that TAM has several distinct effects on the transcriptome of LCCTam cells, that this resistant cell model has acquired copy number alterations and mutations that impinge on MAPK and metabotropic glutamate receptor (GRM/mGluR) signaling networks, and that pharmacological inhibition of either improves or restores the growth-inhibitory actions of endocrine therapy.</p></div><div class="sec"><strong class="kwd-title">Keywords: </strong><span class="kwd-text">Invasive lobular breast cancer (ILC), Tamoxifen resistance, MAPK/ERK (<em>MAPK1</em>), ESRRG (<em>ERRgamma</em>), mGluR (GRM), Riluzole</span></div></div><div id="S1" class="tsec sec"><h2 class="head no_bottom_margin" id="S1title">1. Introduction</h2><p id="P3" class="p p-first">Invasive lobular breast cancer (ILC) is a special histologic subtype of breast cancer that accounts for 10&#x02013;15% of annually diagnosed cases &#x02013; an identical percentage to triple negative breast cancer. ILC has unique clinical features that distinguish it from the more common invasive ductal breast cancer (IDC) (<a href="#R6" rid="R6" class=" bibr popnode">Barroso-Sousa and Metzger-Filho 2016</a>; <a href="#R15" rid="R15" class=" bibr popnode">Christgen, et al. 2016</a>; <a href="#R94" rid="R94" class=" bibr popnode">Sledge, et al. 2016</a>) &#x02013; it forms a long, thin mass that is often missed by screening mammograms, and metastatic ILC frequently spreads to distinct sites (e.g. peritoneum, gastrointestinal tract, orbital cavity) that differ from IDC. This unique biology of ILC impacts disease prognosis. ILC has a greater risk of late recurrence and death (&#x0003e;10 years post-diagnosis) than IDC (<a href="#R80" rid="R80" class=" bibr popnode">Pestalozzi, et al. 2008</a>; <a href="#R83" rid="R83" class=" bibr popnode">Rakha, et al. 2008</a>). Grade 2 (moderately differentiated) ILC has an equally poor breast cancer-specific survival to grade 3 (poorly differentiated) IDC (<a href="#R29" rid="R29" class=" bibr popnode">Engstr&#x000f8;m, et al. 2015</a>). The most common genetic lesion in ILC is mutation of <em>CDH1</em> leading to loss of E-cadherin expression, which is thought to underlie ILC&#x02019;s unusual metastatic pattern as well as its tendency to be multifocal and affect the contralateral breast. Recent studies have performed genomic, transcriptomic, and proteomic characterization of ILC clinical specimens to identify additional events that are enriched in ILC vs. IDC; these include higher rates of <em>PTEN</em> loss, <em>FOXA1</em> mutation, and AKT phosphorylation (<a href="#R16" rid="R16" class=" bibr popnode">Ciriello, et al. 2015</a>; <a href="#R24" rid="R24" class=" bibr popnode">Desmedt, et al. 2016</a>; <a href="#R72" rid="R72" class=" bibr popnode">Michaut, et al. 2016</a>).</p><p id="P4">Molecular profiling of breast cancer classifies most ILC as Luminal A &#x02013; estrogen receptor positive (ER+), and slow-growing) &#x02013; for which 10 years of treatment with the antiestrogen Tamoxifen (TAM) or an aromatase inhibitor (AI) is recommended (<a href="#R4" rid="R4" class=" bibr popnode">Azim, et al. 2016</a>; <a href="#R89" rid="R89" class=" bibr popnode">Rugo, et al. 2016</a>). Within ILC, there are 2&#x02013;3 additional molecular subtypes (<a href="#R16" rid="R16" class=" bibr popnode">Ciriello et al. 2015</a>; <a href="#R72" rid="R72" class=" bibr popnode">Michaut et al. 2016</a>). Among ER+ or Luminal A breast tumors, lobular histology is still independently and significantly associated with worse long-term survival outcome than ductal histology (<a href="#R80" rid="R80" class=" bibr popnode">Pestalozzi et al. 2008</a>; <a href="#R83" rid="R83" class=" bibr popnode">Rakha et al. 2008</a>), and multiple studies show that ER+ ILC has a significantly worse response to TAM than the non-steroidal AIs letrozole or anastrozole (<a href="#R55" rid="R55" class=" bibr popnode">Knauer, et al. 2015</a>; <a href="#R71" rid="R71" class=" bibr popnode">Metzger Filho, et al. 2015</a>). ILC patients also have inferior overall survival on the steroidal AI exemestane vs. anastrozole, while in IDC they have equivalent efficacy (<a href="#R98" rid="R98" class=" bibr popnode">Strasser-Weippl, et al. 2016</a>).</p><p id="P5" class="p p-last">ILC is an understudied malignancy and thus the reasons for its relatively poor response to TAM are not well defined. We previously established the first cellular model of TAM-resistant ILC (<a href="#R85" rid="R85" class=" bibr popnode">Riggins, et al. 2008</a>); SUM44 cells are the parental, TAM sensitive cell line while LCCTam cells are TAM-resistant. These initial studies identified an orphan member of the nuclear receptor superfamily, estrogen-related receptor gamma (ERR&#x003b3;, <em>ESRRG</em>), as a key mediator of the TAM-resistant phenotype. In the current work, we comprehensively characterize this ILC model system through integrated analysis of genome-wide gene expression, copy number, and whole exome sequencing (WES), with the goal of identifying actionable alterations relevant to clinical ILC that can be targeted to improve therapeutic outcomes. We find that 4-hydroxytamoxifen (4HT) has a distinct effect on the transcriptome of LCCTam cells, that this resistant cell model has acquired copy number alterations and specific gene mutations that impinge on MAPK and metabotropic glutamate receptor (GRM/mGluR) signaling networks, and that pharmacological inhibition of either improves or restores the growth-inhibitory actions of endocrine therapy.</p></div><div id="S2" class="tsec sec"><h2 class="head no_bottom_margin" id="S2title">2. Materials and Methods</h2><div id="S3" class="sec sec-first"><h3 id="S3title">2.1 General study design</h3><p id="P6" class="p p-first-last">We have previously reported the establishment and initial validation of a TAM-resistant ILC cell line (LCCTam) established from the parental SUM44 (<a href="#R85" rid="R85" class=" bibr popnode">Riggins et al. 2008</a>). Here, we demonstrate the utility of this model system for studying TAM-resistant ILC by comparing SUM44 with publicly available breast cancer patient datasets. Subsequent comprehensive molecular analysis of LCCTam cells was performed in comparison to SUM44 cells utilizing gene expression array, Whole Exome Sequencing (WES), and Array Comparative Genomic Hybridization (aCGH). Selected molecular targets from this analysis were validated and functional analyses were performed using drugs of interest that resensitize TAM-resistant cells to TAM as measured by growth inhibition.</p></div><div id="S4" class="sec"><h3 id="S4title">2.2 TCGA and METABRIC Datasets, and Tumor-Derived ILC Signature (TIS)</h3><p id="P7" class="p p-first-last">cBioPortal (<a href="#R11" rid="R11" class=" bibr popnode">Cerami, et al. 2012</a>; <a href="#R38" rid="R38" class=" bibr popnode">Gao, et al. 2013</a>) was used to query processed gene expression microarray, whole-exome, and RNA sequencing data for Luminal A IDC and Luminal A ILC tumors from The Cancer Genome Atlas (TCGA, (<a href="#R16" rid="R16" class=" bibr popnode">Ciriello et al. 2015</a>)) and the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC, (<a href="#R21" rid="R21" class=" bibr popnode">Curtis, et al. 2012</a>; <a href="#R79" rid="R79" class=" bibr popnode">Pereira, et al. 2016</a>)). To establish the tumor-derived ILC signature (TIS, <a href="/pmc/articles/PMC5858970/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1A</span></a>), RNA-seq data for Luminal A ILC (n=106) and IDC (n=201) were downloaded from the TCGA Portal (<a href="http://cbio.mskcc.org/cancergenomics/tcga/brca_tcga/" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">http://cbio.mskcc.org/cancergenomics/tcga/brca_tcga/</a>). The differentially expressed genes between these two histologic subtypes were identified using the &#x02018;ComparativeMarkerSelection&#x02019; module from GenePattern (<a href="#R84" rid="R84" class=" bibr popnode">Reich, et al. 2006</a>), and plotted by alignment of their tested t-score after permutation. The top 100 genes including both directions (2x 50) were defined as a &#x02018;tumor-derived ILC gene signature&#x02019; (TIS) for the comparison of signature profiles among different cell models, using a t-score method as described previously (<a href="#R19" rid="R19" class=" bibr popnode">Creighton, et al. 2010</a>). <a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Table 1</a> shows sample identifiers for Distant metastasis-free survival (DMFS) data for <em>GRM2</em> and <em>GRM4</em> mRNA expression by Affymetrix gene expression microarray in ER+, TAM-treated, chemotherapy-na&#x000ef;ve patients were obtained from multiple combined datasets as described previously (<a href="#R73" rid="R73" class=" bibr popnode">Mih&#x000e1;ly, et al. 2013</a>) (<a href="#SD5" rid="SD5" class=" supplementary-material">Supplementary Figure 2</a>). The final database included patients from <a id="__tag_706920044" class="tag_hotlink" href="/geo/query/acc.cgi?acc=GSE2990" ref="/geo/query/acc.cgi?acc=GSE2990"><span class="tag-json" style="display:none">{"type":"entrez-geo","attrs":{"text":"GSE2990","term_id":"2990"}}</span>GSE2990</a>, <a id="__tag_706920050" class="tag_hotlink" href="/geo/query/acc.cgi?acc=GSE3494" ref="/geo/query/acc.cgi?acc=GSE3494"><span class="tag-json" style="display:none">{"type":"entrez-geo","attrs":{"text":"GSE3494","term_id":"3494"}}</span>GSE3494</a>, <a id="__tag_706920040" class="tag_hotlink" href="/geo/query/acc.cgi?acc=GSE6532" ref="/geo/query/acc.cgi?acc=GSE6532"><span class="tag-json" style="display:none">{"type":"entrez-geo","attrs":{"text":"GSE6532","term_id":"6532"}}</span>GSE6532</a>, <a id="__tag_706920041" class="tag_hotlink" href="/geo/query/acc.cgi?acc=GSE12093" ref="/geo/query/acc.cgi?acc=GSE12093"><span class="tag-json" style="display:none">{"type":"entrez-geo","attrs":{"text":"GSE12093","term_id":"12093"}}</span>GSE12093</a>, <a id="__tag_706920043" class="tag_hotlink" href="/geo/query/acc.cgi?acc=GSE9195" ref="/geo/query/acc.cgi?acc=GSE9195"><span class="tag-json" style="display:none">{"type":"entrez-geo","attrs":{"text":"GSE9195","term_id":"9195"}}</span>GSE9195</a>, <a id="__tag_706920048" class="tag_hotlink" href="/geo/query/acc.cgi?acc=GSE16391" ref="/geo/query/acc.cgi?acc=GSE16391"><span class="tag-json" style="display:none">{"type":"entrez-geo","attrs":{"text":"GSE16391","term_id":"16391"}}</span>GSE16391</a>, <a id="__tag_706920042" class="tag_hotlink" href="/geo/query/acc.cgi?acc=GSE17705" ref="/geo/query/acc.cgi?acc=GSE17705"><span class="tag-json" style="display:none">{"type":"entrez-geo","attrs":{"text":"GSE17705","term_id":"17705"}}</span>GSE17705</a>, <a id="__tag_706920047" class="tag_hotlink" href="/geo/query/acc.cgi?acc=GSE19615" ref="/geo/query/acc.cgi?acc=GSE19615"><span class="tag-json" style="display:none">{"type":"entrez-geo","attrs":{"text":"GSE19615","term_id":"19615"}}</span>GSE19615</a>, <a id="__tag_706920049" class="tag_hotlink" href="/geo/query/acc.cgi?acc=GSE26971" ref="/geo/query/acc.cgi?acc=GSE26971"><span class="tag-json" style="display:none">{"type":"entrez-geo","attrs":{"text":"GSE26971","term_id":"26971"}}</span>GSE26971</a>, and <a id="__tag_706920054" class="tag_hotlink" href="/geo/query/acc.cgi?acc=GSE45255" ref="/geo/query/acc.cgi?acc=GSE45255"><span class="tag-json" style="display:none">{"type":"entrez-geo","attrs":{"text":"GSE45255","term_id":"45255"}}</span>GSE45255</a>.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F1" co-legend-rid="lgnd_F1"><a href="/pmc/articles/PMC5858970/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139947203511792"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=5858970_nihms909796f1.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms909796f1.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC5858970/bin/nihms909796f1.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139947203511792"><a target="object" rel="noopener" href="/pmc/articles/PMC5858970/figure/F1/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F1"><div><a class="figpopup" href="/pmc/articles/PMC5858970/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1">Figure 1</a></div><!--caption a7--><div class="caption"><p>Expression of <em>ESRRG</em> and receptor target genes in Luminal A ILC. A, Tumor-derived ILC Signature (TIS) comprises top discriminant genes (50 up, 50 down) differentially expressed between Luminal A ILC and Luminal A IDC in the TCGA dataset from (<a href="#R16" rid="R16" class=" bibr popnode">Ciriello et al. 2015</a>). Down-regulated genes in ILC vs. IDC include <em>CDH1</em> and <em>PTEN</em>, which are mutated and deleted in ILC respectively. B, <em>ESRRG</em> mRNA expression is significantly higher in Luminal A ILC vs. Luminal A IDC in the combined METABRIC dataset in cBioPortal. Gene expression microarray data were compared by Mann-Whitney U test. C and D, mRNA expression of a four-gene <em>ESRRG</em> target signature is associated with poor outcome in Luminal A ILCs from TCGA (C) and METABRIC (D). mRNA levels are as measured by RNAseq (TCGA) or gene expression microarray (METABRIC), and high or low expression corresponds to above or below the median, respectively. Log-rank values calculated by cBioPortal.</p></div></div></div></div><div id="S5" class="sec"><h3 id="S5title">2.3 Cell culture and general reagents</h3><p id="P8" class="p p-first-last">The ILC-derived, ER+ parental SUM44 breast cancer cells were initially characterized by (<a href="#R31" rid="R31" class=" bibr popnode">Ethier, et al. 1993</a>), and the ER+, TAM-resistant variant LCCTam were first reported in (<a href="#R85" rid="R85" class=" bibr popnode">Riggins et al. 2008</a>). SUM44 cells were maintained in serum-free Ham&#x02019;s F12 media (Life Technologies, Carlsbad, CA; 100 nM glutamate) containing 5 &#x003bc;g/ml insulin and 1 &#x003bc;g/ml hydrocortisone (SFIH) plus other supplements as follows: 5 mM ethanolamine, 10 mM HEPES, 5 &#x003bc;g/ml Transferrin, 10 nM Tri-iodo thyronine, 50 &#x003bc;M sodium selenite, 0.5 g/L bovine serum albumin, 2.5 &#x003bc;g/ml amphotericin B, and 5 &#x003bc;g/ml gentamicin (all purchased from either Life Technologies or Sigma Aldrich, St. Louis, MO). LCCTam cells were maintained in SFIH with the addition of 500 nM 4HT (Sigma Aldrich), and switched to SFIH lacking 4HT as indicated below. The IDC-derived, ER&#x02212; MDA-MB-231 cell line was obtained from the Lombardi Comprehensive Cancer Center (LCCC) Tissue Culture Shared Resource (TCSR), and was maintained in phenol red-containing improved minimal essential media (IMEM) supplemented with 5% heat-inactivated fetal bovine serum (FBS). All cells routinely tested negative for <em>Mycoplasma spp</em>., and were maintained in a 37&#x000b0;C, humidified incubator with 95% air: 5% carbon dioxide. Cells were fingerprinted by the TCSR to verify their authenticity using 9 standard short tandem repeat (STR) loci and the Y chromosome-specific amelogenin, most recently in October 2016. Fulvestrant (ICI), Riluzole (RIL), and U0126 were purchased from Tocris Bioscience (RNDSystems, Minneapolis, MN) and used at the indicated concentrations. Unless otherwise specified, general laboratory chemicals were obtained from Sigma Aldrich.</p></div><div id="S6" class="sec"><h3 id="S6title">2.4 Gene expression</h3><p id="P9" class="p p-first-last">Gene expression microarray data for parental SUM44 breast cancer cells, and the resistant variant LCCTam maintained in the presence of 500 nM 4HT, have been previously published and deposited with Gene Expression Omnibus (GEO; <a id="__tag_706920053" class="tag_hotlink" href="/geo/query/acc.cgi?acc=GSE12708" ref="/geo/query/acc.cgi?acc=GSE12708"><span class="tag-json" style="display:none">{"type":"entrez-geo","attrs":{"text":"GSE12708","term_id":"12708"}}</span>GSE12708</a>, (<a href="#R85" rid="R85" class=" bibr popnode">Riggins et al. 2008</a>)). Total RNA was isolated from SUM44 cells treated with 500 nM 4HT for 24 hours, or LCCTam cells cultured in the absence of 4HT for 14 days, using TRIzol (ThermoFisher, Waltham, MA) and the RNEasy Mini Kit (Qiagen, Germantown, MD). Total RNA was labeled and processed for hybridization to Affymetrix U133A GeneChips as described previously (<a href="#R41" rid="R41" class=" bibr popnode">Gomez, et al. 2007</a>; <a href="#R85" rid="R85" class=" bibr popnode">Riggins et al. 2008</a>). These data are available through GEO accession number <a id="__tag_706920045" class="tag_hotlink" href="/geo/query/acc.cgi?acc=GSE96570" ref="/geo/query/acc.cgi?acc=GSE96570"><span class="tag-json" style="display:none">{"type":"entrez-geo","attrs":{"text":"GSE96570","term_id":"96570"}}</span>GSE96570</a>, and together as SuperSeries <a id="__tag_706920052" class="tag_hotlink" href="/geo/query/acc.cgi?acc=GSE96670" ref="/geo/query/acc.cgi?acc=GSE96670"><span class="tag-json" style="display:none">{"type":"entrez-geo","attrs":{"text":"GSE96670","term_id":"96670"}}</span>GSE96670</a>. Raw data for these and our previously published data (<a id="__tag_706920046" class="tag_hotlink" href="/geo/query/acc.cgi?acc=GSE12708" ref="/geo/query/acc.cgi?acc=GSE12708"><span class="tag-json" style="display:none">{"type":"entrez-geo","attrs":{"text":"GSE12708","term_id":"12708"}}</span>GSE12708</a>, (<a href="#R85" rid="R85" class=" bibr popnode">Riggins et al., 2008</a>)) were preprocessed together using the Robust Multiple-Array Average (RMA) method (<a href="#R50" rid="R50" class=" bibr popnode">Irizarry, et al. 2003</a>) using Bioconductor.</p></div><div id="S7" class="sec"><h3 id="S7title">2.5 Array Comparative Genomic Hybridization (aCGH)</h3><p id="P10" class="p p-first">Genomic DNA was isolated from SUM44 and LCCTam cells, the latter cultured in the absence of 4HT for 14 days, using the illustra triplePrep kit (GE Healthcare, Buckinghamshire, UK) according to manufacturer&#x02019;s instructions. DNA copy number analysis was performed using an oligonucleotide array-CGH platform (SurePrint G3 Human CGH Microarray 8&#x000d7;60K; Agilent Technologies Inc., Santa Clara, CA), as published previously (<a href="#R101" rid="R101" class=" bibr popnode">Torresan, et al. 2014</a>). DNA isolated from peripheral blood from multiple normal individuals was used as reference DNA. Briefly, equal amounts of cell line and reference DNA were directly labeled with Cy3 and Cy5, respectively, using the SureTag Labeling Kit (Agilent Technologies) and hybridized in the presence of human Cot1-DNA (Life Technologies) to the array for 40 hours. The array was scanned using an Agilent array scanner and data was extracted using Feature Extraction (FE) software v10.10. For data analysis we used two different global analysis methods: Aberration Detection Module-2 (ADM-2, Agilent Technologies) and Circular Binary Segmentation (CBS).</p><div id="S8" class="sec"><p></p><h4 id="S8title" class="inline">ADM-2 </h4><p id="P11" class="p p-first-last">Data were analyzed using the Genome Workbench version 7.0 software (Agilent Technologies). For each sample, FE gave a log<sub>10</sub> ratio (log of sample processed signal over reference processed signal for each gene) that was imported into Genome Workbench and transformed and viewed as a log<sub>2</sub>-based ratio. Outliers detected by the FE were excluded from the analysis. The algorithm ADM-2 and a threshold value of 6.0 were applied with an aberration filter with a minimum number of 3 consecutive probes. Gene amplifications and deletions were considered when the corresponding plotted oligo-probes presented values of log<sub>2</sub> ratio (intensity of the Cy5 dye (reference DNA)/intensity of the Cy3 dye (test DNA) &#x0003e;7/6 and log<sub>2</sub> &#x0003c;5/6, respectively.</p></div><div id="S9" class="sec sec-last"><p></p><h4 id="S9title" class="inline">CBS </h4><p id="P12" class="p p-first-last">To calculate log2(copy number ratio) for each probe, we considered only probes that had ControlType equal to &#x02018;0&#x02019;. We took the log2 of the ratio of the green to red signal after correction (gProcessedSignal/rProcessedSignal) for each probe. Segmentation analysis for the aCGH copy number log-ratio was then performed through the use of the Circular Binary Segmentation (CBS) Algorithm, as implemented in the DNAcopy package in R version 3.1.2 (<a href="#R76" rid="R76" class=" bibr popnode">Olshen, et al. 2004</a>; <a href="#R105" rid="R105" class=" bibr popnode">Venkatraman and Olshen 2007</a>). Default values for all parameters were used, except that consecutive segments were merged using the undo.splits = &#x0201c;sdundo&#x0201d; option with the undo.SD parameter set to 0.3/DLRS, where DLRS (derivative log ratio spread) represents the local SD in log ratio units, a well-known measure of local variability for aCGH microarrays. In this way, the segmentation algorithm was tuned to detect copy number changes of at least 0.3 in magnitude on the log2 scale. Segments were reported as amplified or deleted if the corresponding estimated copy number ratio was greater than 1.3 or less than 0.7, respectively. Copy-number plots were created in R showing the log2 green:red ratios as colored points and the CBS-generated segments as black lines; any segments falling outside the plot range are indicated as labeled black points.</p></div></div><div id="S10" class="sec"><h3 id="S10title">2.6 Whole-Exome Sequencing (WES)</h3><p id="P13" class="p p-first-last">Genomic DNA was isolated from SUM44 and LCCTam cells, the latter cultured in the absence of 4HT for 14 days, using the DNeasy Mini kit (Qiagen). Exome enrichment was performed using the Illumina TruSeq Exome Library Prep Kit (San Diego, CA), then sequenced on an Illumina HiScanQ instrument at Children&#x02019;s National Medical Center. Paired-end sequencing reads were obtained for all samples. NGS reads were mapped to the hg19 human reference genome using BWA-MEM (<a href="#R60" rid="R60" class=" bibr popnode">Li and Durbin, 2009</a>), duplicate reads were removed using Picard (unpublished, <a href="http://broadinstitute.github.io/picard/" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">http://broadinstitute.github.io/picard/</a>), local realignments were performed using GATK (<a href="#R66" rid="R66" class=" bibr popnode">McKenna, et al. 2010</a>), and .bam files of biological replicates were merged using SAMtools (<a href="#R60" rid="R60" class=" bibr popnode">Li, et al. 2009</a>) to increase the total coverage. The variants were called using Atlas2 Suite (<a href="#R12" rid="R12" class=" bibr popnode">Challis, et al. 2012</a>). A population frequency threshold of 1% was used to filter out common variants. Four next-generation sequencing (NGS) cohort databases were used to determine allele frequencies in population, including 1000 Genome Project (<a href="#R1" rid="R1" class=" bibr popnode">Abecasis, et al. 2012</a>), Human Genetic Variation Database (<a href="#R46" rid="R46" class=" bibr popnode">Higasa, et al. 2016</a>), Exome Aggregation Consortium (<a href="#R59" rid="R59" class=" bibr popnode">Lek, et al. 2016</a>) and CHARGE cohort (<a href="#R82" rid="R82" class=" bibr popnode">Psaty, et al. 2009</a>). After the frequency-based filtering step, the putative functional consequences of remaining rare variants were annotated using ANNOVAR (<a href="#R107" rid="R107" class=" bibr popnode">Wang, et al. 2010</a>). The synonymous variants were further filtered out and dbNSFP (<a href="#R61" rid="R61" class=" bibr popnode">Liu, et al. 2013</a>) was used to compile <em>in silico</em> predictions about the deleteriousness of nonsynonymous variants.</p></div><div id="S11" class="sec"><h3 id="S11title">2.7 Quantitative Real-Time PCR (qRTPCR) and Endpoint PCR</h3><p id="P14" class="p p-first-last">Total RNA was isolated from SUM44 cells or LCCTam cells cultured in the absence of 4HT for 14 days, using TRIzol (ThermoFisher) and the RNEasy Mini Kit (Qiagen). RNA was reverse transcribed using the High Capacity cDNA Reverse Transcription kit (ThermoFisher). Primers were synthesized by Integrated DNA Technologies (Coralville, IA) and sequences are listed in <a href="/pmc/articles/PMC5858970/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>. qRTPCR was performed using Power SYBR Green PCR Master Mix (ThermoFisher) in 384-well plates using the Applied Biosystems 7900HT Fast Real-Time PCR System. For each gene of interest, the 2<sup>&#x02212;&#x00394;&#x00394;ct</sup> method described by Applied Biosystems (Life Technologies) compared with the geometric mean of the Ct values for &#x003b2;-actin (<em>ACTB</em>) and &#x003b2;-tubulin (<em>TUBB</em>) acting as housekeeping genes was used to calculate relative expression.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap anchored whole_rhythm" id="T1"><h3>Table 1</h3><div class="xtable"><table frame="box" rules="all" class="rendered small default_table"><thead><tr><th valign="middle" align="left" rowspan="1" colspan="1">Gene</th><th valign="middle" align="left" rowspan="1" colspan="1">Forward</th><th valign="middle" align="left" rowspan="1" colspan="1">Reverse</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1"><em>NF1</em></td><td align="left" valign="middle" rowspan="1" colspan="1">GAAGTAGGCAGCTGACAGAAA</td><td align="left" valign="middle" rowspan="1" colspan="1">TCAACCACCATGGACTGAAC</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><em>MAPK1</em></td><td align="left" valign="middle" rowspan="1" colspan="1">TCCCAAATGCTGACTCCAAA</td><td align="left" valign="middle" rowspan="1" colspan="1">TCGTCACTCGGGTCGTAATA</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><em>FOXA1</em></td><td align="left" valign="middle" rowspan="1" colspan="1">GGGGGTTTGTCTGGCATAGC</td><td align="left" valign="middle" rowspan="1" colspan="1">GCACTGGGGGAAAGGTTGTG</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><em>GRM2</em></td><td align="left" valign="middle" rowspan="1" colspan="1">AACTTCAACGAGGCCAAG</td><td align="left" valign="middle" rowspan="1" colspan="1">TCACTGGAGGTGACATAGAA</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><em>ACTB</em></td><td align="left" valign="middle" rowspan="1" colspan="1">GAGCACAGAGCCTCGCCTTT</td><td align="left" valign="middle" rowspan="1" colspan="1">TCATCATCCATGGTGAGCTGG</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><em>TUBB</em></td><td align="left" valign="middle" rowspan="1" colspan="1">ATTCCAACCTTCCAGCCTGC</td><td align="left" valign="middle" rowspan="1" colspan="1">CCAGAACTTGGCACCGATCT</td></tr></tbody></table></div><div class="largeobj-link align_right" id="largeobj_idm139947103859472"><a target="object" rel="noopener" href="/pmc/articles/PMC5858970/table/T1/?report=objectonly">Open in a separate window</a></div></div></div><div id="S12" class="sec"><h3 id="S12title">2.8 Western blot</h3><p id="P15" class="p p-first-last">SUM44 and LCCTam cells were seeded in 6-well plastic tissue culture plates at 250,000 cells/well 24 to 48 hours prior to treatment with the indicated concentrations of drug, or prior to lysis in the case of untreated cells. Cell lysate preparation in modified RIPA buffer, SDS-PAGE, and transfer to nitrocellulose membrane were carried out as described previously (<a href="#R44" rid="R44" class=" bibr popnode">Heckler, et al. 2014</a>; <a href="#R45" rid="R45" class=" bibr popnode">Heckler, et al. 2016</a>; <a href="#R85" rid="R85" class=" bibr popnode">Riggins et al. 2008</a>). Membranes were blocked in 5% nonfat dry milk in TBST buffer, then probed overnight with the following primary antibodies: phospho-MAPK (1:500&#x02013;1:1000) and total MAPK (1:500&#x02013;1:1000) from Cell Signaling (Danvers, MA); phospho-Serine 118 ERalpha (1:500) from EMD Millipore (Billerica, MA); and total ERalpha (clone 6F11, 1:500&#x02013;1:1000) from Vector Labs (Burlingame, CA). Incubation with horseradish peroxidase (HRP)-conjugated secondary antibodies from GE Healthcare (1:5000) and exposure to film were performed as described previously (<a href="#R44" rid="R44" class=" bibr popnode">Heckler et al. 2014</a>; <a href="#R45" rid="R45" class=" bibr popnode">Heckler et al. 2016</a>; <a href="#R85" rid="R85" class=" bibr popnode">Riggins et al. 2008</a>). Membranes were reprobed for beta-actin (Sigma Aldrich, 1:10,000) or GAPDH (Santa Cruz Biotechnology, 1:5000) for &#x02265;1 hour at room temperature as a loading control.</p></div><div id="S13" class="sec"><h3 id="S13title">2.9 Immunofluorescence microscopy</h3><p id="P16" class="p p-first-last">SUM44 and LCCTam cells were seeded on poly-l-lysine (Sigma) coated 18mm diameter round coverslips in 24-well plastic tissue culture plates at 80,000 cells/well. 48 hours later, cells were fixed in 3.2% paraformaldehyde for 5 minutes, washed with PBS, then permeabilized with 0.2% Triton X-100 for 5 minutes. Cells were incubated with an anti-GRM1/mGluR1 primary antibody (Cell Signaling, 1:200) in antibody diluent (0.1% gelatin, 10% normal donkey serum in PBS). Staining negative controls were incubated in antibody diluent only. All coverslips were then co-incubated for 20 minutes with AlexaFluor594-conjugated anti-rabbit secondary antibody (Life Technologies, 1:200), DAPI (Life Technologies, 1:500), and AlexaFluor488-conjugated phalloidin (Cytoskeleton, Denver, CO, 1:300). Phalloidin was used to establish consistent focal planes across samples for image capture, but not included in the final image stack. Stained cells were imaged on a Leica SP8 AOBS++ laser scanning confocal microscope in the LCCC Microscopy and Imaging Shared Resource (MISR). Gain and exposure time were established for LCCTam cells prior to imaging SUM44 and negative control coverslips, changing only focus to acquire these images.</p></div><div id="S14" class="sec"><h3 id="S14title">2.10 Cell proliferation</h3><p id="P17" class="p p-first-last">SUM44 and LCCTam cells were seeded in 96-well plastic tissue culture plates at 10,000 cells/well. MDA-MB-231 cells were seeded at 1000 cells/well. 24 to 48 hours later, cells were treated with the indicated concentrations of 4HT, U0126, Riluzole (RIL), Fulvestrant (ICI), or combinations thereof. For 4HT/U0126 experiments, SUM44 and LCCTam cells were treated for 10 days while MDA-MB-231 cells were treated for 6 days. For RIL/ICI experiments, SUM44 and LCCTam cells were treated for 8 days. At the conclusion of each experiment, cells were stained with a solution of 0.5% crystal violet in 25% methanol. Once dry, the crystal violet stain was resolubilized with citrate buffer and a dual-wavelength absorbance measurement was obtained from an ELx808 plate reader (BioTek, Winooski, VT) in the LCCC Genomics and Epigenomics Shared Resource (GESR) at 562 and 405 nm as previously described (<a href="#R45" rid="R45" class=" bibr popnode">Heckler et al. 2016</a>).</p></div><div id="S15" class="sec sec-last"><h3 id="S15title">2.11 Image and Statistical Analysis</h3><p id="P18" class="p p-first-last">Image compilation was performed using Adobe Photoshop Creative Suite 5.1 (San Jose CA), and all statistical analyses other than those discussed above for &#x02013;omics assays were performed using GraphPad Prism 6.0 or 7.0 (La Jolla CA). Venn diagrams were generated using Venny 2.1 (<a href="http://bioinfogp.cnb.csic.es/tools/venny/index.html" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">http://bioinfogp.cnb.csic.es/tools/venny/index.html</a>). Statistical significance is defined as p&#x02264;0.05, with the following labeling convention: *p&#x0003c;0.05; **p&#x0003c;0.01; ***p&#x0003c;0.001; and ****p&#x0003c;0.0001. The details of each test performed are shown in the relevant Figure Legends. In the survival analysis including multiple genes the mean expression of the signature was computed first and the median of the mean was used as the final cutoff in the Cox regression analysis. Relative index (RI) calculations were used to test the nature of the interaction between U0126 and 4HT, or Riluzole (RIL) and Fulvestrant (ICI) (<a href="#R88" rid="R88" class=" bibr popnode">Romanelli, et al. 1998</a>). Briefly, the R index is calculated as the expected cell survival (S<sub>exp</sub>; the product of relative survival in 4HT or ICI and relative survival in U0126 or RIL) divided by the observed relative survival in the presence of the combination (S<sub>obs</sub>, 4HT+U0126 or ICI+RIL). S<sub>exp</sub>/S<sub>obs</sub> = 1.0 denotes an additive interaction, while &#x0003e;1.0 denotes a synergistic interaction, though R index values approaching 2.0 are indicative of more robust synergy (<a href="#R88" rid="R88" class=" bibr popnode">Romanelli et al. 1998</a>).</p></div></div><div id="S16" class="tsec sec"><h2 class="head no_bottom_margin" id="S16title">3. Results and Discussion</h2><div id="S17" class="sec sec-first"><h3 id="S17title">3.1 Relevance of ESRRG and the SUM44/LCCTam model system to Luminal A ILC clinical specimens</h3><p id="P19" class="p p-first-last">We previously demonstrated that ERR&#x003b3; stimulates TAM-resistance in the SUM44/LCCTam model of ILC (<a href="#R85" rid="R85" class=" bibr popnode">Riggins et al. 2008</a>), now characterized as belonging to the hormone related (HR) ILC subtype (<a href="#R72" rid="R72" class=" bibr popnode">Michaut et al. 2016</a>). Exogenous expression of <em>ESRRG</em> was later shown to induce TAM-resistance in other, non-ILC breast cancer models (<a href="#R40" rid="R40" class=" bibr popnode">Girard, et al. 2015</a>; <a href="#R63" rid="R63" class=" bibr popnode">L&#x000fc;, et al. 2015</a>). <em>ESRRG</em> is located at chromosome 1q41, which is more often amplified in ILC vs. IDC (<a href="#R24" rid="R24" class=" bibr popnode">Desmedt et al. 2016</a>; <a href="#R42" rid="R42" class=" bibr popnode">Gruel, et al. 2010</a>; <a href="#R72" rid="R72" class=" bibr popnode">Michaut et al. 2016</a>). Accordingly, <em>ESRRG</em> mRNA expression is significantly higher in primary Luminal A ILC vs. IDC tumors in both The Cancer Genome Atlas (TCGA) (<a href="/pmc/articles/PMC5858970/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1A</span></a>) and METABRIC datasets (<a href="/pmc/articles/PMC5858970/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1B</span></a>). In TCGA, <em>ESRRG</em> is among the top ~100 genes that discriminate ILC from IDC. We recently published a signature of 37 validated transcriptional target genes of <em>ESRRG</em> that is prognostic in TAM-treated breast tumors irrespective of histologic subtype (<a href="#R64" rid="R64" class=" bibr popnode">Madhavan, et al. 2015</a>), and show here that a 4-gene subset of this signature (<em>AHSA1, TIMM17A, TRRAP, SPTLC2</em>) has better prognostic value in Luminal A ILC (<a href="/pmc/articles/PMC5858970/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1C</span></a>) than Luminal A IDC (<a href="#SD4" rid="SD4" class=" supplementary-material">Supplementary Figure 1A</a>) in the TCGA dataset. There is a similar trend in Luminal A ILC from the METABRIC dataset, but it does not reach statistical significance (<a href="/pmc/articles/PMC5858970/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1D</span></a>, <a href="#SD4" rid="SD4" class=" supplementary-material">Supplementary Figure 1B</a>). These data support the relevance of the SUM44/LCCTam model system as a platform to identify additional alterations in gene expression, as well as copy number and mutations, in ILC that are associated with poor response to TAM.</p></div><div id="S18" class="sec"><h3 id="S18title">3.2 Gene expression analysis identifies differential transcriptome response to 4HT in LCCTam cells</h3><p id="P20" class="p p-first">The LCCTam cell line was selected by growing cells in increasing doses of 4HT, and thus microarray analysis of how SUM44 and LCCTam cells respond to 4HT gives insight into what drives resistance. We previously reported that, in conjunction with <em>ESRRG</em>, aberrant activating protein 1 (AP1) activity plays a key functional role in the TAM-resistant phenotype of LCCTam cells, and identified candidate AP1-regulated genes whose expression is increased in LCCTam cells (<a href="#R85" rid="R85" class=" bibr popnode">Riggins et al. 2008</a>). This was based on gene expression microarray analysis comparing parental SUM44 cells with LCCTam cells continually maintained in 500 nM 4HT (<a id="__tag_706920051" class="tag_hotlink" href="/geo/query/acc.cgi?acc=GSE12708" ref="/geo/query/acc.cgi?acc=GSE12708"><span class="tag-json" style="display:none">{"type":"entrez-geo","attrs":{"text":"GSE12708","term_id":"12708"}}</span>GSE12708</a>). To extend these findings and determine how 4HT might differentially affect the transcriptome of SUM44 and LCCTam cells, we performed additional gene expression microarrays on RNA extracted from SUM44 cells treated with 500 nM 4HT for 24 hours, and from LCCTam cells cultured in the absence of 4HT for 14 days. Affymetrix U133A raw data from all four experimental conditions (2 pre-existing, 2 new) were preprocessed together, and we identified genes with a fold change of &#x02265;1.45 for each pairwise comparison with a univariate p value &#x02264;0.05 (<a href="/pmc/articles/PMC5858970/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Figure 2A</span></a>). Specifically, SUM44 cells treated with 4HT were compared with untreated cells, and LCCTam grown in 4HT were compared with those removed from 4HT. As anticipated, there are fewer overall changes in gene expression in response to 4HT in LCCTam cells. The 1,980 genes that are differentially expressed in response to 4HT in both SUM44 and LCCTam are largely regulated in the same direction, and presumably represent genes that do not drive TAM-resistance, since their induction or repression by 4HT occurs despite differences in growth response between these two cell lines.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F2" co-legend-rid="lgnd_F2"><a href="/pmc/articles/PMC5858970/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139947097275936"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=5858970_nihms909796f2.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms909796f2.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC5858970/bin/nihms909796f2.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139947097275936"><a target="object" rel="noopener" href="/pmc/articles/PMC5858970/figure/F2/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F2"><div><a class="figpopup" href="/pmc/articles/PMC5858970/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2">Figure 2</a></div><!--caption a7--><div class="caption"><p>Response to 4HT differs in SUM44 and LCCTam and suggests targetable pathways of TAM-resistance. A, SUM44 cells were treated with 500 nM 4HT for 24 hours and compared with controls while LCCTam maintained in 500 nM 4HT were compared with cells that were not treated with 4HT for 2 weeks. Affymetrix probe IDs for each comparison that had a fold change of &#x02265;1.45 with a univariate p-value &#x02264;0.05 were compared. B and C, Ingenuity Pathway Analysis (IPA) of Canonical Pathways for each cell line was completed and the top 20 affected pathways are shown; those discussed in the Results section are bolded. Red denotes pathways predicted to be downregulated in response to 4HT while green denotes upregulation.</p></div></div></div><p id="P21">We then compared gene networks and pathways that are altered in response to 4HT in sensitive (SUM44) and resistant (LCCTam) cell lines using Ingenuity Pathway Analysis (IPA, <a href="/pmc/articles/PMC5858970/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Figure 2B, 2C</span></a> and <a href="#SD2" rid="SD2" class=" supplementary-material">Supplementary Tables 2</a> and <a href="#SD3" rid="SD3" class=" supplementary-material">3</a>). The PI3K/AKT pathway is differentially regulated in response to 4HT in SUM44 and LCCTam, whereby &#x0201c;PI3K/AKT Signaling&#x0201d; is increased in LCCTam in the presence of 4HT (Z score 0.7303) but decreased in SUM44 in the presence of 4HT (Z score &#x02212;0.8485) in the presence of 4HT. <em>PIK3CA</em> mutation is enriched in Luminal A ILC (<a href="#R16" rid="R16" class=" bibr popnode">Ciriello et al. 2015</a>) and a likely driver of ILC endocrine resistance that could be targeted with PI3K inhibitors (<a href="#R8" rid="R8" class=" bibr popnode">Bosch, et al. 2015</a>). Pharmacological inhibition of this pathway is critical for overcoming endocrine resistance in long-term estrogen deprived (LTED) models of AI resistance (<a href="#R74" rid="R74" class=" bibr popnode">Miller, et al. 2010</a>) and in PTEN-knockdown breast cancer cells (<a href="#R36" rid="R36" class=" bibr popnode">Fu, et al. 2014</a>), though these are all of IDC origin.</p><p id="P22" class="p p-last">Changes in gene expression seen only in SUM44 in response to 4HT should represent changes that drive growth inhibition, as this phenotype is not seen in LCCTam. &#x0201c;Aryl Hydrocarbon Receptor (AHR) Signaling&#x0201d; is the 5th most enriched pathway in SUM44, but the 26th for LCCTam. AHR signaling is repressed by 4HT in SUM44, but induced in LCCTam. Normally, AHR signals the presence of xenobiotics, but has also been implicated as important for organogenesis and the renewal of breast cancer stem-like cells (<a href="#R7" rid="R7" class=" bibr popnode">Bock and K&#x000f6;hle 2006</a>; <a href="#R97" rid="R97" class=" bibr popnode">Stanford, et al. 2016</a>). In an IDC xenograft model, TAM-resistant tumors treated with an AHR antagonist and 4HT exhibit decreased tumor growth compared with those treated with 4HT alone, or nonresistant tumors treated with an AHR antagonist (<a href="#R27" rid="R27" class=" bibr popnode">Dubrovska, et al. 2012</a>). Finally, significant differences are observed in components of the &#x0201c;Androgen Signaling&#x0201d; pathway. This pathway is the 4th most regulated pathway for the LCCTam list while it is 89th for SUM44 cells. Increased androgen receptor (AR) signaling can drive TAM-resistance in a model of IDC (<a href="#R23" rid="R23" class=" bibr popnode">De Amicis, et al. 2010</a>) and women treated with TAM have increased risk for resistance if their tumors have a high AR:ER protein expression ratio (<a href="#R17" rid="R17" class=" bibr popnode">Cochrane, et al. 2014</a>). We have previously reported that ER mRNA and protein levels are reduced in LCCTam cells (<a href="#R85" rid="R85" class=" bibr popnode">Riggins et al. 2008</a>), suggesting that LCCTam cells may have a functional increase in the AR:ER ratio that contributes to TAM resistance.</p></div><div id="S19" class="sec"><h3 id="S19title">3.3 aCGH implicates <em>MAPK1</em> amplification and <em>FOXA1</em> gain in acquisition of TAM-resistance</h3><p id="P23" class="p p-first-last">Multiple studies have identified recurrent chromosomal amplifications, gains, losses, and deletions characteristic of ILC (<a href="#R24" rid="R24" class=" bibr popnode">Desmedt et al. 2016</a>; <a href="#R42" rid="R42" class=" bibr popnode">Gruel et al. 2010</a>; <a href="#R72" rid="R72" class=" bibr popnode">Michaut et al. 2016</a>). By array comparative genomic hybridization (aCGH) we confirm that the parental SUM44 cell line has many of these features, including broad gain of chromosome 1q, losses on the p arm of chromosome 10 that encompass <em>PTEN</em>, and focal amplification of fibroblast growth factor receptor 1 (<em>FGFR1</em>) and cyclin D1 (<em>CCND1</em>) (<a href="/pmc/articles/PMC5858970/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Figure 3A</span></a> and (<a href="#R33" rid="R33" class=" bibr popnode">Forozan, et al. 1999</a>; <a href="#R102" rid="R102" class=" bibr popnode">Turner, et al. 2010</a>)). When we first established the TAM-resistant variant of SUM44 (LCCTam), we reported that there are no gross chromosomal rearrangements in LCCTam as compared to SUM44 (<a href="#R85" rid="R85" class=" bibr popnode">Riggins et al. 2008</a>). Here, we use aCGH to more finely map focal alterations that have emerged in LCCTam cells (<a href="/pmc/articles/PMC5858970/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Figure 3B, 3C</span></a>). Using two different global analysis methods (CBS and ADM-2), we identify a chromosome 22 amplification that encompasses mitogen activated protein kinase 1 (<em>MAPK1</em>, also known as extracellular signal regulated kinase 2 or ERK2) and a chromosome 8 deletion that includes CCAAT/Enhancer Binding Protein Delta (<em>CEBPD</em>). The ADM-2 method further identifies a chromosome 14 gain that includes the gene encoding forkhead box A1 (<em>FOXA1</em>). All three of these genes have been previously implicated in altered response to endocrine therapy or ER signaling in ER+ breast cancer, while <em>FOXA1</em> mutation is significantly enriched in Luminal A ILCs from TCGA (<a href="#R16" rid="R16" class=" bibr popnode">Ciriello et al. 2015</a>; <a href="#R37" rid="R37" class=" bibr popnode">Fu, et al. 2016</a>; <a href="#R48" rid="R48" class=" bibr popnode">Hurtado, et al. 2011</a>; <a href="#R70" rid="R70" class=" bibr popnode">Mendoza-Villanueva, et al. 2016</a>; <a href="#R77" rid="R77" class=" bibr popnode">Oyama, et al. 2011</a>; <a href="#R113" rid="R113" class=" bibr popnode">Wright, et al. 2014</a>). FOXA1 is a pioneer factor known to influence how ER and other steroid hormone receptors function (<a href="#R37" rid="R37" class=" bibr popnode">Fu et al. 2016</a>; <a href="#R48" rid="R48" class=" bibr popnode">Hurtado et al. 2011</a>; <a href="#R53" rid="R53" class=" bibr popnode">Jozwik and Carroll 2012</a>), including SUM44 cells, where FOXA1 motifs are highly enriched at sites of ER chromatin binding in the presence and absence of 17&#x003b2;-estradiol (<a href="#R49" rid="R49" class=" bibr popnode">Irish, et al. 2016</a>). It has been recently shown that <em>FOXA1</em> is amplified in TAM-resistant MCF7 cells and copy-number gain exists in 20% of TCGA breast tumors, especially in the Luminal B subtype (<a href="#R37" rid="R37" class=" bibr popnode">Fu et al. 2016</a>). We subsequently validated a statistically significant increase in <em>MAPK1</em> and <em>FOXA1</em> mRNA expression (<a href="/pmc/articles/PMC5858970/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Figure 3D</span></a>), as well as elevated MAPK1 (ERK2) total protein and activating phosphorylation (<a href="/pmc/articles/PMC5858970/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Figure 3E</span></a>), in the resistant LCCTam cells. Use of an insertional mutational screen in mice with Cdh1 inactivation implicated the MAPK pathway as a second hit necessary for ILC development in mouse models (<a href="#R54" rid="R54" class=" bibr popnode">Kas, et al. 2017</a>). Serine 118 of ER is a known substrate of ERK/MAPK signaling, and ER phosphorylation at this site has been implicated in poor response to TAM (<a href="#R14" rid="R14" class=" bibr popnode">Chen, et al. 2013</a>), though other studies contradict this (<a href="#R58" rid="R58" class=" bibr popnode">Kuske, et al. 2006</a>; <a href="#R75" rid="R75" class=" bibr popnode">Murphy, et al. 2004</a>). Here, we show that ER phosphorylation at Serine 118 is markedly increased in the LCCTam resistant variant, in the presence and absence of 4HT. Recently developed LTED variants of ILC, which mimic resistance to AIs, also have increased MAPK activity (<a href="#R93" rid="R93" class=" bibr popnode">Sikora, et al. 2016</a>), demonstrating MAPK pathway deregulation in multiple, independent endocrine resistant ILC models. PI3K and MAPK pathways overlap and require a delicate balance for normal growth signaling (<a href="#R3" rid="R3" class=" bibr popnode">Aksamitiene, et al. 2012</a>; <a href="#R69" rid="R69" class=" bibr popnode">Mendoza, et al. 2011</a>), and these pathways are both altered in LCCTam. Further study of their functional interaction would be helpful to determine treatment options targeting either or both. This is also relevant clinically, since primary Luminal A ILC tumors are enriched for <em>PTEN</em> loss and AKT activation as compared to IDC (<a href="#R16" rid="R16" class=" bibr popnode">Ciriello et al. 2015</a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F3" co-legend-rid="lgnd_F3"><a href="/pmc/articles/PMC5858970/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139947110344032"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=5858970_nihms909796f3.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms909796f3.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC5858970/bin/nihms909796f3.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139947110344032"><a target="object" rel="noopener" href="/pmc/articles/PMC5858970/figure/F3/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F3"><div><a class="figpopup" href="/pmc/articles/PMC5858970/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3">Figure 3</a></div><!--caption a7--><div class="caption"><p><em>MAPK1</em> amplification and <em>FOXA1</em> gain in TAM-resistant ILC cells. A, Copy number plot for parental SUM44 cell line. Log2 copy number (CN) ratios (Y axis) are shown as colored points and the circular binary segmentation (CBS)-generated segments are shown as black lines. Gains and losses characteristic of ILC are shown. B, Copy number alterations in LCCTam vs. SUM44 cells. Genes within largest amplification and deletion as determined by CBS are shown as black squares. C, Table of selected chromosome locations, cytobands, and genes showing significant amplification, gain, or deletion in LCCTam cells as determined by ADM-2. *denotes chromosome 14 gain identified only by ADM-2, whereas others were identified by both CBS and ADM-2. D, Quantitative real-time polymerase chain reaction (RTPCR) validation of increased <em>MAPK1</em> and <em>FOXA1</em> mRNA expression in LCCTam cells. Data are presented as relative expression calculated by the 2<sup>&#x02212;&#x00394;&#x00394;Ct</sup> method and are the mean of 5 biological replicates &#x000b1; standard deviation, with each biological replicate comprised of 3 technical replicates. Data were analyzed by Mann-Whitney U test. E, Western blot analysis of phosphorylated and total ERK1/2 (<em>MAPK1</em> gene = ERK2 protein), phosphorylated and total ER, and GAPDH as a loading control. LCCTam &#x02212;4HT cells were cultured in the absence of 4HT for 48 hours. Data shown are from a single representative experiment that was performed independently twice.</p></div></div></div></div><div id="S20" class="sec"><h3 id="S20title">3.4 Whole-Exome Sequencing identifies <em>NF1</em> and multiple GRM/mGluR mutations in acquired TAM-resistance</h3><p id="P24" class="p p-first">Mutations in <em>CDH1</em> are a hallmark of ILC, while those affecting <em>PIK3CA</em> and <em>FOXA1</em> are overrepresented in Luminal A ILC vs. Luminal A IDC. SUM44 cells have known loss of heterozygosity (LOH) and mutation of <em>CDH1</em> (<a href="#R104" rid="R104" class=" bibr popnode">van de, et al. 2001</a>), but aside from this and LOH/mutation of <em>TP53</em> (p53) (<a href="#R109" rid="R109" class=" bibr popnode">Wasielewski, et al. 2006</a>), the mutational status of key drivers or breast cancer-associated genes in this ILC cell line is not known. With respect to mutations that arise during progression on endocrine therapy, multiple <em>ESR1</em> (ER) mutations are increasingly appreciated as drivers of clinical resistance to AIs, and are also observed in a proportion of TAM- or Fulvestrant-resistant disease (<a href="#R13" rid="R13" class=" bibr popnode">Chandarlapaty, et al. 2016</a>; <a href="#R34" rid="R34" class=" bibr popnode">Fribbens, et al. 2016</a>; <a href="#R39" rid="R39" class=" bibr popnode">Gelsomino, et al. 2016</a>; <a href="#R43" rid="R43" class=" bibr popnode">Gyanchandani, et al. 2016</a>; <a href="#R78" rid="R78" class=" bibr popnode">Paoletti, et al. 2016</a>; <a href="#R91" rid="R91" class=" bibr popnode">Schiavon, et al. 2015</a>; <a href="#R96" rid="R96" class=" bibr popnode">Spoerke, et al. 2016</a>; <a href="#R108" rid="R108" class=" bibr popnode">Wang, et al. 2016</a>). However, none of these studies have specifically examined ILC.</p><p id="P25">We performed whole-exome sequencing (WES) analysis of SUM44 and LCCTam cells to identify mutations that arise during acquisition of TAM-resistance. Both the parental SUM44 and resistant variant LCCTam contain wild type <em>ESR1</em>, <em>ERBB2</em> (HER2), and <em>FOXA1</em>, and maintain their previously reported <em>CDH1</em> and <em>TP53</em> mutations (<a href="#SD6" rid="SD6" class=" supplementary-material">Supplementary Table 4</a>). Comparison of LCCTam to SUM44 cells identifies one hundred eighty (180) unique predicted protein- or splice site-altering mutations in one hundred fifty two (152) unique genes (<a href="/pmc/articles/PMC5858970/figure/F4/" target="figure" class="fig-table-link figpopup" rid-figpopup="F4" rid-ob="ob-F4" co-legend-rid="lgnd_F4"><span>Figure 4A</span></a>). The distribution of mutations is not uniform, with chromosomes 16 and 17 having more and chromosomes 10 and 13 having fewer mutations per megabase (Mb) of chromosome length than predicted. We focused on three specific mutations (<a href="/pmc/articles/PMC5858970/figure/F4/" target="figure" class="fig-table-link figpopup" rid-figpopup="F4" rid-ob="ob-F4" co-legend-rid="lgnd_F4"><span>Figure 4B</span></a>). A splice-disrupting mutation is present in exon 43 of Neurofibromin 1 (<em>NF1</em>), a tumor suppressor that is a key negative regulator of the Ras/MAPK pathway, and while NF1 is frequently mutated in sporadic breast cancers (<a href="#R81" rid="R81" class=" bibr popnode">Philpott, et al. 2017</a>), its role in ILC is not fully understood. We confirm that <em>NF1</em> mRNA is expressed in both cell lines (<a href="/pmc/articles/PMC5858970/figure/F4/" target="figure" class="fig-table-link figpopup" rid-figpopup="F4" rid-ob="ob-F4" co-legend-rid="lgnd_F4"><span>Figure 4C</span></a>). Phenotypically, these data are consistent with our aCGH, PCR, and Western blot results in <a href="/pmc/articles/PMC5858970/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Figure 3</span></a> (where we show that MAPK pathway activation is deregulated in LCCTam cells) and with prior studies that implicate <em>NF1</em> loss or mutation with reduced efficacy of endocrine therapy or poor prognostic factors, respectively (<a href="#R68" rid="R68" class=" bibr popnode">Mendes-Pereira, et al. 2012</a>; <a href="#R103" rid="R103" class=" bibr popnode">Uusitalo, et al. 2017</a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F4" co-legend-rid="lgnd_F4"><a href="/pmc/articles/PMC5858970/figure/F4/" target="figure" rid-figpopup="F4" rid-ob="ob-F4"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139947110856496"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=5858970_nihms909796f4.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms909796f4.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC5858970/bin/nihms909796f4.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139947110856496"><a target="object" rel="noopener" href="/pmc/articles/PMC5858970/figure/F4/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F4"><div><a class="figpopup" href="/pmc/articles/PMC5858970/figure/F4/" target="figure" rid-figpopup="F4" rid-ob="ob-F4">Figure 4</a></div><!--caption a7--><div class="caption"><p><em>NF1</em> and multiple GRMs/mGluRs are mutated in TAM-resistant ILC cells. A, Distribution of mutations in LCCTam cells by chromosome. Number of mutations per chromosome were analyzed in relation to chromosome length in megabases (Mb) by linear regression analysis. Dashed lines represent the 90%, 95%, and 99% confidence intervals. Red points denote chromosomes (numbers shown) with a greater than expected number of mutations, while green points denote those with fewer than expected. B, Table of selected chromosome locations, exons, alterations, and predicted functional consequences for genes mutated in LCCTam cells. C, Quantitative RTPCR validation of <em>NF1</em> mRNA expression in LCCTam cells. Data are presented as relative expression calculated by the 2<sup>&#x02212;&#x00394;&#x00394;Ct</sup> method and are the mean of 5 biological replicates &#x000b1; standard deviation, with each biological replicate comprised of 3 technical replicates. Data were analyzed by Mann-Whitney U test. D, Lollipop plot showing location of <em>GRM1</em> mutations in Luminal A ILC from the TCGA dataset, and the A229E mutation detected in LCCTam cells. Green denotes missense and black denotes nonsense mutations. Positions of the extracellular ligand (glutamate) binding domain (green rectangle) and 7-pass transmembrane domain (7Tm, blue rectangle) are shown. E, GRM1 protein expression in SUM44 and LCCTam cells by fluorescent immunocytochemistry. Negative staining control = no Ab (no primary antibody). Data shown are from a single representative experiment that was performed independently twice. F, Quantitative RTPCR validation of <em>GRM2</em> mRNA expression in LCCTam cells. Data are presented as relative expression calculated by the 2<sup>&#x02212;&#x00394;&#x00394;Ct</sup> method and are the mean of 3 biological replicates &#x000b1; standard deviation, with each biological replicate comprised of 3 technical replicates. Data were analyzed by Mann-Whitney U test. G, Multiple GRMs/mGluRs are upregulated in LCCTam cells. Affymetrix gene expression microarray data are presented as mean fold change (increase) in LCCTam &#x02212;4HT vs. SUM44 cells for three biological replicates compared by unpaired t test.</p></div></div></div><p id="P26" class="p p-last">We further identify missense mutations in two members of the GRM/mGluR family, <em>GRM1</em> on chromosome 6 and <em>GRM2</em> on chromosome 3 (<a href="/pmc/articles/PMC5858970/figure/F4/" target="figure" class="fig-table-link figpopup" rid-figpopup="F4" rid-ob="ob-F4" co-legend-rid="lgnd_F4"><span>Figure 4B</span></a>). These members of the G-protein coupled receptor (GPCR) superfamily are key players in normal and pathologic neurologic function, and there is a growing appreciation of their contribution to cancer (<a href="#R32" rid="R32" class=" bibr popnode">Feigin 2013</a>). The <em>GRM1</em> A229E and <em>GRM2</em> I315V mutations found in LCCTam cells reside in the extracellular glutamate binding regions of the receptors (<a href="/pmc/articles/PMC5858970/figure/F4/" target="figure" class="fig-table-link figpopup" rid-figpopup="F4" rid-ob="ob-F4" co-legend-rid="lgnd_F4"><span>Figure 4D</span></a> for <em>GRM1</em>). In TCGA, <em>GRM1</em> mutations occur at a greater frequency in primary Luminal A ILC tumors (3%, <a href="/pmc/articles/PMC5858970/figure/F4/" target="figure" class="fig-table-link figpopup" rid-figpopup="F4" rid-ob="ob-F4" co-legend-rid="lgnd_F4"><span>Figure 4D</span></a>) than primary Luminal A IDC tumors (0.5%, &#x003c7;<sup>2</sup> = 0.08), while <em>GRM2</em> mutations are not observed in ILC. By fluorescent immunocytochemistry, mGluR1/GRM1 protein expression is markedly upregulated in LCCTam cells (<a href="/pmc/articles/PMC5858970/figure/F4/" target="figure" class="fig-table-link figpopup" rid-figpopup="F4" rid-ob="ob-F4" co-legend-rid="lgnd_F4"><span>Figure 4E</span></a>), while mRNA for GRM2 and five (5) other GRM family genes are increased in LCCTam cells (<a href="/pmc/articles/PMC5858970/figure/F4/" target="figure" class="fig-table-link figpopup" rid-figpopup="F4" rid-ob="ob-F4" co-legend-rid="lgnd_F4"><span>Figure 4F, 4G</span></a>). There is precedent for a functional interaction between <em>GRM1</em>, <em>GRM2</em> and <em>GRM4</em> and loss of <em>CDH1</em>, a hallmark of ILC. (<a href="#R100" rid="R100" class=" bibr popnode">Telford, et al. 2015</a>) used a genome-wide small inhibitory ribonucleic acid (siRNA) library in isogenic mammary epithelial cells &#x02013; wild type vs. <em>CDH1</em>-deleted &#x02013; to identify synthetic lethal vulnerabilities in cells lacking <em>CDH1.</em> The most enriched functional category that preferentially inhibits <em>CDH1</em>-null cell viability (when silenced) contains &#x0003e;200 genes that code for GPCR signaling components, including these three GRMs/mGluRs. Finally, high expression of GRM1, GRM2, or GRM4 mRNA is each associated with poor distant-metastasis free survival in women with ER+ breast cancer treated with TAM, independent of lobular histology ((<a href="#R67" rid="R67" class=" bibr popnode">Mehta, et al. 2013</a>) and <a href="#SD5" rid="SD5" class=" supplementary-material">Supplementary Figure 2</a>). However, mechanistic studies of GRM/mGluR function in breast cancer have largely focused on the triple negative or basal type (<a href="#R5" rid="R5" class=" bibr popnode">Banda, et al. 2014</a>; <a href="#R99" rid="R99" class=" bibr popnode">Teh, et al. 2015</a>). Altogether these data suggest multiple GRMs/mGluRs as potential players in TAM-resistant breast tumors, including ILC.</p></div><div id="S21" class="sec sec-last"><h3 id="S21title">3.5 MEK or glutamate release inhibitors restore or enhance endocrine response in SUM44/LCCTam cells</h3><p id="P27" class="p p-first">Hyperactivation of the MAPK/ERK cascade is a common feature of endocrine resistance in ER+ breast cancer patients (<a href="#R89" rid="R89" class=" bibr popnode">Rugo et al. 2016</a>) and preclinical models (<a href="#R20" rid="R20" class=" bibr popnode">Creighton, et al. 2006</a>; <a href="#R86" rid="R86" class=" bibr popnode">Riggins, et al. 2007</a>). Here, we identify <em>NF1</em> mutation and downregulation, <em>MAPK1</em> amplification and upregulation, and increased MAPK substrate phosphorylation (ER Serine 118) in TAM-resistant ILC cells. MAPK activity is also increased in ILC-derived LTED cells, a model for resistance to AIs (<a href="#R93" rid="R93" class=" bibr popnode">Sikora et al. 2016</a>). Accordingly, U0126 &#x02013; a potent and selective MEK inhibitor chemical probe (<a href="#R28" rid="R28" class=" bibr popnode">Duncia, et al. 1998</a>) known to enhance TAM responsiveness (<a href="#R26" rid="R26" class=" bibr popnode">Donovan, et al. 2001</a>; <a href="#R56" rid="R56" class=" bibr popnode">Kronblad, et al. 2005</a>; <a href="#R57" rid="R57" class=" bibr popnode">Kurokawa, et al. 2000</a>) &#x02013; suppresses MAPK/ERK phosphorylation in ILC cells (<a href="/pmc/articles/PMC5858970/figure/F5/" target="figure" class="fig-table-link figpopup" rid-figpopup="F5" rid-ob="ob-F5" co-legend-rid="lgnd_F5"><span>Figure 5A</span></a>), and is additive or better-than-additive in combination with TAM in suppressing the growth of responsive (SUM44) or resistant (LCCTam) ILC cells, respectively (<a href="/pmc/articles/PMC5858970/figure/F5/" target="figure" class="fig-table-link figpopup" rid-figpopup="F5" rid-ob="ob-F5" co-legend-rid="lgnd_F5"><span>Figure 5B</span></a>). U0126 does not confer TAM response to ER-negative MDA-MB-231 cells (<a href="/pmc/articles/PMC5858970/figure/F5/" target="figure" class="fig-table-link figpopup" rid-figpopup="F5" rid-ob="ob-F5" co-legend-rid="lgnd_F5"><span>Figure 5B</span></a>), suggesting that interaction between MEK inhibition and TAM requires ER.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F5" co-legend-rid="lgnd_F5"><a href="/pmc/articles/PMC5858970/figure/F5/" target="figure" rid-figpopup="F5" rid-ob="ob-F5"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139947107846992"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=5858970_nihms909796f5.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms909796f5.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC5858970/bin/nihms909796f5.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139947107846992"><a target="object" rel="noopener" href="/pmc/articles/PMC5858970/figure/F5/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F5"><div><a class="figpopup" href="/pmc/articles/PMC5858970/figure/F5/" target="figure" rid-figpopup="F5" rid-ob="ob-F5">Figure 5</a></div><!--caption a7--><div class="caption"><p>The MEK inhibitor U0126 or the glutamate release inhibitor Riluzole enhances or restores endocrine response in ILC cells. A, MEK inhibitor U0126 suppresses ERK phosphorylation. Cells were treated as indicated for 48 hours prior to Western blot analysis for phosphorylated ERK1/2 (<em>MAPK1</em> gene = ERK2 protein), and &#x003b2;-actin as a loading control. Data shown are from a single representative experiment. B, Crystal violet cell proliferation assays conducted for 10 days (SUM44, LCCTam) or 6 days (MDA-MB-231) in the presence of the indicated concentrations of 4HT and/or U0126. Media were changed twice (SUM44, LCCTam) or once (MDA-MB-231) during the course of the experiment. Data are presented as mean relative cell number &#x000b1; standard deviation for 5&#x02013;6 technical replicates from an independent experiment performed at least twice. Data were analyzed by two-way ANOVA with post hoc Bonferroni correction. Relative index (RI) values = 1 are additive, &#x0003e; 1 are synergistic. C, Crystal violet proliferation assays conducted for 8 days in the presence of 1 &#x003bc;M Fulvestrant (ICI), 10 &#x003bc;M Riluzole (RIL), or the combination (Combo). Media were changed once during the course of the experiment. Data are presented as mean % survival for 5&#x02013;6 technical replicates from an independent experiment performed three times. Data were analyzed by two-way ANOVA with post hoc Tukey&#x02019;s test. Relative index (RI) values = 1 are additive, &#x0003e; 1 are synergistic. D, Expression of ER protein in SUM44 and LCCTam cells following 24 hours treatment with the indicated concentrations of Riluzole (RIL) alone or in combination with 1 &#x003bc;M Fulvestrant (ICI), with &#x003b2;-actin as a loading control. Data shown are from a single representative experiment performed independently three times.</p></div></div></div><p id="P28" class="p p-last">The clinical efficacy of MEK inhibitors is unfortunately quite variable, even in malignancies like non-small cell lung cancer and melanoma where mutations in MAPK/ERK pathway components are very common (<a href="#R9" rid="R9" class=" bibr popnode">Brant, et al. 2016</a>). These drugs also have frequent dose-limiting toxicities. An attractive alternative to MEK inhibition as a therapeutic strategy in ER+ ILC may be inhibition of GRMs/mGluRs. Multiple GRMs upregulated in LCCTam cells (<a href="/pmc/articles/PMC5858970/figure/F4/" target="figure" class="fig-table-link figpopup" rid-figpopup="F4" rid-ob="ob-F4" co-legend-rid="lgnd_F4"><span>Figure 4G</span></a>) are transducers of pro-proliferative glutamate signaling (<a href="#R32" rid="R32" class=" bibr popnode">Feigin 2013</a>; <a href="#R112" rid="R112" class=" bibr popnode">Willard and Koochekpour 2013</a>; <a href="#R114" rid="R114" class=" bibr popnode">Yu, et al. 2016</a>), and <em>GRM1</em> mutations can lead to hyperactivation of the MAPK pathway in response to paracrine or autocrine glutamate (<a href="#R30" rid="R30" class=" bibr popnode">Esseltine, et al. 2013</a>). Riluzole (Rilutek, RIL) is a broad-spectrum glutamate release inhibitor that can inhibit paracrine or autocrine signaling through multiple GRM family members (<a href="#R2" rid="R2" class=" bibr popnode">Abushahba, et al. 2012</a>; <a href="#R65" rid="R65" class=" bibr popnode">Martino, et al. 2013</a>; <a href="#R111" rid="R111" class=" bibr popnode">Wen, et al. 2014</a>), and has preclinical efficacy in several different cancer models (<a href="#R95" rid="R95" class=" bibr popnode">Speyer, et al. 2016</a>; <a href="#R99" rid="R99" class=" bibr popnode">Teh et al. 2015</a>; <a href="#R114" rid="R114" class=" bibr popnode">Yu et al. 2016</a>). We therefore tested RIL&#x02019;s ability to inhibit ILC cell growth alone or in combination with endocrine therapy. RIL has single agent growth-inhibitory activity and is significantly better than additive in combination with Fulvestrant (ICI), a selective estrogen receptor degrader (SERD) in both cell lines (<a href="/pmc/articles/PMC5858970/figure/F5/" target="figure" class="fig-table-link figpopup" rid-figpopup="F5" rid-ob="ob-F5" co-legend-rid="lgnd_F5"><span>Figure 5C</span></a>). RIL alone has no effect on ER expression, nor does it modify downregulation of ER by ICI (<a href="/pmc/articles/PMC5858970/figure/F5/" target="figure" class="fig-table-link figpopup" rid-figpopup="F5" rid-ob="ob-F5" co-legend-rid="lgnd_F5"><span>Figure 5D</span></a>). Together these data show that perturbation of two different actionable alterations identified in this study (<em>MAPK</em> amplification and hyperactivation, GRM/mGluR mutation and upregulation) are effective against TAM-resistant and responsive ILC cells. These data also provide (to our knowledge) the first preclinical proof of concept for the combination of RIL with endocrine therapy in ER+ breast cancer, and specifically ILC.</p></div></div><div id="S22" class="tsec sec"><h2 class="head no_bottom_margin" id="S22title">Conclusions and Future Directions</h2><p id="P29" class="p p-first">A comprehensive analysis of genetic alterations in a preclinical model of TAM-resistant ILC provides an opportunity to identify novel pathways of resistance, ultimately leading to better treatment options for patients. We completed Affymetrix gene expression arrays, Agilent aCGH, and Illumina WES on the parental SUM44 and TAM-resistant LCCTam cell lines to gain insight into similarities and differences in affected pathways across all three platforms.</p><p id="P30">Analysis of AHR ChIPseq data shows enrichment of a consensus <em>FOXA1</em> binding motif in MCF7 cells (<a href="#R62" rid="R62" class=" bibr popnode">Lo and Matthews 2012</a>). <em>FOXA1</em> mutation is a defining feature of Luminal A ILC (<a href="#R16" rid="R16" class=" bibr popnode">Ciriello et al. 2015</a>), and in LCCTam cells we report <em>FOXA1</em> gain and increased mRNA expression, although its sequence is wild type based on our WES data. Altogether, these data suggest that further study of the cross talk between <em>FOXA1</em> and AHR in this and other ILC models is warranted. In prostate cancer, FOXA1 directs where AR binds in the genome (<a href="#R90" rid="R90" class=" bibr popnode">Sahu, et al. 2011</a>; <a href="#R106" rid="R106" class=" bibr popnode">Wang, et al. 2011</a>), and in a TNBC AR-positive cell line, AR binding sites almost completely overlap with FOXA1 (<a href="#R87" rid="R87" class=" bibr popnode">Robinson, et al. 2011</a>). While AR signaling is predicted to be upregulated in LCCTam, knowledge of how FOXA1 influences AR signaling in ILC requires further study. Therapies targeting FOXA1 in breast cancer are in early stages of development, and may prove useful in the treatment of ILC as they mature (<a href="#R52" rid="R52" class=" bibr popnode">Johnston, et al. 2016</a>).</p><p id="P31">Multiple alterations in copy number, sequence, and mRNA or protein expression acquired by LCCTam cells impinge on the MAPK/ERK signaling network, including <em>MAPK1</em> amplification, upregulation, and hyperactivation, as well as <em>NF1</em> mutation and downregulation. Functional validation further shows that MEK inhibition by U0126 improves or restores TAM response in SUM44 and LCCTam cells. These data suggest that MAPK deregulation is a core feature of the TAM resistant phenotype of LCCTam cells, but we cannot rule out the potential contributions of other alterations detected by aCGH and/or WES. For example, LCCTam cells have acquired a frameshift deletion mutation in X-box binding protein 1 (<em>XBP1</em>, c.333delA, K111fs). <em>XBP1</em> is a known mediator of endocrine resistance (<a href="#R22" rid="R22" class=" bibr popnode">Davies, et al. 2008</a>; <a href="#R41" rid="R41" class=" bibr popnode">Gomez et al. 2007</a>; <a href="#R47" rid="R47" class=" bibr popnode">Hu, et al. 2015</a>) and, if translated, this truncated XBP1 protein product would encode the first 111 amino acids, which contain the region required for binding and activating ER in the absence of estrogen (<a href="#R25" rid="R25" class=" bibr popnode">Ding, et al. 2003</a>). Whether this mutant <em>XBP1</em> may contribute to TAM resistance in LCCTam cells requires further study.</p><p id="P32">In the TCGA dataset <em>GRM1</em> mutations are more prevalent in primary Luminal A ILC than IDC, and most somatic <em>GRM1</em> mutations lead to hyperactivation of the MAPK pathway in response to glutamate (<a href="#R30" rid="R30" class=" bibr popnode">Esseltine et al. 2013</a>)et al., 2013). Here, we show that multiple members of the GRM/mGluR family are mutated and/or upregulated at the mRNA and protein level in LCCTam cells. The most novel finding of our study is that RIL, a broad-spectrum glutamate release inhibitor that inhibits paracrine or autocrine signaling through multiple GRM family members, has significant single-agent and combinatorial activity with ICI in TAM-responsive and &#x02013;resistant ILC cells. RIL&#x02019;s activity in other breast cancer models is not specifically dependent upon GRM1, since silencing or overexpression of GRM1 does not alter RIL-mediated growth inhibition (<a href="#R95" rid="R95" class=" bibr popnode">Speyer et al. 2016</a>). This is in contrast to RIL efficacy in melanoma, which is tightly associated with GRM1 expression. It may be that multiple GRM/mGluR family members are required to transduce RIL&#x02019;s anti-proliferative effect in breast cancer, an attractive idea given that our data show multiple GRMs/mGluRs are simultaneously mutated and/or upregulated in TAM-resistant ILC cells. RIL is currently FDA approved for slowing the progression of Amyotrophic Lateral Sclerosis (ALS), and in Phase 1 clinical trials for melanoma (<a id="__tag_706920059" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT01303341" ref="reftype=extlink-clinical-trial&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT01303341","term_id":"NCT01303341"}}</span>NCT01303341</a>). RIL is also the subject of a Phase 4 study testing its ability to inhibit inflammation-associated fatigue and cognitive dysfunction in breast cancer survivors by lowering levels of glutamate in the central nervous system (<a id="__tag_706920061" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT02796755" ref="reftype=extlink-clinical-trial&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT02796755","term_id":"NCT02796755"}}</span>NCT02796755</a>). Our data provide novel evidence supporting the rational combination of RIL with endocrine agents, specifically in ILC where there already appears to be a GRM/mGluR dependency in the presence of <em>CDH1</em> loss (<a href="#R100" rid="R100" class=" bibr popnode">Telford et al. 2015</a>). The extensive pre-existing clinical experience with RIL in other disease settings makes repurposing this drug for endocrine resistant, ER+ breast cancer, and in particular ILC, a viable strategy to improve treatment outcomes in the near term.</p><p id="P33" class="p p-last">There remains a lack of clear consensus whether patients with ILC have a worse outcome than patients with IDC (<a href="#R10" rid="R10" class=" bibr popnode">Brouckaert, et al. 2014</a>; <a href="#R18" rid="R18" class=" bibr popnode">Colleoni, et al. 2012</a>; <a href="#R35" rid="R35" class=" bibr popnode">Fritz, et al. 2010</a>; <a href="#R80" rid="R80" class=" bibr popnode">Pestalozzi et al. 2008</a>). What is clear is that IDC and ILC have distinct molecular signaling and treatment regimens should consider these histologic subtypes as distinct (<a href="#R35" rid="R35" class=" bibr popnode">Fritz et al. 2010</a>; <a href="#R110" rid="R110" class=" bibr popnode">Weigelt, et al. 2010</a>). ILC tumors are more commonly ER+ (<a href="#R80" rid="R80" class=" bibr popnode">Pestalozzi et al. 2008</a>), historically suggesting endocrine therapies should be beneficial for these patients. However, recent retrospective studies now show that patients with ILC do not fare as well on TAM (<a href="#R71" rid="R71" class=" bibr popnode">Metzger Filho et al. 2015</a>) or exemestane (<a href="#R98" rid="R98" class=" bibr popnode">Strasser-Weippl et al. 2016</a>) as compared to those with IDC. Two ongoing prospective clinical trials seek to clarify which endocrine therapy is most effective for ER+ ILC. The first, <a id="__tag_706920060" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT02206984" ref="reftype=extlink-clinical-trial&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT02206984","term_id":"NCT02206984"}}</span>NCT02206984</a>, is a neoadjuvant window trial comparing 21&#x02013;24 days of Fulvestrant, TAM, or Anastrazole in women with ER+, HER2&#x02212; ILC. The second, <a id="__tag_706920058" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT02764541" ref="reftype=extlink-clinical-trial&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT02764541","term_id":"NCT02764541"}}</span>NCT02764541</a>, is a perioperative study in which the neoadjuvant phase will compare 15 days of Letrozole to TAM in cohorts of women with either ER+ ILC or IDC; in the adjuvant phase, women will continue on endocrine therapy with or without the addition of the CDK4/6 inhibitor palbociclib. In each study, the primary objective is to determine change in proliferation (Ki67) pre- and post-neoadjuvant treatment, with secondary objectives that include assessments of ER, ER-regulated genes and other measures with the goal of identifying markers of endocrine response and resistance unique to ILC. Coupled with our preclinical models and those of others in the field (<a href="#R51" rid="R51" class=" bibr popnode">Jambal, et al. 2013</a>; <a href="#R92" rid="R92" class=" bibr popnode">Sikora, et al. 2014</a>; <a href="#R93" rid="R93" class=" bibr popnode">Sikora et al. 2016</a>), these efforts should identify a number of actionable alterations that can be targeted to improve therapeutic outcomes for women with ER+ ILC</p></div><div id="unreferenced-ft" class="tsec sec"><div class="unreferenced">​
                    <div class="boxed-text-box whole_rhythm hide-overflow" id="BX1"><div class="caption"><h3 id="caption-a.w.g.atitle">Highlights</h3></div><ul class="unordered" style="list-style-type:disc" id="L1"><li><div id="P34">ILC is an understudied breast cancer subtype with a relatively poor response to TAM</div></li><li><div id="P35">In TAM-resistant ILC cells, TAM treatment is associated with activation of <em>PIK3CA</em>, <em>AHR</em>, and androgen signaling</div></li><li><div id="P36">TAM-resistant ILC cells show <em>MAPK1</em> amplification and hyperactivation, <em>FOXA1</em> gain, and <em>CEBPD</em> loss</div></li><li><div id="P37">TAM-resistant ILC cells are characterized by mutation of <em>NF1</em> and multiple GRMs/mGluRs</div></li><li><div id="P38">Inhibition of MEK or glutamate release using Riluzole improves and restores endocrine therapy response in ILC cells</div></li></ul></div></div></div><div id="S24" class="tsec sec"><a id="supplementary-material-sec"></a><h2 class="head no_bottom_margin" id="S24title">Supplementary Material</h2><!--/article/body/sec/--><div class="sec suppmat" id="SD1"><h4>1</h4><div class="sup-box half_rhythm" id="d36e1271"><a href="/pmc/articles/PMC5858970/bin/NIHMS909796-supplement-1.xlsx" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(14K, xlsx)</sup></div></div><div class="sec suppmat" id="SD2"><h4>10</h4><div class="sup-box half_rhythm" id="d36e1275"><a href="/pmc/articles/PMC5858970/bin/NIHMS909796-supplement-10.xlsx" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(35K, xlsx)</sup></div></div><div class="sec suppmat" id="SD3"><h4>11</h4><div class="sup-box half_rhythm" id="d36e1279"><a href="/pmc/articles/PMC5858970/bin/NIHMS909796-supplement-11.xlsx" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(9.4K, xlsx)</sup></div></div><div class="sec suppmat" id="SD4"><h4>2</h4><div class="sup-box half_rhythm" id="d36e1283"><a href="/pmc/articles/PMC5858970/bin/NIHMS909796-supplement-2.tif" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(16M, tif)</sup></div></div><div class="sec suppmat" id="SD5"><h4>3</h4><div class="sup-box half_rhythm" id="d36e1287"><a href="/pmc/articles/PMC5858970/bin/NIHMS909796-supplement-3.tif" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(19M, tif)</sup></div></div><div class="sec suppmat" id="SD6"><h4>4</h4><div class="sup-box half_rhythm" id="d36e1291"><a href="/pmc/articles/PMC5858970/bin/NIHMS909796-supplement-4.pdf" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(153K, pdf)</sup></div></div><div class="sec suppmat" id="SD7"><h4>5</h4><div class="sup-box half_rhythm" id="d36e1295"><a href="/pmc/articles/PMC5858970/bin/NIHMS909796-supplement-5.docx" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(74K, docx)</sup></div></div><div class="sec suppmat" id="SD8"><h4>6</h4><div class="sup-box half_rhythm" id="d36e1299"><a href="/pmc/articles/PMC5858970/bin/NIHMS909796-supplement-6.tif" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(16M, tif)</sup></div></div><div class="sec suppmat" id="SD9"><h4>7</h4><div class="sup-box half_rhythm" id="d36e1303"><a href="/pmc/articles/PMC5858970/bin/NIHMS909796-supplement-7.tif" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(16M, tif)</sup></div></div><div class="sec suppmat" id="SD10"><h4>8</h4><div class="sup-box half_rhythm" id="d36e1307"><a href="/pmc/articles/PMC5858970/bin/NIHMS909796-supplement-8.xlsx" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(61K, xlsx)</sup></div></div><div class="sec suppmat" id="SD11"><h4>9</h4><div class="sup-box half_rhythm" id="d36e1312"><a href="/pmc/articles/PMC5858970/bin/NIHMS909796-supplement-9.xlsx" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(36K, xlsx)</sup></div></div></div><div id="S25" class="tsec sec"><h2 class="head no_bottom_margin" id="S25title">Acknowledgments</h2><div class="sec"><p>We are grateful to C. Savio Chan, Aileen Fernandez, Britta Jacobsen, Michael Johnson, Filipa Lynce, Raquel Nunes, Matthew Sikora, Deanna Tiek, and members of the Georgetown Breast Cancer Advocates (<a href="https://breastcanceradvocacy.georgetown.edu" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">https://breastcanceradvocacy.georgetown.edu</a>) for their insights and/or critical reading of the manuscript. We would also like to thank Peter Johnson (MISR) and Dionyssia Clagett (TCSR) for technical assistance.</p><p><strong>Funding Sources</strong></p><p>These studies were supported in part by a Career Catalyst Research Grant from Susan G. Komen for the Cure (KG090187) to RBR, by pilot and start-up funds to RBR from the Lombardi Comprehensive Cancer Center (LCCC) Support Grant (P30-CA-051008; Principal Investigator Louis M. Weiner), U54-CA-149147 (Principal Investigator Robert Clarke) and HHSN2612200800001E (co-Program Directors Robert Clarke and Subha Madhavan), as well as by a Department of Defense Breast Cancer Research Program Breakthrough Award (W81XWH-14-1-0326) to XF. This work was also generously supported by funds from Georgetown Lombardi Women &#x00026; Wine, a philanthropic group that supports research at the Nina Hyde Center for Breast Cancer Research. HS and MMH were supported by the LCCC&#x02019;s Training Grant in Tumor Biology (T32-CA-009686; Principal Investigator Anna T. Riegel). MMH was also supported by the LCCC&#x02019;s Post Baccalaureate Training in Breast Cancer Health Disparities Research grant (PBTDR12228366; Principal Investigator Lucile L. Adams-Campbell). Technical services were provided by the LCCC Genomics &#x00026; Epigenomics Shared Resource (GESR), Microscopy and Imaging Shared Resource (MISR) and Tissue Culture Shared Resource (TCSR), which are also supported in part by P30-CA-051008. The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute, the National Institutes of Health, Susan G. Komen for the Cure, or the Department of Defense Breast Cancer Research Program.</p></div></div><div id="fn-group-a.v.b" class="tsec sec"><h2 class="head no_bottom_margin" id="fn-group-a.v.btitle">Footnotes</h2><!--back/fn-group--><div class="fm-sec half_rhythm small"><p class="fn sec" id="FN2"><p class="p p-first-last"><strong>Publisher's Disclaimer: </strong>This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.</p></p></div></div><div id="ref-list-a.v.c" class="tsec sec"><h2 class="head no_bottom_margin" id="ref-list-a.v.ctitle">References</h2><div class="ref-list-sec sec" id="reference-list"><ul class="back-ref-list" style="list-style-type:decimal;"><li id="R1"><span class="element-citation">Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, Kang HM, Marth GT, McVean GA Consortium GP. An integrated map of genetic variation from 1,092 human genomes. <span><span class="ref-journal">Nature. </span>2012;<span class="ref-vol">491</span>:56–65.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3498066/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23128226" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=An+integrated+map+of+genetic+variation+from+1,092+human+genomes&amp;author=GR+Abecasis&amp;author=A+Auton&amp;author=LD+Brooks&amp;author=MA+DePristo&amp;author=RM+Durbin&amp;volume=491&amp;publication_year=2012&amp;pages=56-65&amp;pmid=23128226&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R2"><span class="element-citation">Abushahba W, Olabisi OO, Jeong BS, Boregowda RK, Wen Y, Liu F, Goydos JS, Lasfar A, Cohen-Solal KA. Non-canonical Smads phosphorylation induced by the glutamate release inhibitor, riluzole, through GSK3 activation in melanoma. <span><span class="ref-journal">PLoS One. </span>2012;<span class="ref-vol">7</span>:e47312.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3470581/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23077590" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=PLoS+One&amp;title=Non-canonical+Smads+phosphorylation+induced+by+the+glutamate+release+inhibitor,+riluzole,+through+GSK3+activation+in+melanoma&amp;author=W+Abushahba&amp;author=OO+Olabisi&amp;author=BS+Jeong&amp;author=RK+Boregowda&amp;author=Y+Wen&amp;volume=7&amp;publication_year=2012&amp;pages=e47312&amp;pmid=23077590&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R3"><span class="element-citation">Aksamitiene E, Kiyatkin A, Kholodenko BN. Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance. <span><span class="ref-journal">Biochem Soc Trans. </span>2012;<span class="ref-vol">40</span>:139–146.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22260680" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biochem+Soc+Trans&amp;title=Cross-talk+between+mitogenic+Ras/MAPK+and+survival+PI3K/Akt+pathways:+a+fine+balance&amp;author=E+Aksamitiene&amp;author=A+Kiyatkin&amp;author=BN+Kholodenko&amp;volume=40&amp;publication_year=2012&amp;pages=139-146&amp;pmid=22260680&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R4"><span class="element-citation">Azim HA, Davidson NE, Ruddy KJ. Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer. <span><span class="ref-journal">Am Soc Clin Oncol Educ Book. </span>2016;<span class="ref-vol">35</span>:23–32.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27249683" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+Soc+Clin+Oncol+Educ+Book&amp;title=Challenges+in+Treating+Premenopausal+Women+with+Endocrine-Sensitive+Breast+Cancer&amp;author=HA+Azim&amp;author=NE+Davidson&amp;author=KJ+Ruddy&amp;volume=35&amp;publication_year=2016&amp;pages=23-32&amp;pmid=27249683&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R5"><span class="element-citation">Banda M, Speyer CL, Semma SN, Osuala KO, Kounalakis N, Torres Torres KE, Barnard NJ, Kim HJ, Sloane BF, Miller FR, et al. Metabotropic glutamate receptor-1 contributes to progression in triple negative breast cancer. <span><span class="ref-journal">PLoS One. </span>2014;<span class="ref-vol">9</span>:e81126.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3880256/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24404125" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=PLoS+One&amp;title=Metabotropic+glutamate+receptor-1+contributes+to+progression+in+triple+negative+breast+cancer&amp;author=M+Banda&amp;author=CL+Speyer&amp;author=SN+Semma&amp;author=KO+Osuala&amp;author=N+Kounalakis&amp;volume=9&amp;publication_year=2014&amp;pages=e81126&amp;pmid=24404125&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R6"><span class="element-citation">Barroso-Sousa R, Metzger-Filho O. Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implications. <span><span class="ref-journal">Ther Adv Med Oncol. </span>2016;<span class="ref-vol">8</span>:261–266.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4952020/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27482285" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Ther+Adv+Med+Oncol&amp;title=Differences+between+invasive+lobular+and+invasive+ductal+carcinoma+of+the+breast:+results+and+therapeutic+implications&amp;author=R+Barroso-Sousa&amp;author=O+Metzger-Filho&amp;volume=8&amp;publication_year=2016&amp;pages=261-266&amp;pmid=27482285&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R7"><span class="element-citation">Bock KW, K&#x000f6;hle C. Ah receptor: dioxin-mediated toxic responses as hints to deregulated physiologic functions. <span><span class="ref-journal">Biochem Pharmacol. </span>2006;<span class="ref-vol">72</span>:393–404.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16545780" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biochem+Pharmacol&amp;title=Ah+receptor:+dioxin-mediated+toxic+responses+as+hints+to+deregulated+physiologic+functions&amp;author=KW+Bock&amp;author=C+K&#x000f6;hle&amp;volume=72&amp;publication_year=2006&amp;pages=393-404&amp;pmid=16545780&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R8"><span class="element-citation">Bosch A, Li Z, Bergamaschi A, Ellis H, Toska E, Prat A, Tao JJ, Spratt DE, Viola-Villegas NT, Castel P, et al. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. <span><span class="ref-journal">Sci Transl Med. </span>2015;<span class="ref-vol">7</span>:283ra251.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4433148/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25877889" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Sci+Transl+Med&amp;title=PI3K+inhibition+results+in+enhanced+estrogen+receptor+function+and+dependence+in+hormone+receptor-positive+breast+cancer&amp;author=A+Bosch&amp;author=Z+Li&amp;author=A+Bergamaschi&amp;author=H+Ellis&amp;author=E+Toska&amp;volume=7&amp;publication_year=2015&amp;pages=283ra251&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R9"><span class="element-citation">Brant RG, Sharpe A, Liptrot T, Dry J, Harrington EA, Barrett JC, Whalley N, Womack C, Smith PD, Hodgson D. Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors. <span><span class="ref-journal">Clin Cancer Res </span>2016</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27733477" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>]</span></li><li id="R10"><span class="element-citation">Brouckaert O, Laenen A, Smeets A, Christiaens MR, Vergote I, Wildiers H, Moerman P, Floris G, Neven P, Leuven M. Prognostic implications of lobular breast cancer histology: new insights from a single hospital cross-sectional study and SEER data. <span><span class="ref-journal">Breast. </span>2014;<span class="ref-vol">23</span>:371–377.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24530094" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Breast&amp;title=Prognostic+implications+of+lobular+breast+cancer+histology:+new+insights+from+a+single+hospital+cross-sectional+study+and+SEER+data&amp;author=O+Brouckaert&amp;author=A+Laenen&amp;author=A+Smeets&amp;author=MR+Christiaens&amp;author=I+Vergote&amp;volume=23&amp;publication_year=2014&amp;pages=371-377&amp;pmid=24530094&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R11"><span class="element-citation">Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. <span><span class="ref-journal">Cancer Discov. </span>2012;<span class="ref-vol">2</span>:401–404.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3956037/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22588877" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Discov&amp;title=The+cBio+cancer+genomics+portal:+an+open+platform+for+exploring+multidimensional+cancer+genomics+data&amp;author=E+Cerami&amp;author=J+Gao&amp;author=U+Dogrusoz&amp;author=BE+Gross&amp;author=SO+Sumer&amp;volume=2&amp;publication_year=2012&amp;pages=401-404&amp;pmid=22588877&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R12"><span class="element-citation">Challis D, Yu J, Evani US, Jackson AR, Paithankar S, Coarfa C, Milosavljevic A, Gibbs RA, Yu F. An integrative variant analysis suite for whole exome next-generation sequencing data. <span><span class="ref-journal">BMC Bioinformatics. </span>2012;<span class="ref-vol">13</span>:8.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3292476/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22239737" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=BMC+Bioinformatics&amp;title=An+integrative+variant+analysis+suite+for+whole+exome+next-generation+sequencing+data&amp;author=D+Challis&amp;author=J+Yu&amp;author=US+Evani&amp;author=AR+Jackson&amp;author=S+Paithankar&amp;volume=13&amp;publication_year=2012&amp;pages=8&amp;pmid=22239737&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R13"><span class="element-citation">Chandarlapaty S, Chen D, He W, Sung P, Samoila A, You D, Bhatt T, Patel P, Voi M, Gnant M, et al. Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial. <span><span class="ref-journal">JAMA Oncol. </span>2016;<span class="ref-vol">2</span>:1310–1315.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5063698/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27532364" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=JAMA+Oncol&amp;title=Prevalence+of+ESR1+Mutations+in+Cell-Free+DNA+and+Outcomes+in+Metastatic+Breast+Cancer:+A+Secondary+Analysis+of+the+BOLERO-2+Clinical+Trial&amp;author=S+Chandarlapaty&amp;author=D+Chen&amp;author=W+He&amp;author=P+Sung&amp;author=A+Samoila&amp;volume=2&amp;publication_year=2016&amp;pages=1310-1315&amp;pmid=27532364&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R14"><span class="element-citation">Chen M, Cui YK, Huang WH, Man K, Zhang GJ. Phosphorylation of estrogen receptor &#x003b1; at serine 118 is correlated with breast cancer resistance to tamoxifen. <span><span class="ref-journal">Oncol Lett. </span>2013;<span class="ref-vol">6</span>:118–124.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3742566/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23946788" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncol+Lett&amp;title=Phosphorylation+of+estrogen+receptor+&#x003b1;+at+serine+118+is+correlated+with+breast+cancer+resistance+to+tamoxifen&amp;author=M+Chen&amp;author=YK+Cui&amp;author=WH+Huang&amp;author=K+Man&amp;author=GJ+Zhang&amp;volume=6&amp;publication_year=2013&amp;pages=118-124&amp;pmid=23946788&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R15"><span class="element-citation">Christgen M, Steinemann D, K&#x000fc;hnle E, L&#x000e4;nger F, Gluz O, Harbeck N, Kreipe H. Lobular breast cancer: Clinical, molecular and morphological characteristics. <span><span class="ref-journal">Pathol Res Pract. </span>2016;<span class="ref-vol">212</span>:583–597.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27233940" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Pathol+Res+Pract&amp;title=Lobular+breast+cancer:+Clinical,+molecular+and+morphological+characteristics&amp;author=M+Christgen&amp;author=D+Steinemann&amp;author=E+K&#x000fc;hnle&amp;author=F+L&#x000e4;nger&amp;author=O+Gluz&amp;volume=212&amp;publication_year=2016&amp;pages=583-597&amp;pmid=27233940&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R16"><span class="element-citation">Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, et al. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. <span><span class="ref-journal">Cell. </span>2015;<span class="ref-vol">163</span>:506–519.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4603750/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26451490" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=Comprehensive+Molecular+Portraits+of+Invasive+Lobular+Breast+Cancer&amp;author=G+Ciriello&amp;author=ML+Gatza&amp;author=AH+Beck&amp;author=MD+Wilkerson&amp;author=SK+Rhie&amp;volume=163&amp;publication_year=2015&amp;pages=506-519&amp;pmid=26451490&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R17"><span class="element-citation">Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D&#x02019;Amato NC, Spoelstra NS, Edgerton SM, Jean A, Guerrero J, et al. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. <span><span class="ref-journal">Breast Cancer Res. </span>2014;<span class="ref-vol">16</span>:R7.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3978822/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24451109" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Breast+Cancer+Res&amp;title=Role+of+the+androgen+receptor+in+breast+cancer+and+preclinical+analysis+of+enzalutamide&amp;author=DR+Cochrane&amp;author=S+Bernales&amp;author=BM+Jacobsen&amp;author=DM+Cittelly&amp;author=EN+Howe&amp;volume=16&amp;publication_year=2014&amp;pages=R7&amp;pmid=24451109&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R18"><span class="element-citation">Colleoni M, Rotmensz N, Maisonneuve P, Mastropasqua MG, Luini A, Veronesi P, Intra M, Montagna E, Cancello G, Cardillo A, et al. Outcome of special types of luminal breast cancer. <span><span class="ref-journal">Ann Oncol. </span>2012;<span class="ref-vol">23</span>:1428–1436.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22039080" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Ann+Oncol&amp;title=Outcome+of+special+types+of+luminal+breast+cancer&amp;author=M+Colleoni&amp;author=N+Rotmensz&amp;author=P+Maisonneuve&amp;author=MG+Mastropasqua&amp;author=A+Luini&amp;volume=23&amp;publication_year=2012&amp;pages=1428-1436&amp;pmid=22039080&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R19"><span class="element-citation">Creighton CJ, Fu X, Hennessy BT, Casa AJ, Zhang Y, Gonzalez-Angulo AM, Lluch A, Gray JW, Brown PH, Hilsenbeck SG, et al. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. <span><span class="ref-journal">Breast Cancer Res. </span>2010;<span class="ref-vol">12</span>:R40.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2917035/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20569503" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Breast+Cancer+Res&amp;title=Proteomic+and+transcriptomic+profiling+reveals+a+link+between+the+PI3K+pathway+and+lower+estrogen-receptor+(ER)+levels+and+activity+in+ER++breast+cancer&amp;author=CJ+Creighton&amp;author=X+Fu&amp;author=BT+Hennessy&amp;author=AJ+Casa&amp;author=Y+Zhang&amp;volume=12&amp;publication_year=2010&amp;pages=R40&amp;pmid=20569503&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R20"><span class="element-citation">Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM, El-Ashry D. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. <span><span class="ref-journal">Cancer Res. </span>2006;<span class="ref-vol">66</span>:3903–3911.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16585219" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Activation+of+mitogen-activated+protein+kinase+in+estrogen+receptor+alpha-positive+breast+cancer+cells+in+vitro+induces+an+in+vivo+molecular+phenotype+of+estrogen+receptor+alpha-negative+human+breast+tumors&amp;author=CJ+Creighton&amp;author=AM+Hilger&amp;author=S+Murthy&amp;author=JM+Rae&amp;author=AM+Chinnaiyan&amp;volume=66&amp;publication_year=2006&amp;pages=3903-3911&amp;pmid=16585219&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R21"><span class="element-citation">Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. <span><span class="ref-journal">Nature. </span>2012;<span class="ref-vol">486</span>:346–352.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3440846/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22522925" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=The+genomic+and+transcriptomic+architecture+of+2,000+breast+tumours+reveals+novel+subgroups&amp;author=C+Curtis&amp;author=SP+Shah&amp;author=SF+Chin&amp;author=G+Turashvili&amp;author=OM+Rueda&amp;volume=486&amp;publication_year=2012&amp;pages=346-352&amp;pmid=22522925&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R22"><span class="element-citation">Davies M, Barraclough D, Stewart C, Joyce K, Eccles R, Barraclough R, Rudland P, Sibson D. Expression and splicing of the unfolded protein response gene XBP-1 are significantly associated with clinical outcome of endocrine-treated breast cancer. <span><span class="ref-journal">Int J Cancer. </span>2008;<span class="ref-vol">123</span>:85–88.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18386815" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int+J+Cancer&amp;title=Expression+and+splicing+of+the+unfolded+protein+response+gene+XBP-1+are+significantly+associated+with+clinical+outcome+of+endocrine-treated+breast+cancer&amp;author=M+Davies&amp;author=D+Barraclough&amp;author=C+Stewart&amp;author=K+Joyce&amp;author=R+Eccles&amp;volume=123&amp;publication_year=2008&amp;pages=85-88&amp;pmid=18386815&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R23"><span class="element-citation">De Amicis F, Thirugnansampanthan J, Cui Y, Selever J, Beyer A, Parra I, Weigel NL, Herynk MH, Tsimelzon A, Lewis MT, et al. Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. <span><span class="ref-journal">Breast Cancer Res Treat. </span>2010;<span class="ref-vol">121</span>:1–11.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2995248/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19533338" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Breast+Cancer+Res+Treat&amp;title=Androgen+receptor+overexpression+induces+tamoxifen+resistance+in+human+breast+cancer+cells&amp;author=F+De+Amicis&amp;author=J+Thirugnansampanthan&amp;author=Y+Cui&amp;author=J+Selever&amp;author=A+Beyer&amp;volume=121&amp;publication_year=2010&amp;pages=1-11&amp;pmid=19533338&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R24"><span class="element-citation">Desmedt C, Zoppoli G, Gundem G, Pruneri G, Larsimont D, Fornili M, Fumagalli D, Brown D, Roth&#x000e9; F, Vincent D, et al. Genomic Characterization of Primary Invasive Lobular Breast Cancer. <span><span class="ref-journal">J Clin Oncol. </span>2016;<span class="ref-vol">34</span>:1872–1881.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26926684" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&amp;title=Genomic+Characterization+of+Primary+Invasive+Lobular+Breast+Cancer&amp;author=C+Desmedt&amp;author=G+Zoppoli&amp;author=G+Gundem&amp;author=G+Pruneri&amp;author=D+Larsimont&amp;volume=34&amp;publication_year=2016&amp;pages=1872-1881&amp;pmid=26926684&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R25"><span class="element-citation">Ding L, Yan J, Zhu J, Zhong H, Lu Q, Wang Z, Huang C, Ye Q. Ligand-independent activation of estrogen receptor alpha by XBP-1. <span><span class="ref-journal">Nucleic Acids Res. </span>2003;<span class="ref-vol">31</span>:5266–5274.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC203316/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12954762" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nucleic+Acids+Res&amp;title=Ligand-independent+activation+of+estrogen+receptor+alpha+by+XBP-1&amp;author=L+Ding&amp;author=J+Yan&amp;author=J+Zhu&amp;author=H+Zhong&amp;author=Q+Lu&amp;volume=31&amp;publication_year=2003&amp;pages=5266-5274&amp;pmid=12954762&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R26"><span class="element-citation">Donovan JCH, Milic A, Slingerland JM. Constitutive MEK/MAPK Activation Leads to p27Kip1 Deregulation and Antiestrogen Resistance in Human Breast Cancer Cells. <span><span class="ref-journal">Journal of Biological Chemistry. </span>2001;<span class="ref-vol">276</span>:40888–40895.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11527971" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Biological+Chemistry&amp;title=Constitutive+MEK/MAPK+Activation+Leads+to+p27Kip1+Deregulation+and+Antiestrogen+Resistance+in+Human+Breast+Cancer+Cells&amp;author=JCH+Donovan&amp;author=A+Milic&amp;author=JM+Slingerland&amp;volume=276&amp;publication_year=2001&amp;pages=40888-40895&amp;pmid=11527971&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R27"><span class="element-citation">Dubrovska A, Hartung A, Bouchez LC, Walker JR, Reddy VA, Cho CY, Schultz PG. CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling. <span><span class="ref-journal">Br J Cancer. </span>2012;<span class="ref-vol">107</span>:43–52.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3389396/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22644306" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Br+J+Cancer&amp;title=CXCR4+activation+maintains+a+stem+cell+population+in+tamoxifen-resistant+breast+cancer+cells+through+AhR+signalling&amp;author=A+Dubrovska&amp;author=A+Hartung&amp;author=LC+Bouchez&amp;author=JR+Walker&amp;author=VA+Reddy&amp;volume=107&amp;publication_year=2012&amp;pages=43-52&amp;pmid=22644306&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R28"><span class="element-citation">Duncia JV, Santella JB, III, Higley CA, Pitts WJ, Wityak J, Frietze WE, Rankin FW, Sun JH, Earl RA, Tabaka AC, et al. MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization products. <span><span class="ref-journal">Bioorg Med Chem Lett. </span>1998;<span class="ref-vol">8</span>:2839–2844.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/9873633" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Bioorg+Med+Chem+Lett&amp;title=MEK+inhibitors:+the+chemistry+and+biological+activity+of+U0126,+its+analogs,+and+cyclization+products&amp;author=JV+Duncia&amp;author=JB+Santella&amp;author=CA+Higley&amp;author=WJ+Pitts&amp;author=J+Wityak&amp;volume=8&amp;publication_year=1998&amp;pages=2839-2844&amp;pmid=9873633&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R29"><span class="element-citation">Engstr&#x000f8;m MJ, Opdahl S, Vatten LJ, Haugen OA, Bofin AM. Invasive lobular breast cancer: the prognostic impact of histopathological grade, E-cadherin and molecular subtypes. <span><span class="ref-journal">Histopathology. </span>2015;<span class="ref-vol">66</span>:409–419.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4329418/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25283075" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Histopathology&amp;title=Invasive+lobular+breast+cancer:+the+prognostic+impact+of+histopathological+grade,+E-cadherin+and+molecular+subtypes&amp;author=MJ+Engstr&#x000f8;m&amp;author=S+Opdahl&amp;author=LJ+Vatten&amp;author=OA+Haugen&amp;author=AM+Bofin&amp;volume=66&amp;publication_year=2015&amp;pages=409-419&amp;pmid=25283075&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R30"><span class="element-citation">Esseltine JL, Willard MD, Wulur IH, Lajiness ME, Barber TD, Ferguson SS. Somatic mutations in GRM1 in cancer alter metabotropic glutamate receptor 1 intracellular localization and signaling. <span><span class="ref-journal">Mol Pharmacol. </span>2013;<span class="ref-vol">83</span>:770–780.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23303475" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Pharmacol&amp;title=Somatic+mutations+in+GRM1+in+cancer+alter+metabotropic+glutamate+receptor+1+intracellular+localization+and+signaling&amp;author=JL+Esseltine&amp;author=MD+Willard&amp;author=IH+Wulur&amp;author=ME+Lajiness&amp;author=TD+Barber&amp;volume=83&amp;publication_year=2013&amp;pages=770-780&amp;pmid=23303475&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R31"><span class="element-citation">Ethier SP, Mahacek ML, Gullick WJ, Frank TS, Weber BL. Differential isolation of normal liminal mammary epithelial cells and breast cancer cells from primary and metastatic sites using selective media. <span><span class="ref-journal">Cancer Research. </span>1993;<span class="ref-vol">53</span>:627–635.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/8425198" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Research&amp;title=Differential+isolation+of+normal+liminal+mammary+epithelial+cells+and+breast+cancer+cells+from+primary+and+metastatic+sites+using+selective+media&amp;author=SP+Ethier&amp;author=ML+Mahacek&amp;author=WJ+Gullick&amp;author=TS+Frank&amp;author=BL+Weber&amp;volume=53&amp;publication_year=1993&amp;pages=627-635&amp;pmid=8425198&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R32"><span class="element-citation">Feigin ME. Harnessing the genome for characterization of G-protein coupled receptors in cancer pathogenesis. <span><span class="ref-journal">FEBS J. </span>2013;<span class="ref-vol">280</span>:4729–4738.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4283816/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23927072" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=FEBS+J&amp;title=Harnessing+the+genome+for+characterization+of+G-protein+coupled+receptors+in+cancer+pathogenesis&amp;author=ME+Feigin&amp;volume=280&amp;publication_year=2013&amp;pages=4729-4738&amp;pmid=23927072&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R33"><span class="element-citation">Forozan F, Veldman R, Ammerman CA, Parsa NZ, Kallioniemi A, Kallioniemi OP, Ethier SP. Molecular cytogenetic analysis of 11 new breast cancer cell lines 1. <span><span class="ref-journal">Br J Cancer. </span>1999;<span class="ref-vol">81</span>:1328–1334.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2362964/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/10604729" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Br+J+Cancer&amp;title=Molecular+cytogenetic+analysis+of+11+new+breast+cancer+cell+lines+1&amp;author=F+Forozan&amp;author=R+Veldman&amp;author=CA+Ammerman&amp;author=NZ+Parsa&amp;author=A+Kallioniemi&amp;volume=81&amp;publication_year=1999&amp;pages=1328-1334&amp;pmid=10604729&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R34"><span class="element-citation">Fribbens C, O&#x02019;Leary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M, Cristofanilli M, Andre F, Loi S, Loibl S, et al. Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. <span><span class="ref-journal">J Clin Oncol. </span>2016;<span class="ref-vol">34</span>:2961–2968.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27269946" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&amp;title=Plasma+ESR1+Mutations+and+the+Treatment+of+Estrogen+Receptor-Positive+Advanced+Breast+Cancer&amp;author=C+Fribbens&amp;author=B+O&#x02019;Leary&amp;author=L+Kilburn&amp;author=S+Hrebien&amp;author=I+Garcia-Murillas&amp;volume=34&amp;publication_year=2016&amp;pages=2961-2968&amp;pmid=27269946&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R35"><span class="element-citation">Fritz P, Klenk S, Goletz S, Gerteis A, Simon W, Brinkmann F, Heidemann E, L&#x000fc;tttgen E, Ott G, Alscher MD, et al. Clinical impacts of histological subtyping primary breast cancer. <span><span class="ref-journal">Anticancer Res. </span>2010;<span class="ref-vol">30</span>:5137–5144.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21187502" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Anticancer+Res&amp;title=Clinical+impacts+of+histological+subtyping+primary+breast+cancer&amp;author=P+Fritz&amp;author=S+Klenk&amp;author=S+Goletz&amp;author=A+Gerteis&amp;author=W+Simon&amp;volume=30&amp;publication_year=2010&amp;pages=5137-5144&amp;pmid=21187502&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R36"><span class="element-citation">Fu X, Creighton CJ, Biswal NC, Kumar V, Shea M, Herrera S, Contreras A, Gutierrez C, Wang T, Nanda S, et al. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. <span><span class="ref-journal">Breast Cancer Res. </span>2014;<span class="ref-vol">16</span>:430.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4303114/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25212826" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Breast+Cancer+Res&amp;title=Overcoming+endocrine+resistance+due+to+reduced+PTEN+levels+in+estrogen+receptor-positive+breast+cancer+by+co-targeting+mammalian+target+of+rapamycin,+protein+kinase+B,+or+mitogen-activated+protein+kinase+kinase&amp;author=X+Fu&amp;author=CJ+Creighton&amp;author=NC+Biswal&amp;author=V+Kumar&amp;author=M+Shea&amp;volume=16&amp;publication_year=2014&amp;pages=430&amp;pmid=25212826&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R37"><span class="element-citation">Fu X, Jeselsohn R, Pereira R, Hollingsworth EF, Creighton CJ, Li F, Shea M, Nardone A, De Angelis C, Heiser LM, et al. FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2016;<span class="ref-vol">113</span>:E6600–E6609.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5087040/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27791031" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+U+S+A&amp;title=FOXA1+overexpression+mediates+endocrine+resistance+by+altering+the+ER+transcriptome+and+IL-8+expression+in+ER-positive+breast+cancer&amp;author=X+Fu&amp;author=R+Jeselsohn&amp;author=R+Pereira&amp;author=EF+Hollingsworth&amp;author=CJ+Creighton&amp;volume=113&amp;publication_year=2016&amp;pages=E6600-E6609&amp;pmid=27791031&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R38"><span class="element-citation">Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. <span><span class="ref-journal">Sci Signal. </span>2013;<span class="ref-vol">6</span>:pl1.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4160307/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23550210" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Sci+Signal&amp;title=Integrative+analysis+of+complex+cancer+genomics+and+clinical+profiles+using+the+cBioPortal&amp;author=J+Gao&amp;author=BA+Aksoy&amp;author=U+Dogrusoz&amp;author=G+Dresdner&amp;author=B+Gross&amp;volume=6&amp;publication_year=2013&amp;pages=pl1&amp;pmid=23550210&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R39"><span class="element-citation">Gelsomino L, Gu G, Rechoum Y, Beyer AR, Pejerrey SM, Tsimelzon A, Wang T, Huffman K, Ludlow A, And&#x000f2; S, et al. ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling. <span><span class="ref-journal">Breast Cancer Res Treat. </span>2016;<span class="ref-vol">157</span>:253–265.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5510243/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27178332" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Breast+Cancer+Res+Treat&amp;title=ESR1+mutations+affect+anti-proliferative+responses+to+tamoxifen+through+enhanced+cross-talk+with+IGF+signaling&amp;author=L+Gelsomino&amp;author=G+Gu&amp;author=Y+Rechoum&amp;author=AR+Beyer&amp;author=SM+Pejerrey&amp;volume=157&amp;publication_year=2016&amp;pages=253-265&amp;pmid=27178332&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R40"><span class="element-citation">Girard BJ, Regan Anderson TM, Welch SL, Nicely J, Seewaldt VL, Ostrander JH. Cytoplasmic PELP1 and ERRgamma Protect Human Mammary Epithelial Cells from Tam-Induced Cell Death. <span><span class="ref-journal">PLoS One. </span>2015;<span class="ref-vol">10</span>:e0121206.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4366195/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25789479" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=PLoS+One&amp;title=Cytoplasmic+PELP1+and+ERRgamma+Protect+Human+Mammary+Epithelial+Cells+from+Tam-Induced+Cell+Death&amp;author=BJ+Girard&amp;author=TM+Regan+Anderson&amp;author=SL+Welch&amp;author=J+Nicely&amp;author=VL+Seewaldt&amp;volume=10&amp;publication_year=2015&amp;pages=e0121206&amp;pmid=25789479&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R41"><span class="element-citation">Gomez BP, Riggins RB, Shajahan AN, Klimach U, Wang A, Crawford AC, Zhu Y, Zwart A, Wang M, Clarke R. Human X-box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines. <span><span class="ref-journal">The FASEB Journal. </span>2007;<span class="ref-vol">21</span>:4013–4027.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17660348" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=The+FASEB+Journal&amp;title=Human+X-box+binding+protein-1+confers+both+estrogen+independence+and+antiestrogen+resistance+in+breast+cancer+cell+lines&amp;author=BP+Gomez&amp;author=RB+Riggins&amp;author=AN+Shajahan&amp;author=U+Klimach&amp;author=A+Wang&amp;volume=21&amp;publication_year=2007&amp;pages=4013-4027&amp;pmid=17660348&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R42"><span class="element-citation">Gruel N, Lucchesi C, Raynal V, Rodrigues MJ, Pierron G, Goudefroye R, Cottu P, Reyal F, Sastre-Garau X, Fourquet A, et al. Lobular invasive carcinoma of the breast is a molecular entity distinct from luminal invasive ductal carcinoma. <span><span class="ref-journal">Eur J Cancer. </span>2010;<span class="ref-vol">46</span>:2399–2407.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20570624" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Eur+J+Cancer&amp;title=Lobular+invasive+carcinoma+of+the+breast+is+a+molecular+entity+distinct+from+luminal+invasive+ductal+carcinoma&amp;author=N+Gruel&amp;author=C+Lucchesi&amp;author=V+Raynal&amp;author=MJ+Rodrigues&amp;author=G+Pierron&amp;volume=46&amp;publication_year=2010&amp;pages=2399-2407&amp;pmid=20570624&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R43"><span class="element-citation">Gyanchandani R, Kota KJ, Jonnalagadda AR, Minteer T, Knapick BA, Oesterreich S, Brufsky AM, Lee AV, Puhalla SL. Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole. <span><span class="ref-journal">Oncotarget </span>2016</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5620144/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28978004" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>]</span></li><li id="R44"><span class="element-citation">Heckler MM, Thakor H, Schafer CC, Riggins RB. ERK/MAPK regulates ERR&#x003b3; expression, transcriptional activity and receptor-mediated tamoxifen resistance in ER+ breast cancer. <span><span class="ref-journal">FEBS J. </span>2014;<span class="ref-vol">281</span>:2431–2442.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4079056/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24684682" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=FEBS+J&amp;title=ERK/MAPK+regulates+ERR&#x003b3;+expression,+transcriptional+activity+and+receptor-mediated+tamoxifen+resistance+in+ER++breast+cancer&amp;author=MM+Heckler&amp;author=H+Thakor&amp;author=CC+Schafer&amp;author=RB+Riggins&amp;volume=281&amp;publication_year=2014&amp;pages=2431-2442&amp;pmid=24684682&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R45"><span class="element-citation">Heckler MM, Zeleke TZ, Divekar SD, Fernandez AI, Tiek DM, Woodrick J, Farzanegan A, Roy R, &#x000dc;ren A, Mueller SC, et al. Antimitotic activity of DY131 and the estrogen-related receptor beta 2 (ERR&#x003b2;2) splice variant in breast cancer. <span><span class="ref-journal">Oncotarget. </span>2016;<span class="ref-vol">7</span>:47201–47220.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5216935/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27363015" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=Antimitotic+activity+of+DY131+and+the+estrogen-related+receptor+beta+2+(ERR&#x003b2;2)+splice+variant+in+breast+cancer&amp;author=MM+Heckler&amp;author=TZ+Zeleke&amp;author=SD+Divekar&amp;author=AI+Fernandez&amp;author=DM+Tiek&amp;volume=7&amp;publication_year=2016&amp;pages=47201-47220&amp;pmid=27363015&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R46"><span class="element-citation">Higasa K, Miyake N, Yoshimura J, Okamura K, Niihori T, Saitsu H, Doi K, Shimizu M, Nakabayashi K, Aoki Y, et al. Human genetic variation database, a reference database of genetic variations in the Japanese population. <span><span class="ref-journal">J Hum Genet. </span>2016;<span class="ref-vol">61</span>:547–553.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4931044/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26911352" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Hum+Genet&amp;title=Human+genetic+variation+database,+a+reference+database+of+genetic+variations+in+the+Japanese+population&amp;author=K+Higasa&amp;author=N+Miyake&amp;author=J+Yoshimura&amp;author=K+Okamura&amp;author=T+Niihori&amp;volume=61&amp;publication_year=2016&amp;pages=547-553&amp;pmid=26911352&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R47"><span class="element-citation">Hu R, Warri A, Jin L, Zwart A, Riggins RB, Fang HB, Clarke R. NF-&#x003ba;B signaling is required for XBP1 (unspliced and spliced)-mediated effects on antiestrogen responsiveness and cell fate decisions in breast cancer. <span><span class="ref-journal">Mol Cell Biol. </span>2015;<span class="ref-vol">35</span>:379–390.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4272419/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25368386" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cell+Biol&amp;title=NF-&#x003ba;B+signaling+is+required+for+XBP1+(unspliced+and+spliced)-mediated+effects+on+antiestrogen+responsiveness+and+cell+fate+decisions+in+breast+cancer&amp;author=R+Hu&amp;author=A+Warri&amp;author=L+Jin&amp;author=A+Zwart&amp;author=RB+Riggins&amp;volume=35&amp;publication_year=2015&amp;pages=379-390&amp;pmid=25368386&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R48"><span class="element-citation">Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS. FOXA1 is a key determinant of estrogen receptor function and endocrine response. <span><span class="ref-journal">Nat Genet. </span>2011;<span class="ref-vol">43</span>:27–33.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3024537/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21151129" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Genet&amp;title=FOXA1+is+a+key+determinant+of+estrogen+receptor+function+and+endocrine+response&amp;author=A+Hurtado&amp;author=KA+Holmes&amp;author=CS+Ross-Innes&amp;author=D+Schmidt&amp;author=JS+Carroll&amp;volume=43&amp;publication_year=2011&amp;pages=27-33&amp;pmid=21151129&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R49"><span class="element-citation">Irish JC, Mills JN, Turner-Ivey B, Wilson RC, Guest ST, Rutkovsky A, Dombkowski A, Kappler CS, Hardiman G, Ethier SP. Amplification of WHSC1L1 regulates expression and estrogen-independent activation of ER&#x003b1; in SUM-44 breast cancer cells and is associated with ER&#x003b1; over-expression in breast cancer. <span><span class="ref-journal">Mol Oncol. </span>2016;<span class="ref-vol">10</span>:850–865.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4920706/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27005559" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Oncol&amp;title=Amplification+of+WHSC1L1+regulates+expression+and+estrogen-independent+activation+of+ER&#x003b1;+in+SUM-44+breast+cancer+cells+and+is+associated+with+ER&#x003b1;+over-expression+in+breast+cancer&amp;author=JC+Irish&amp;author=JN+Mills&amp;author=B+Turner-Ivey&amp;author=RC+Wilson&amp;author=ST+Guest&amp;volume=10&amp;publication_year=2016&amp;pages=850-865&amp;pmid=27005559&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R50"><span class="element-citation">Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. <span><span class="ref-journal">Biostatistics. </span>2003;<span class="ref-vol">4</span>:249–264.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12925520" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biostatistics&amp;title=Exploration,+normalization,+and+summaries+of+high+density+oligonucleotide+array+probe+level+data&amp;author=RA+Irizarry&amp;author=B+Hobbs&amp;author=F+Collin&amp;author=YD+Beazer-Barclay&amp;author=KJ+Antonellis&amp;volume=4&amp;publication_year=2003&amp;pages=249-264&amp;pmid=12925520&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R51"><span class="element-citation">Jambal P, Badtke MM, Harrell JC, Borges VF, Post MD, Sollender GE, Spillman MA, Horwitz KB, Jacobsen BM. Estrogen switches pure mucinous breast cancer to invasive lobular carcinoma with mucinous features. <span><span class="ref-journal">Breast Cancer Res Treat. </span>2013;<span class="ref-vol">137</span>:431–448.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3543987/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23247610" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Breast+Cancer+Res+Treat&amp;title=Estrogen+switches+pure+mucinous+breast+cancer+to+invasive+lobular+carcinoma+with+mucinous+features&amp;author=P+Jambal&amp;author=MM+Badtke&amp;author=JC+Harrell&amp;author=VF+Borges&amp;author=MD+Post&amp;volume=137&amp;publication_year=2013&amp;pages=431-448&amp;pmid=23247610&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R52"><span class="element-citation">Johnston S, Holmes K, Carroll J. Abstract 2906: Targeting FoxA1 in estrogen receptor-positive breast cancer: biological characterization of kinase regulators. p Abstract number 2906. <span><span class="ref-journal">Cancer Res </span>2016</span></span></li><li id="R53"><span class="element-citation">Jozwik KM, Carroll JS. Pioneer factors in hormone-dependent cancers. <span><span class="ref-journal">Nat Rev Cancer. </span>2012;<span class="ref-vol">12</span>:381–385.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22555282" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Cancer&amp;title=Pioneer+factors+in+hormone-dependent+cancers&amp;author=KM+Jozwik&amp;author=JS+Carroll&amp;volume=12&amp;publication_year=2012&amp;pages=381-385&amp;pmid=22555282&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R54"><span class="element-citation">Kas SM, de Ruiter JR, Schipper K, Annunziato S, Schut E, Klarenbeek S, Drenth AP, van der Burg E, Klijn C, Ten Hoeve JJ, et al. Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma. <span><span class="ref-journal">Nat Genet </span>2017</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28650484" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Genet&amp;title=Insertional+mutagenesis+identifies+drivers+of+a+novel+oncogenic+pathway+in+invasive+lobular+breast+carcinoma&amp;author=SM+Kas&amp;author=JR+de+Ruiter&amp;author=K+Schipper&amp;author=S+Annunziato&amp;author=E+Schut&amp;publication_year=2017&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R55"><span class="element-citation">Knauer M, Gruber C, Dietze O, Greil R, Stoger H, Rudas M, et al. Abstract S2&#x02013;06: Survival advantage of anastrozol compared to tamoxifen for lobular breast cancer in the ABCSG-8 study. <span><span class="ref-journal">Cancer Res </span>2015</span> Abstract numer S2&#x02013;06. <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Abstract+S2&#x02013;06:+Survival+advantage+of+anastrozol+compared+to+tamoxifen+for+lobular+breast+cancer+in+the+ABCSG-8+study&amp;author=M+Knauer&amp;author=C+Gruber&amp;author=O+Dietze&amp;author=R+Greil&amp;author=H+Stoger&amp;publication_year=2015&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R56"><span class="element-citation">Kronblad A, Hedenfalk I, Nilsson E, P&#x000e5;hlman S, Landberg G. ERK1/2 inhibition increases antiestrogen treatment efficacy by interfering with hypoxia-induced downregulation of ERalpha: a combination therapy potentially targeting hypoxic and dormant tumor cells. <span><span class="ref-journal">Oncogene. </span>2005;<span class="ref-vol">24</span>:6835–6841.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16007158" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncogene&amp;title=ERK1/2+inhibition+increases+antiestrogen+treatment+efficacy+by+interfering+with+hypoxia-induced+downregulation+of+ERalpha:+a+combination+therapy+potentially+targeting+hypoxic+and+dormant+tumor+cells&amp;author=A+Kronblad&amp;author=I+Hedenfalk&amp;author=E+Nilsson&amp;author=S+P&#x000e5;hlman&amp;author=G+Landberg&amp;volume=24&amp;publication_year=2005&amp;pages=6835-6841&amp;pmid=16007158&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R57"><span class="element-citation">Kurokawa H, Lenferink AE, Simpson JF, Pisacane PI, Sliwkowski MX, Forbes JT, Arteaga CL. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. <span><span class="ref-journal">Cancer Research. </span>2000;<span class="ref-vol">60</span>:5887–5894.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11059787" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Research&amp;title=Inhibition+of+HER2/neu+(erbB-2)+and+mitogen-activated+protein+kinases+enhances+tamoxifen+action+against+HER2-overexpressing,+tamoxifen-resistant+breast+cancer+cells&amp;author=H+Kurokawa&amp;author=AE+Lenferink&amp;author=JF+Simpson&amp;author=PI+Pisacane&amp;author=MX+Sliwkowski&amp;volume=60&amp;publication_year=2000&amp;pages=5887-5894&amp;pmid=11059787&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R58"><span class="element-citation">Kuske B, Naughton C, Moore K, MacLeod KG, Miller WR, Clarke R, Langdon SP, Cameron DA. Endocrine therapy resistance can be associated with high estrogen receptor {alpha} (ER{alpha}) expression and reduced ER{alpha} phosphorylation in breast cancer models. <span><span class="ref-journal">Endocrine-Related Cancer. </span>2006;<span class="ref-vol">13</span>:1121–1133.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17158758" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Endocrine-Related+Cancer&amp;title=Endocrine+therapy+resistance+can+be+associated+with+high+estrogen+receptor+{alpha}+(ER{alpha})+expression+and+reduced+ER{alpha}+phosphorylation+in+breast+cancer+models&amp;author=B+Kuske&amp;author=C+Naughton&amp;author=K+Moore&amp;author=KG+MacLeod&amp;author=WR+Miller&amp;volume=13&amp;publication_year=2006&amp;pages=1121-1133&amp;pmid=17158758&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R59"><span class="element-citation">Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, O&#x02019;Donnell-Luria AH, Ware JS, Hill AJ, Cummings BB, et al. Analysis of protein-coding genetic variation in 60,706 humans. <span><span class="ref-journal">Nature. </span>2016;<span class="ref-vol">536</span>:285–291.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5018207/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27535533" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Analysis+of+protein-coding+genetic+variation+in+60,706+humans&amp;author=M+Lek&amp;author=KJ+Karczewski&amp;author=EV+Minikel&amp;author=KE+Samocha&amp;author=E+Banks&amp;volume=536&amp;publication_year=2016&amp;pages=285-291&amp;pmid=27535533&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R60"><span class="element-citation">Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, Subgroup GPDP. The Sequence Alignment/Map format and SAMtools. <span><span class="ref-journal">Bioinformatics. </span>2009;<span class="ref-vol">25</span>:2078–2079.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2723002/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19505943" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Bioinformatics&amp;title=The+Sequence+Alignment/Map+format+and+SAMtools&amp;author=H+Li&amp;author=B+Handsaker&amp;author=A+Wysoker&amp;author=T+Fennell&amp;author=J+Ruan&amp;volume=25&amp;publication_year=2009&amp;pages=2078-2079&amp;pmid=19505943&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R61"><span class="element-citation">Liu X, Jian X, Boerwinkle E. dbNSFP v2.0: a database of human non-synonymous SNVs and their functional predictions and annotations. <span><span class="ref-journal">Hum Mutat. </span>2013;<span class="ref-vol">34</span>:E2393–2402.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4109890/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23843252" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Hum+Mutat&amp;title=dbNSFP+v2.0:+a+database+of+human+non-synonymous+SNVs+and+their+functional+predictions+and+annotations&amp;author=X+Liu&amp;author=X+Jian&amp;author=E+Boerwinkle&amp;volume=34&amp;publication_year=2013&amp;pages=E2393-2402&amp;pmid=23843252&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R62"><span class="element-citation">Lo R, Matthews J. High-resolution genome-wide mapping of AHR and ARNT binding sites by ChIP-Seq. <span><span class="ref-journal">Toxicol Sci. </span>2012;<span class="ref-vol">130</span>:349–361.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22903824" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Toxicol+Sci&amp;title=High-resolution+genome-wide+mapping+of+AHR+and+ARNT+binding+sites+by+ChIP-Seq&amp;author=R+Lo&amp;author=J+Matthews&amp;volume=130&amp;publication_year=2012&amp;pages=349-361&amp;pmid=22903824&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R63"><span class="element-citation">L&#x000fc; M, Ding K, Zhang G, Yin M, Yao G, Tian H, Lian J, Liu L, Liang M, Zhu T, et al. MicroRNA-320a sensitizes tamoxifen-resistant breast cancer cells to tamoxifen by targeting ARPP-19 and ERR&#x003b3; <span><span class="ref-journal">Sci Rep. </span>2015;<span class="ref-vol">5</span>:8735.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4348640/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25736597" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Sci+Rep&amp;title=MicroRNA-320a+sensitizes+tamoxifen-resistant+breast+cancer+cells+to+tamoxifen+by+targeting+ARPP-19+and+ERR&#x003b3;&amp;author=M+L&#x000fc;&amp;author=K+Ding&amp;author=G+Zhang&amp;author=M+Yin&amp;author=G+Yao&amp;volume=5&amp;publication_year=2015&amp;pages=8735&amp;pmid=25736597&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R64"><span class="element-citation">Madhavan S, Gusev Y, Singh S, Riggins RB. ERR&#x003b3; target genes are poor prognostic factors in Tamoxifen-treated breast cancer. <span><span class="ref-journal">J Exp Clin Cancer Res. </span>2015;<span class="ref-vol">34</span>:45.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4436109/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25971350" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Exp+Clin+Cancer+Res&amp;title=ERR&#x003b3;+target+genes+are+poor+prognostic+factors+in+Tamoxifen-treated+breast+cancer&amp;author=S+Madhavan&amp;author=Y+Gusev&amp;author=S+Singh&amp;author=RB+Riggins&amp;volume=34&amp;publication_year=2015&amp;pages=45&amp;pmid=25971350&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R65"><span class="element-citation">Martino JJ, Wall BA, Mastrantoni E, Wilimczyk BJ, La Cava SN, Degenhardt K, White E, Chen S. Metabotropic glutamate receptor 1 (Grm1) is an oncogene in epithelial cells. <span><span class="ref-journal">Oncogene. </span>2013;<span class="ref-vol">32</span>:4366–4376.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3910169/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23085756" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncogene&amp;title=Metabotropic+glutamate+receptor+1+(Grm1)+is+an+oncogene+in+epithelial+cells&amp;author=JJ+Martino&amp;author=BA+Wall&amp;author=E+Mastrantoni&amp;author=BJ+Wilimczyk&amp;author=SN+La+Cava&amp;volume=32&amp;publication_year=2013&amp;pages=4366-4376&amp;pmid=23085756&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R66"><span class="element-citation">McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. <span><span class="ref-journal">Genome Res. </span>2010;<span class="ref-vol">20</span>:1297–1303.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2928508/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20644199" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Genome+Res&amp;title=The+Genome+Analysis+Toolkit:+a+MapReduce+framework+for+analyzing+next-generation+DNA+sequencing+data&amp;author=A+McKenna&amp;author=M+Hanna&amp;author=E+Banks&amp;author=A+Sivachenko&amp;author=K+Cibulskis&amp;volume=20&amp;publication_year=2010&amp;pages=1297-1303&amp;pmid=20644199&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R67"><span class="element-citation">Mehta MS, Dolfi SC, Bronfenbrener R, Bilal E, Chen C, Moore D, Lin Y, Rahim H, Aisner S, Kersellius RD, et al. Metabotropic glutamate receptor 1 expression and its polymorphic variants associate with breast cancer phenotypes. <span><span class="ref-journal">PLoS One. </span>2013;<span class="ref-vol">8</span>:e69851.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3724883/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23922822" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=PLoS+One&amp;title=Metabotropic+glutamate+receptor+1+expression+and+its+polymorphic+variants+associate+with+breast+cancer+phenotypes&amp;author=MS+Mehta&amp;author=SC+Dolfi&amp;author=R+Bronfenbrener&amp;author=E+Bilal&amp;author=C+Chen&amp;volume=8&amp;publication_year=2013&amp;pages=e69851&amp;pmid=23922822&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R68"><span class="element-citation">Mendes-Pereira AM, Sims D, Dexter T, Fenwick K, Assiotis I, Kozarewa I, Mitsopoulos C, Hakas J, Zvelebil M, Lord CJ, et al. Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2012;<span class="ref-vol">109</span>:2730–2735.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3286962/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21482774" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+U+S+A&amp;title=Genome-wide+functional+screen+identifies+a+compendium+of+genes+affecting+sensitivity+to+tamoxifen&amp;author=AM+Mendes-Pereira&amp;author=D+Sims&amp;author=T+Dexter&amp;author=K+Fenwick&amp;author=I+Assiotis&amp;volume=109&amp;publication_year=2012&amp;pages=2730-2735&amp;pmid=21482774&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R69"><span class="element-citation">Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. <span><span class="ref-journal">Trends Biochem Sci. </span>2011;<span class="ref-vol">36</span>:320–328.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3112285/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21531565" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Trends+Biochem+Sci&amp;title=The+Ras-ERK+and+PI3K-mTOR+pathways:+cross-talk+and+compensation&amp;author=MC+Mendoza&amp;author=EE+Er&amp;author=J+Blenis&amp;volume=36&amp;publication_year=2011&amp;pages=320-328&amp;pmid=21531565&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R70"><span class="element-citation">Mendoza-Villanueva D, Balamurugan K, Ali HR, Kim SR, Sharan S, Johnson RC, Merchant AS, Caldas C, Landberg G, Sterneck E. The C/EBP&#x003b4; protein is stabilized by estrogen receptor &#x003b1; activity, inhibits SNAI2 expression and associates with good prognosis in breast cancer. <span><span class="ref-journal">Oncogene. </span>2016;<span class="ref-vol">35</span>:6166–6176.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5112156/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27181204" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncogene&amp;title=The+C/EBP&#x003b4;+protein+is+stabilized+by+estrogen+receptor+&#x003b1;+activity,+inhibits+SNAI2+expression+and+associates+with+good+prognosis+in+breast+cancer&amp;author=D+Mendoza-Villanueva&amp;author=K+Balamurugan&amp;author=HR+Ali&amp;author=SR+Kim&amp;author=S+Sharan&amp;volume=35&amp;publication_year=2016&amp;pages=6166-6176&amp;pmid=27181204&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R71"><span class="element-citation">Metzger Filho O, Giobbie-Hurder A, Mallon E, Gusterson B, Viale G, Winer EP, Th&#x000fc;rlimann B, Gelber RD, Colleoni M, Ejlertsen B, et al. Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1&#x02013;98 Trial. <span><span class="ref-journal">J Clin Oncol. </span>2015;<span class="ref-vol">33</span>:2772–2779.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4550691/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26215945" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&amp;title=Relative+Effectiveness+of+Letrozole+Compared+With+Tamoxifen+for+Patients+With+Lobular+Carcinoma+in+the+BIG+1&#x02013;98+Trial&amp;author=O+Metzger+Filho&amp;author=A+Giobbie-Hurder&amp;author=E+Mallon&amp;author=B+Gusterson&amp;author=G+Viale&amp;volume=33&amp;publication_year=2015&amp;pages=2772-2779&amp;pmid=26215945&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R72"><span class="element-citation">Michaut M, Chin SF, Majewski I, Severson TM, Bismeijer T, de Koning L, Peeters JK, Schouten PC, Rueda OM, Bosma AJ, et al. Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer. <span><span class="ref-journal">Sci Rep. </span>2016;<span class="ref-vol">6</span>:18517.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4700448/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26729235" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Sci+Rep&amp;title=Integration+of+genomic,+transcriptomic+and+proteomic+data+identifies+two+biologically+distinct+subtypes+of+invasive+lobular+breast+cancer&amp;author=M+Michaut&amp;author=SF+Chin&amp;author=I+Majewski&amp;author=TM+Severson&amp;author=T+Bismeijer&amp;volume=6&amp;publication_year=2016&amp;pages=18517&amp;pmid=26729235&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R73"><span class="element-citation">Mih&#x000e1;ly Z, Kormos M, L&#x000e1;nczky A, Dank M, Budczies J, Sz&#x000e1;sz MA, Gy&#x00151;rffy B. A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer. <span><span class="ref-journal">Breast Cancer Res Treat. </span>2013;<span class="ref-vol">140</span>:219–232.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23836010" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Breast+Cancer+Res+Treat&amp;title=A+meta-analysis+of+gene+expression-based+biomarkers+predicting+outcome+after+tamoxifen+treatment+in+breast+cancer&amp;author=Z+Mih&#x000e1;ly&amp;author=M+Kormos&amp;author=A+L&#x000e1;nczky&amp;author=M+Dank&amp;author=J+Budczies&amp;volume=140&amp;publication_year=2013&amp;pages=219-232&amp;pmid=23836010&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R74"><span class="element-citation">Miller TW, Hennessy BT, Gonz&#x000e1;lez-Angulo AM, Fox EM, Mills GB, Chen H, Higham C, Garc&#x000ed;a-Echeverr&#x000ed;a C, Shyr Y, Arteaga CL. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. <span><span class="ref-journal">J Clin Invest. </span>2010;<span class="ref-vol">120</span>:2406–2413.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2898598/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20530877" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Invest&amp;title=Hyperactivation+of+phosphatidylinositol-3+kinase+promotes+escape+from+hormone+dependence+in+estrogen+receptor-positive+human+breast+cancer&amp;author=TW+Miller&amp;author=BT+Hennessy&amp;author=AM+Gonz&#x000e1;lez-Angulo&amp;author=EM+Fox&amp;author=GB+Mills&amp;volume=120&amp;publication_year=2010&amp;pages=2406-2413&amp;pmid=20530877&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R75"><span class="element-citation">Murphy LC, Niu Y, Snell L, Watson P. Phospho-Serine-118 Estrogen Receptor-{alpha} Expression Is Associated with Better Disease Outcome in Women Treated with Tamoxifen. <span><span class="ref-journal">Clin Cancer Res. </span>2004;<span class="ref-vol">10</span>:5902–5906.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15355923" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&amp;title=Phospho-Serine-118+Estrogen+Receptor-{alpha}+Expression+Is+Associated+with+Better+Disease+Outcome+in+Women+Treated+with+Tamoxifen&amp;author=LC+Murphy&amp;author=Y+Niu&amp;author=L+Snell&amp;author=P+Watson&amp;volume=10&amp;publication_year=2004&amp;pages=5902-5906&amp;pmid=15355923&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R76"><span class="element-citation">Olshen AB, Venkatraman ES, Lucito R, Wigler M. Circular binary segmentation for the analysis of array-based DNA copy number data. <span><span class="ref-journal">Biostatistics. </span>2004;<span class="ref-vol">5</span>:557–572.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15475419" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biostatistics&amp;title=Circular+binary+segmentation+for+the+analysis+of+array-based+DNA+copy+number+data&amp;author=AB+Olshen&amp;author=ES+Venkatraman&amp;author=R+Lucito&amp;author=M+Wigler&amp;volume=5&amp;publication_year=2004&amp;pages=557-572&amp;pmid=15475419&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R77"><span class="element-citation">Oyama M, Nagashima T, Suzuki T, Kozuka-Hata H, Yumoto N, Shiraishi Y, Ikeda K, Kuroki Y, Gotoh N, Ishida T, et al. Integrated quantitative analysis of the phosphoproteome and transcriptome in tamoxifen-resistant breast cancer. <span><span class="ref-journal">J Biol Chem. </span>2011;<span class="ref-vol">286</span>:818–829.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3013041/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21044952" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Biol+Chem&amp;title=Integrated+quantitative+analysis+of+the+phosphoproteome+and+transcriptome+in+tamoxifen-resistant+breast+cancer&amp;author=M+Oyama&amp;author=T+Nagashima&amp;author=T+Suzuki&amp;author=H+Kozuka-Hata&amp;author=N+Yumoto&amp;volume=286&amp;publication_year=2011&amp;pages=818-829&amp;pmid=21044952&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R78"><span class="element-citation">Paoletti C, Larios JM, Mu&#x000f1;iz MC, Aung K, Cannell EM, Darga EP, Kidwell KM, Thomas DG, Tokudome N, Brown ME, et al. Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistance. <span><span class="ref-journal">Mol Oncol. </span>2016;<span class="ref-vol">10</span>:1078–1085.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5423180/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27178224" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Oncol&amp;title=Heterogeneous+estrogen+receptor+expression+in+circulating+tumor+cells+suggests+diverse+mechanisms+of+fulvestrant+resistance&amp;author=C+Paoletti&amp;author=JM+Larios&amp;author=MC+Mu&#x000f1;iz&amp;author=K+Aung&amp;author=EM+Cannell&amp;volume=10&amp;publication_year=2016&amp;pages=1078-1085&amp;pmid=27178224&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R79"><span class="element-citation">Pereira B, Chin SF, Rueda OM, Vollan HK, Provenzano E, Bardwell HA, Pugh M, Jones L, Russell R, Sammut SJ, et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. <span><span class="ref-journal">Nat Commun. </span>2016;<span class="ref-vol">7</span>:11479.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4866047/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27161491" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Commun&amp;title=The+somatic+mutation+profiles+of+2,433+breast+cancers+refines+their+genomic+and+transcriptomic+landscapes&amp;author=B+Pereira&amp;author=SF+Chin&amp;author=OM+Rueda&amp;author=HK+Vollan&amp;author=E+Provenzano&amp;volume=7&amp;publication_year=2016&amp;pages=11479&amp;pmid=27161491&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R80"><span class="element-citation">Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD, Holmberg SB, Lindtner J, Snyder R, Th&#x000fc;rlimann B, et al. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. <span><span class="ref-journal">J Clin Oncol. </span>2008;<span class="ref-vol">26</span>:3006–3014.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18458044" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&amp;title=Distinct+clinical+and+prognostic+features+of+infiltrating+lobular+carcinoma+of+the+breast:+combined+results+of+15+International+Breast+Cancer+Study+Group+clinical+trials&amp;author=BC+Pestalozzi&amp;author=D+Zahrieh&amp;author=E+Mallon&amp;author=BA+Gusterson&amp;author=KN+Price&amp;volume=26&amp;publication_year=2008&amp;pages=3006-3014&amp;pmid=18458044&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R81"><span class="element-citation">Philpott C, Tovell H, Frayling IM, Cooper DN, Upadhyaya M. The NF1 somatic mutational landscape in sporadic human cancers. <span><span class="ref-journal">Hum Genomics. </span>2017;<span class="ref-vol">11</span>:13.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5480124/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28637487" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Hum+Genomics&amp;title=The+NF1+somatic+mutational+landscape+in+sporadic+human+cancers&amp;author=C+Philpott&amp;author=H+Tovell&amp;author=IM+Frayling&amp;author=DN+Cooper&amp;author=M+Upadhyaya&amp;volume=11&amp;publication_year=2017&amp;pages=13&amp;pmid=28637487&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R82"><span class="element-citation">Psaty BM, O&#x02019;Donnell CJ, Gudnason V, Lunetta KL, Folsom AR, Rotter JI, Uitterlinden AG, Harris TB, Witteman JC, Boerwinkle E, et al. Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium: Design of prospective meta-analyses of genome-wide association studies from 5 cohorts. <span><span class="ref-journal">Circ Cardiovasc Genet. </span>2009;<span class="ref-vol">2</span>:73–80.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2875693/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20031568" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Circ+Cardiovasc+Genet&amp;title=Cohorts+for+Heart+and+Aging+Research+in+Genomic+Epidemiology+(CHARGE)+Consortium:+Design+of+prospective+meta-analyses+of+genome-wide+association+studies+from+5+cohorts&amp;author=BM+Psaty&amp;author=CJ+O&#x02019;Donnell&amp;author=V+Gudnason&amp;author=KL+Lunetta&amp;author=AR+Folsom&amp;volume=2&amp;publication_year=2009&amp;pages=73-80&amp;pmid=20031568&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R83"><span class="element-citation">Rakha EA, El-Sayed ME, Powe DG, Green AR, Habashy H, Grainge MJ, Robertson JF, Blamey R, Gee J, Nicholson RI, et al. Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. <span><span class="ref-journal">Eur J Cancer. </span>2008;<span class="ref-vol">44</span>:73–83.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18035533" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Eur+J+Cancer&amp;title=Invasive+lobular+carcinoma+of+the+breast:+response+to+hormonal+therapy+and+outcomes&amp;author=EA+Rakha&amp;author=ME+El-Sayed&amp;author=DG+Powe&amp;author=AR+Green&amp;author=H+Habashy&amp;volume=44&amp;publication_year=2008&amp;pages=73-83&amp;pmid=18035533&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R84"><span class="element-citation">Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP. GenePattern 2.0. <span><span class="ref-journal">Nat Genet. </span>2006;<span class="ref-vol">38</span>:500–501.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16642009" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Genet&amp;title=GenePattern+2.0&amp;author=M+Reich&amp;author=T+Liefeld&amp;author=J+Gould&amp;author=J+Lerner&amp;author=P+Tamayo&amp;volume=38&amp;publication_year=2006&amp;pages=500-501&amp;pmid=16642009&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R85"><span class="element-citation">Riggins RB, Lan JP, Zhu Y, Klimach U, Zwart A, Cavalli LR, Haddad BR, Chen L, Gong T, Xuan J, et al. ERRgamma Mediates Tamoxifen Resistance in Novel Models of Invasive Lobular Breast Cancer. <span><span class="ref-journal">Cancer Res. </span>2008;<span class="ref-vol">68</span>:8908–8917.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2701641/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18974135" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=ERRgamma+Mediates+Tamoxifen+Resistance+in+Novel+Models+of+Invasive+Lobular+Breast+Cancer&amp;author=RB+Riggins&amp;author=JP+Lan&amp;author=Y+Zhu&amp;author=U+Klimach&amp;author=A+Zwart&amp;volume=68&amp;publication_year=2008&amp;pages=8908-8917&amp;pmid=18974135&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R86"><span class="element-citation">Riggins RB, Schrecengost RS, Guerrero MS, Bouton AH. Pathways to tamoxifen resistance. <span><span class="ref-journal">Cancer Lett. </span>2007;<span class="ref-vol">256</span>:1–24.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2533271/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17475399" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Lett&amp;title=Pathways+to+tamoxifen+resistance&amp;author=RB+Riggins&amp;author=RS+Schrecengost&amp;author=MS+Guerrero&amp;author=AH+Bouton&amp;volume=256&amp;publication_year=2007&amp;pages=1-24&amp;pmid=17475399&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R87"><span class="element-citation">Robinson JL, Macarthur S, Ross-Innes CS, Tilley WD, Neal DE, Mills IG, Carroll JS. Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. <span><span class="ref-journal">EMBO J. </span>2011;<span class="ref-vol">30</span>:3019–3027.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3160190/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21701558" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=EMBO+J&amp;title=Androgen+receptor+driven+transcription+in+molecular+apocrine+breast+cancer+is+mediated+by+FoxA1&amp;author=JL+Robinson&amp;author=S+Macarthur&amp;author=CS+Ross-Innes&amp;author=WD+Tilley&amp;author=DE+Neal&amp;volume=30&amp;publication_year=2011&amp;pages=3019-3027&amp;pmid=21701558&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R88"><span class="element-citation">Romanelli S, Perego P, Pratesi G, Carenini N, Tortoreto M, Zunino F. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems. <span><span class="ref-journal">Cancer Chemother Pharmacol. </span>1998;<span class="ref-vol">41</span>:385–390.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/9523734" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Chemother+Pharmacol&amp;title=In+vitro+and+in+vivo+interaction+between+cisplatin+and+topotecan+in+ovarian+carcinoma+systems&amp;author=S+Romanelli&amp;author=P+Perego&amp;author=G+Pratesi&amp;author=N+Carenini&amp;author=M+Tortoreto&amp;volume=41&amp;publication_year=1998&amp;pages=385-390&amp;pmid=9523734&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R89"><span class="element-citation">Rugo HS, Vidula N, Ma C. Improving Response to Hormone Therapy in Breast Cancer: New Targets, New Therapeutic Options. <span><span class="ref-journal">Am Soc Clin Oncol Educ Book. </span>2016;<span class="ref-vol">35</span>:e40–54.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27249746" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+Soc+Clin+Oncol+Educ+Book&amp;title=Improving+Response+to+Hormone+Therapy+in+Breast+Cancer:+New+Targets,+New+Therapeutic+Options&amp;author=HS+Rugo&amp;author=N+Vidula&amp;author=C+Ma&amp;volume=35&amp;publication_year=2016&amp;pages=e40-54&amp;pmid=27249746&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R90"><span class="element-citation">Sahu B, Laakso M, Ovaska K, Mirtti T, Lundin J, Rannikko A, Sankila A, Turunen JP, Lundin M, Konsti J, et al. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. <span><span class="ref-journal">EMBO J. </span>2011;<span class="ref-vol">30</span>:3962–3976.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3209787/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21915096" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=EMBO+J&amp;title=Dual+role+of+FoxA1+in+androgen+receptor+binding+to+chromatin,+androgen+signalling+and+prostate+cancer&amp;author=B+Sahu&amp;author=M+Laakso&amp;author=K+Ovaska&amp;author=T+Mirtti&amp;author=J+Lundin&amp;volume=30&amp;publication_year=2011&amp;pages=3962-3976&amp;pmid=21915096&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R91"><span class="element-citation">Schiavon G, Hrebien S, Garcia-Murillas I, Cutts RJ, Pearson A, Tarazona N, Fenwick K, Kozarewa I, Lopez-Knowles E, Ribas R, et al. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. <span><span class="ref-journal">Sci Transl Med. </span>2015;<span class="ref-vol">7</span>:313ra182.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4998737/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26560360" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Sci+Transl+Med&amp;title=Analysis+of+ESR1+mutation+in+circulating+tumor+DNA+demonstrates+evolution+during+therapy+for+metastatic+breast+cancer&amp;author=G+Schiavon&amp;author=S+Hrebien&amp;author=I+Garcia-Murillas&amp;author=RJ+Cutts&amp;author=A+Pearson&amp;volume=7&amp;publication_year=2015&amp;pages=313ra182&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R92"><span class="element-citation">Sikora MJ, Cooper KL, Bahreini A, Luthra S, Wang G, Chandran UR, Davidson NE, Dabbs DJ, Welm AL, Oesterreich S. Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response. <span><span class="ref-journal">Cancer Res. </span>2014;<span class="ref-vol">74</span>:1463–1474.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3955299/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24425047" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Invasive+lobular+carcinoma+cell+lines+are+characterized+by+unique+estrogen-mediated+gene+expression+patterns+and+altered+tamoxifen+response&amp;author=MJ+Sikora&amp;author=KL+Cooper&amp;author=A+Bahreini&amp;author=S+Luthra&amp;author=G+Wang&amp;volume=74&amp;publication_year=2014&amp;pages=1463-1474&amp;pmid=24425047&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R93"><span class="element-citation">Sikora MJ, Jacobsen BM, Levine K, Chen J, Davidson NE, Lee AV, Alexander CM, Oesterreich S. WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines. <span><span class="ref-journal">Breast Cancer Res. </span>2016;<span class="ref-vol">18</span>:92.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5028957/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27650553" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Breast+Cancer+Res&amp;title=WNT4+mediates+estrogen+receptor+signaling+and+endocrine+resistance+in+invasive+lobular+carcinoma+cell+lines&amp;author=MJ+Sikora&amp;author=BM+Jacobsen&amp;author=K+Levine&amp;author=J+Chen&amp;author=NE+Davidson&amp;volume=18&amp;publication_year=2016&amp;pages=92&amp;pmid=27650553&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R94"><span class="element-citation">Sledge GW, Chagpar A, Perou C. Collective Wisdom: Lobular Carcinoma of the Breast. <span><span class="ref-journal">Am Soc Clin Oncol Educ Book. </span>2016;<span class="ref-vol">35</span>:18–21.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27249682" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+Soc+Clin+Oncol+Educ+Book&amp;title=Collective+Wisdom:+Lobular+Carcinoma+of+the+Breast&amp;author=GW+Sledge&amp;author=A+Chagpar&amp;author=C+Perou&amp;volume=35&amp;publication_year=2016&amp;pages=18-21&amp;pmid=27249682&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R95"><span class="element-citation">Speyer CL, Nassar MA, Hachem AH, Bukhsh MA, Jafry WS, Khansa RM, Gorski DH. Riluzole mediates anti-tumor properties in breast cancer cells independent of metabotropic glutamate receptor-1. <span><span class="ref-journal">Breast Cancer Res Treat. </span>2016;<span class="ref-vol">157</span>:217–228.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27146584" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Breast+Cancer+Res+Treat&amp;title=Riluzole+mediates+anti-tumor+properties+in+breast+cancer+cells+independent+of+metabotropic+glutamate+receptor-1&amp;author=CL+Speyer&amp;author=MA+Nassar&amp;author=AH+Hachem&amp;author=MA+Bukhsh&amp;author=WS+Jafry&amp;volume=157&amp;publication_year=2016&amp;pages=217-228&amp;pmid=27146584&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R96"><span class="element-citation">Spoerke JM, Gendreau S, Walter K, Qiu J, Wilson TR, Savage H, Aimi J, Derynck MK, Chen M, Chan IT, et al. Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. <span><span class="ref-journal">Nat Commun. </span>2016;<span class="ref-vol">7</span>:11579.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4869259/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27174596" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Commun&amp;title=Heterogeneity+and+clinical+significance+of+ESR1+mutations+in+ER-positive+metastatic+breast+cancer+patients+receiving+fulvestrant&amp;author=JM+Spoerke&amp;author=S+Gendreau&amp;author=K+Walter&amp;author=J+Qiu&amp;author=TR+Wilson&amp;volume=7&amp;publication_year=2016&amp;pages=11579&amp;pmid=27174596&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R97"><span class="element-citation">Stanford EA, Wang Z, Novikov O, Mulas F, Landesman-Bollag E, Monti S, Smith BW, Seldin DC, Murphy GJ, Sherr DH. The role of the aryl hydrocarbon receptor in the development of cells with the molecular and functional characteristics of cancer stem-like cells. <span><span class="ref-journal">BMC Biol. </span>2016;<span class="ref-vol">14</span>:20.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4794823/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26984638" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=BMC+Biol&amp;title=The+role+of+the+aryl+hydrocarbon+receptor+in+the+development+of+cells+with+the+molecular+and+functional+characteristics+of+cancer+stem-like+cells&amp;author=EA+Stanford&amp;author=Z+Wang&amp;author=O+Novikov&amp;author=F+Mulas&amp;author=E+Landesman-Bollag&amp;volume=14&amp;publication_year=2016&amp;pages=20&amp;pmid=26984638&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R98"><span class="element-citation">Strasser-Weippl K, Sudan G, Ramjeesingh R, Shepherd L, et al. Outcomes of invasive ductal (ID) or invasive lobular (IL) early stage breast cancer in women treated with anastrozole or exemestane in the Canadian cancer trials Group MA.27. p suppl; abstr 521. <span><span class="ref-journal">J Clin Oncol </span>2016</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29274617" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&amp;title=Outcomes+of+invasive+ductal+(ID)+or+invasive+lobular+(IL)+early+stage+breast+cancer+in+women+treated+with+anastrozole+or+exemestane+in+the+Canadian+cancer+trials+Group+MA.27.+p+suppl;+abstr+521&amp;author=K+Strasser-Weippl&amp;author=G+Sudan&amp;author=R+Ramjeesingh&amp;author=L+Shepherd&amp;publication_year=2016&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R99"><span class="element-citation">Teh JL, Shah R, La Cava S, Dolfi SC, Mehta MS, Kongara S, Price S, Ganesan S, Reuhl KR, Hirshfield KM, et al. Metabotropic glutamate receptor 1 disrupts mammary acinar architecture and initiates malignant transformation of mammary epithelial cells. <span><span class="ref-journal">Breast Cancer Res Treat. </span>2015;<span class="ref-vol">151</span>:57–73.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5193007/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25859923" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Breast+Cancer+Res+Treat&amp;title=Metabotropic+glutamate+receptor+1+disrupts+mammary+acinar+architecture+and+initiates+malignant+transformation+of+mammary+epithelial+cells&amp;author=JL+Teh&amp;author=R+Shah&amp;author=S+La+Cava&amp;author=SC+Dolfi&amp;author=MS+Mehta&amp;volume=151&amp;publication_year=2015&amp;pages=57-73&amp;pmid=25859923&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R100"><span class="element-citation">Telford BJ, Chen A, Beetham H, Frick J, Brew TP, Gould CM, Single A, Godwin T, Simpson KJ, Guilford P. Synthetic Lethal Screens Identify Vulnerabilities in GPCR Signaling and Cytoskeletal Organization in E-Cadherin-Deficient Cells. <span><span class="ref-journal">Mol Cancer Ther. </span>2015;<span class="ref-vol">14</span>:1213–1223.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25777964" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cancer+Ther&amp;title=Synthetic+Lethal+Screens+Identify+Vulnerabilities+in+GPCR+Signaling+and+Cytoskeletal+Organization+in+E-Cadherin-Deficient+Cells&amp;author=BJ+Telford&amp;author=A+Chen&amp;author=H+Beetham&amp;author=J+Frick&amp;author=TP+Brew&amp;volume=14&amp;publication_year=2015&amp;pages=1213-1223&amp;pmid=25777964&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R101"><span class="element-citation">Torresan C, Oliveira MM, Pereira SR, Ribeiro EM, Marian C, Gusev Y, Lima RS, Urban CA, Berg PE, Haddad BR, et al. Increased copy number of the DLX4 homeobox gene in breast axillary lymph node metastasis. <span><span class="ref-journal">Cancer Genet. </span>2014;<span class="ref-vol">207</span>:177–187.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5806608/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24947980" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Genet&amp;title=Increased+copy+number+of+the+DLX4+homeobox+gene+in+breast+axillary+lymph+node+metastasis&amp;author=C+Torresan&amp;author=MM+Oliveira&amp;author=SR+Pereira&amp;author=EM+Ribeiro&amp;author=C+Marian&amp;volume=207&amp;publication_year=2014&amp;pages=177-187&amp;pmid=24947980&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R102"><span class="element-citation">Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, Natrajan R, Marchio C, Iorns E, Mackay A, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. <span><span class="ref-journal">Cancer Res. </span>2010;<span class="ref-vol">70</span>:2085–2094.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2832818/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20179196" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=FGFR1+amplification+drives+endocrine+therapy+resistance+and+is+a+therapeutic+target+in+breast+cancer&amp;author=N+Turner&amp;author=A+Pearson&amp;author=R+Sharpe&amp;author=M+Lambros&amp;author=F+Geyer&amp;volume=70&amp;publication_year=2010&amp;pages=2085-2094&amp;pmid=20179196&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R103"><span class="element-citation">Uusitalo E, Kallionp&#x000e4;&#x000e4; RA, Kurki S, Rantanen M, Pitk&#x000e4;niemi J, Kronqvist P, H&#x000e4;rk&#x000f6;nen P, Huovinen R, Carpen O, P&#x000f6;yh&#x000f6;nen M, et al. Breast cancer in neurofibromatosis type 1: overrepresentation of unfavourable prognostic factors. <span><span class="ref-journal">Br J Cancer. </span>2017;<span class="ref-vol">116</span>:211–217.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5243991/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27931045" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Br+J+Cancer&amp;title=Breast+cancer+in+neurofibromatosis+type+1:+overrepresentation+of+unfavourable+prognostic+factors&amp;author=E+Uusitalo&amp;author=RA+Kallionp&#x000e4;&#x000e4;&amp;author=S+Kurki&amp;author=M+Rantanen&amp;author=J+Pitk&#x000e4;niemi&amp;volume=116&amp;publication_year=2017&amp;pages=211-217&amp;pmid=27931045&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R104"><span class="element-citation">van de WM, Barker N, Harkes IC, van der HM, Dijk NJ, Hollestelle A, Klijn JG, Clevers H, Schutte M. Mutant E-cadherin breast cancer cells do not display constitutive Wnt signaling. <span><span class="ref-journal">Cancer Res. </span>2001;<span class="ref-vol">61</span>:278–284.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11196175" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Mutant+E-cadherin+breast+cancer+cells+do+not+display+constitutive+Wnt+signaling&amp;author=WM+van+de&amp;author=N+Barker&amp;author=IC+Harkes&amp;author=HM+van+der&amp;author=NJ+Dijk&amp;volume=61&amp;publication_year=2001&amp;pages=278-284&amp;pmid=11196175&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R105"><span class="element-citation">Venkatraman ES, Olshen AB. A faster circular binary segmentation algorithm for the analysis of array CGH data. <span><span class="ref-journal">Bioinformatics. </span>2007;<span class="ref-vol">23</span>:657–663.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17234643" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Bioinformatics&amp;title=A+faster+circular+binary+segmentation+algorithm+for+the+analysis+of+array+CGH+data&amp;author=ES+Venkatraman&amp;author=AB+Olshen&amp;volume=23&amp;publication_year=2007&amp;pages=657-663&amp;pmid=17234643&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R106"><span class="element-citation">Wang D, Garcia-Bassets I, Benner C, Li W, Su X, Zhou Y, Qiu J, Liu W, Kaikkonen MU, Ohgi KA, et al. Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. <span><span class="ref-journal">Nature. </span>2011;<span class="ref-vol">474</span>:390–394.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3117022/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21572438" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Reprogramming+transcription+by+distinct+classes+of+enhancers+functionally+defined+by+eRNA&amp;author=D+Wang&amp;author=I+Garcia-Bassets&amp;author=C+Benner&amp;author=W+Li&amp;author=X+Su&amp;volume=474&amp;publication_year=2011&amp;pages=390-394&amp;pmid=21572438&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R107"><span class="element-citation">Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. <span><span class="ref-journal">Nucleic Acids Res. </span>2010;<span class="ref-vol">38</span>:e164.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2938201/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20601685" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nucleic+Acids+Res&amp;title=ANNOVAR:+functional+annotation+of+genetic+variants+from+high-throughput+sequencing+data&amp;author=K+Wang&amp;author=M+Li&amp;author=H+Hakonarson&amp;volume=38&amp;publication_year=2010&amp;pages=e164&amp;pmid=20601685&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R108"><span class="element-citation">Wang P, Bahreini A, Gyanchandani R, Lucas PC, Hartmaier RJ, Watters RJ, Jonnalagadda AR, Trejo Bittar HE, Berg A, Hamilton RL, et al. Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients. <span><span class="ref-journal">Clin Cancer Res. </span>2016;<span class="ref-vol">22</span>:1130–1137.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4775406/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26500237" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&amp;title=Sensitive+Detection+of+Mono-+and+Polyclonal+ESR1+Mutations+in+Primary+Tumors,+Metastatic+Lesions,+and+Cell-Free+DNA+of+Breast+Cancer+Patients&amp;author=P+Wang&amp;author=A+Bahreini&amp;author=R+Gyanchandani&amp;author=PC+Lucas&amp;author=RJ+Hartmaier&amp;volume=22&amp;publication_year=2016&amp;pages=1130-1137&amp;pmid=26500237&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R109"><span class="element-citation">Wasielewski M, Elstrodt F, Klijn JG, Berns EM, Schutte M. Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines. <span><span class="ref-journal">Breast Cancer Res Treat. </span>2006;<span class="ref-vol">99</span>:97–101.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16541312" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Breast+Cancer+Res+Treat&amp;title=Thirteen+new+p53+gene+mutants+identified+among+41+human+breast+cancer+cell+lines&amp;author=M+Wasielewski&amp;author=F+Elstrodt&amp;author=JG+Klijn&amp;author=EM+Berns&amp;author=M+Schutte&amp;volume=99&amp;publication_year=2006&amp;pages=97-101&amp;pmid=16541312&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R110"><span class="element-citation">Weigelt B, Geyer F, Natrajan R, Lopez-Garcia M, Ahmad A, Savage K, Kreike B, Reis-Filho J. The molecular underpinning of lobular histological growth pattern: a genome-wide transcriptomic analysis of invasive lobular carcinomas and grade- and molecular subtype-matched invasive ductal carcinomas of no special type. <span><span class="ref-journal">J Pathol. </span>2010;<span class="ref-vol">220</span>:45–57.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19877120" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Pathol&amp;title=The+molecular+underpinning+of+lobular+histological+growth+pattern:+a+genome-wide+transcriptomic+analysis+of+invasive+lobular+carcinomas+and+grade-+and+molecular+subtype-matched+invasive+ductal+carcinomas+of+no+special+type&amp;author=B+Weigelt&amp;author=F+Geyer&amp;author=R+Natrajan&amp;author=M+Lopez-Garcia&amp;author=A+Ahmad&amp;volume=220&amp;publication_year=2010&amp;pages=45-57&amp;pmid=19877120&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R111"><span class="element-citation">Wen Y, Li J, Koo J, Shin SS, Lin Y, Jeong BS, Mehnert JM, Chen S, Cohen-Sola KA, Goydos JS. Activation of the glutamate receptor GRM1 enhances angiogenic signaling to drive melanoma progression. <span><span class="ref-journal">Cancer Res. </span>2014;<span class="ref-vol">74</span>:2499–2509.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4008638/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24491800" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Activation+of+the+glutamate+receptor+GRM1+enhances+angiogenic+signaling+to+drive+melanoma+progression&amp;author=Y+Wen&amp;author=J+Li&amp;author=J+Koo&amp;author=SS+Shin&amp;author=Y+Lin&amp;volume=74&amp;publication_year=2014&amp;pages=2499-2509&amp;pmid=24491800&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R112"><span class="element-citation">Willard SS, Koochekpour S. Glutamate signaling in benign and malignant disorders: current status, future perspectives, and therapeutic implications. <span><span class="ref-journal">Int J Biol Sci. </span>2013;<span class="ref-vol">9</span>:728–742.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3753409/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23983606" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int+J+Biol+Sci&amp;title=Glutamate+signaling+in+benign+and+malignant+disorders:+current+status,+future+perspectives,+and+therapeutic+implications&amp;author=SS+Willard&amp;author=S+Koochekpour&amp;volume=9&amp;publication_year=2013&amp;pages=728-742&amp;pmid=23983606&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R113"><span class="element-citation">Wright TM, Wardell SE, Jasper JS, Stice JP, Safi R, Nelson ER, McDonnell DP. Delineation of a FOXA1/ER&#x003b1;/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer. <span><span class="ref-journal">Mol Cancer Res. </span>2014;<span class="ref-vol">12</span>:1829–1839.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4272635/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25100862" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cancer+Res&amp;title=Delineation+of+a+FOXA1/ER&#x003b1;/AGR2+regulatory+loop+that+is+dysregulated+in+endocrine+therapy-resistant+breast+cancer&amp;author=TM+Wright&amp;author=SE+Wardell&amp;author=JS+Jasper&amp;author=JP+Stice&amp;author=R+Safi&amp;volume=12&amp;publication_year=2014&amp;pages=1829-1839&amp;pmid=25100862&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="R114"><span class="element-citation">Yu LJ, Wall BA, Wangari-Talbot J, Chen S. Metabotropic glutamate receptors in cancer. <span><span class="ref-journal">Neuropharmacology </span>2016</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4987272/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26896755" ref="reftype=pubmed&amp;article-id=5858970&amp;issue-id=308607&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>]</span></li></ul></div></div></div><!--post-content--><div id="body-link-poppers"><span></span></div></div>
            
        </section>
    </article>
    <aside class="usa-width-one-fourth usa-layout-docs-sidenav pmc-sidebar">
         
  

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pdf-link other_item"><a href="/pmc/articles/PMC5858970/pdf/nihms909796.pdf" class="int-view">PDF (1.5M)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/5858970/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/5858970/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<link type="text/css" href="ncbi-overlay-block/src/overlay-block.css">
<div class="collections-button-container" data-article-id="5858970" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5858970%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="yUtKyB8j6JGOdXlc9jYzZlM9d3SslBfbGWNEKN3ApvpR2WAedMjtCse0fmEBQblj">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-aside "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-aside ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-aside "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-aside ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5858970%2F&amp;text=Integrated%20Molecular%20Analysis%20of%20Tamoxifen-Resistant%20Invasive%20Lobular%20Breast%20Cancer%20Cells%20Identifies%20MAPK%20and%20GRM%2FmGluR%20..." alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5858970%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5858970/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC5858970/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/28935545/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-aside" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC5858970/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/28935545/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-aside"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC5858970/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/5858970/" class="usa-accordion-content" id="links-accordion-aside" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>

    </aside>
</main>

    <div class="overlay" role="dialog" aria-label="Citation Dialog">
  <div class="dialog citation-dialog">
    <button class="close-overlay" tabindex="1">[x]</button>
    <div class="title">Cite</div>
    <div class="citation-text-block">
  <div class="citation-text"></div>
  <div class="citation-actions">
    <button
      class="copy-button dialog-focus"
      data-ga-category="save_share"
      data-ga-action="cite"
      data-ga-label="copy"
      tabindex="2">
      Copy
    </button>

      <a href="#"
              class="export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
          <span class="title">Download .nbib</span>
          <span class="title-mobile">.nbib</span>
      </a>


    

<div class="citation-style-selector-wrapper">
  <label class="selector-label">Format:</label>
  <select aria-label="Format" class="citation-style-selector" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
  </div>
</div>
  </div>
</div>

     <!-- ========== BEGIN FOOTER ========== -->
 <footer>
      <section class="icon-section">
        <div id="icon-section-header" class="icon-section_header">Follow NCBI</div>
        <div class="grid-container container">
          <div class="icon-section_container">
            <a class="footer-icon" id="footer_twitter" href="https://twitter.com/ncbi" aria-label="Twitter"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11 {
                      fill: #737373;
                    }
                  </style>
                </defs>
                <title>Twitter</title>
                <path class="cls-11"
                  d="M250.11,105.48c-7,3.14-13,3.25-19.27.14,8.12-4.86,8.49-8.27,11.43-17.46a78.8,78.8,0,0,1-25,9.55,39.35,39.35,0,0,0-67,35.85,111.6,111.6,0,0,1-81-41.08A39.37,39.37,0,0,0,81.47,145a39.08,39.08,0,0,1-17.8-4.92c0,.17,0,.33,0,.5a39.32,39.32,0,0,0,31.53,38.54,39.26,39.26,0,0,1-17.75.68,39.37,39.37,0,0,0,36.72,27.3A79.07,79.07,0,0,1,56,223.34,111.31,111.31,0,0,0,116.22,241c72.3,0,111.83-59.9,111.83-111.84,0-1.71,0-3.4-.1-5.09C235.62,118.54,244.84,113.37,250.11,105.48Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_facebook" href="https://www.facebook.com/ncbi.nlm" aria-label="Facebook"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>Facebook</title>
                <path class="cls-11"
                  d="M210.5,115.12H171.74V97.82c0-8.14,5.39-10,9.19-10h27.14V52l-39.32-.12c-35.66,0-42.42,26.68-42.42,43.77v19.48H99.09v36.32h27.24v109h45.41v-109h35Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_linkedin"
              href="https://www.linkedin.com/company/ncbinlm"
              aria-label="LinkedIn"><svg data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>LinkedIn</title>
                <path class="cls-11"
                  d="M101.64,243.37H57.79v-114h43.85Zm-22-131.54h-.26c-13.25,0-21.82-10.36-21.82-21.76,0-11.65,8.84-21.15,22.33-21.15S101.7,78.72,102,90.38C102,101.77,93.4,111.83,79.63,111.83Zm100.93,52.61A17.54,17.54,0,0,0,163,182v61.39H119.18s.51-105.23,0-114H163v13a54.33,54.33,0,0,1,34.54-12.66c26,0,44.39,18.8,44.39,55.29v58.35H198.1V182A17.54,17.54,0,0,0,180.56,164.44Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_github" href="https://github.com/ncbi" aria-label="GitHub"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11,
                    .cls-12 {
                      fill: #737373;
                    }

                    .cls-11 {
                      fill-rule: evenodd;
                    }
                  </style>
                </defs>
                <title>GitHub</title>
                <path class="cls-11"
                  d="M151.36,47.28a105.76,105.76,0,0,0-33.43,206.1c5.28,1,7.22-2.3,7.22-5.09,0-2.52-.09-10.85-.14-19.69-29.42,6.4-35.63-12.48-35.63-12.48-4.81-12.22-11.74-15.47-11.74-15.47-9.59-6.56.73-6.43.73-6.43,10.61.75,16.21,10.9,16.21,10.9,9.43,16.17,24.73,11.49,30.77,8.79,1-6.83,3.69-11.5,6.71-14.14C108.57,197.1,83.88,188,83.88,147.51a40.92,40.92,0,0,1,10.9-28.39c-1.1-2.66-4.72-13.42,1-28,0,0,8.88-2.84,29.09,10.84a100.26,100.26,0,0,1,53,0C198,88.3,206.9,91.14,206.9,91.14c5.76,14.56,2.14,25.32,1,28a40.87,40.87,0,0,1,10.89,28.39c0,40.62-24.74,49.56-48.29,52.18,3.79,3.28,7.17,9.71,7.17,19.58,0,14.15-.12,25.54-.12,29,0,2.82,1.9,6.11,7.26,5.07A105.76,105.76,0,0,0,151.36,47.28Z">
                </path>
                <path class="cls-12"
                  d="M85.66,199.12c-.23.52-1.06.68-1.81.32s-1.2-1.06-.95-1.59,1.06-.69,1.82-.33,1.21,1.07.94,1.6Zm-1.3-1">
                </path>
                <path class="cls-12"
                  d="M90,203.89c-.51.47-1.49.25-2.16-.49a1.61,1.61,0,0,1-.31-2.19c.52-.47,1.47-.25,2.17.49s.82,1.72.3,2.19Zm-1-1.08">
                </path>
                <path class="cls-12"
                  d="M94.12,210c-.65.46-1.71,0-2.37-.91s-.64-2.07,0-2.52,1.7,0,2.36.89.65,2.08,0,2.54Zm0,0"></path>
                <path class="cls-12"
                  d="M99.83,215.87c-.58.64-1.82.47-2.72-.41s-1.18-2.06-.6-2.7,1.83-.46,2.74.41,1.2,2.07.58,2.7Zm0,0">
                </path>
                <path class="cls-12"
                  d="M107.71,219.29c-.26.82-1.45,1.2-2.64.85s-2-1.34-1.74-2.17,1.44-1.23,2.65-.85,2,1.32,1.73,2.17Zm0,0">
                </path>
                <path class="cls-12"
                  d="M116.36,219.92c0,.87-1,1.59-2.24,1.61s-2.29-.68-2.3-1.54,1-1.59,2.26-1.61,2.28.67,2.28,1.54Zm0,0">
                </path>
                <path class="cls-12"
                  d="M124.42,218.55c.15.85-.73,1.72-2,1.95s-2.37-.3-2.52-1.14.73-1.75,2-2,2.37.29,2.53,1.16Zm0,0"></path>
              </svg></a>
            <a class="footer-icon" id="footer_blog" href="https://ncbiinsights.ncbi.nlm.nih.gov/" aria-label="Blog">
              <svg id="Layer_1" data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 40"><defs><style>.cls-1{fill:#737373;}</style></defs><path class="cls-1" d="M14,30a4,4,0,1,1-4-4,4,4,0,0,1,4,4Zm11,3A19,19,0,0,0,7.05,15a1,1,0,0,0-1,1v3a1,1,0,0,0,.93,1A14,14,0,0,1,20,33.07,1,1,0,0,0,21,34h3a1,1,0,0,0,1-1Zm9,0A28,28,0,0,0,7,6,1,1,0,0,0,6,7v3a1,1,0,0,0,1,1A23,23,0,0,1,29,33a1,1,0,0,0,1,1h3A1,1,0,0,0,34,33Z"/></svg>
            </a>
          </div>
        </div>
      </section>

      <section class="container-fluid bg-primary">
        <div class="container pt-5">
          <div class="row mt-3">
            <div class="col-lg-3 col-12">
              <p><a class="text-white" href="https://www.nlm.nih.gov/socialmedia/index.html">Connect with NLM</a></p>
              <ul class="list-inline social_media">
                <li class="list-inline-item"><a href="https://twitter.com/NLM_NIH" aria-label="Twitter"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st20 {
                          fill: #FFFFFF;
                        }

                        .st30 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Twitter</title>
                      <g>
                        <g>
                          <g>
                            <path class="st20" d="M192.9,88.1c-5,2.2-9.2,2.3-13.6,0.1c5.7-3.4,6-5.8,8.1-12.3c-5.4,3.2-11.4,5.5-17.6,6.7
                                                c-10.5-11.2-28.1-11.7-39.2-1.2c-7.2,6.8-10.2,16.9-8,26.5c-22.3-1.1-43.1-11.7-57.2-29C58,91.6,61.8,107.9,74,116
                                                c-4.4-0.1-8.7-1.3-12.6-3.4c0,0.1,0,0.2,0,0.4c0,13.2,9.3,24.6,22.3,27.2c-4.1,1.1-8.4,1.3-12.5,0.5c3.6,11.3,14,19,25.9,19.3
                                                c-11.6,9.1-26.4,13.2-41.1,11.5c12.7,8.1,27.4,12.5,42.5,12.5c51,0,78.9-42.2,78.9-78.9c0-1.2,0-2.4-0.1-3.6
                                                C182.7,97.4,189.2,93.7,192.9,88.1z"></path>
                          </g>
                        </g>
                        <circle class="st30" cx="124.4" cy="128.8" r="108.2"></circle>
                      </g>
                    </svg></a></li>
                <li class="list-inline-item"><a href="https://www.facebook.com/nationallibraryofmedicine"
                    aria-label="Facebook" rel="noopener noreferrer" target="_blank">
                    <svg version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px"
                      y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st10 {
                          fill: #FFFFFF;
                        }

                        .st110 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Facebook</title>
                      <g>
                        <g>
                          <path class="st10" d="M159,99.1h-24V88.4c0-5,3.3-6.2,5.7-6.2h16.8V60l-24.4-0.1c-22.1,0-26.2,16.5-26.2,27.1v12.1H90v22.5h16.9
                                                      v67.5H135v-67.5h21.7L159,99.1z"></path>
                        </g>
                      </g>
                      <circle class="st110" cx="123.6" cy="123.2" r="108.2"></circle>
                    </svg>
                  </a></li>
                <li class="list-inline-item"><a href="https://www.youtube.com/user/NLMNIH" aria-label="Youtube"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <title>SM-Youtube</title>
                      <style type="text/css">
                        .st4 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }

                        .st5 {
                          fill: #FFFFFF;
                        }
                      </style>
                      <circle class="st4" cx="124.2" cy="123.4" r="108.2"></circle>
                      <g transform="translate(0,-952.36218)">
                        <path class="st5"
                          d="M88.4,1037.4c-10.4,0-18.7,8.3-18.7,18.7v40.1c0,10.4,8.3,18.7,18.7,18.7h72.1c10.4,0,18.7-8.3,18.7-18.7
                                            v-40.1c0-10.4-8.3-18.7-18.7-18.7H88.4z M115.2,1058.8l29.4,17.4l-29.4,17.4V1058.8z"></path>
                      </g>
                    </svg></a></li>
              </ul>
            </div>
            <div class="col-lg-3 col-12">
              <p class="address_footer text-white">National Library of Medicine<br>
                <a href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323"
                  class="text-white" target="_blank" rel="noopener noreferrer">8600 Rockville Pike<br>
                  Bethesda, MD 20894</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a href="https://www.nlm.nih.gov/web_policies.html" class="text-white">Web Policies</a><br>
                <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office"
                  class="text-white">FOIA</a><br>
                <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="text-white" id="vdp">HHS Vulnerability Disclosure</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a class="supportLink text-white" href="https://support.nlm.nih.gov/">Help</a><br>
                <a href="https://www.nlm.nih.gov/accessibility.html" class="text-white">Accessibility</a><br>
                <a href="https://www.nlm.nih.gov/careers/careers.html" class="text-white">Careers</a></p>
            </div>
          </div>
          <div class="row">
            <div class="col-lg-12 centered-lg">
              <nav class="bottom-links">
                <ul class="mt-3">
                  <li>
                    <a class="text-white" href="//www.nlm.nih.gov/">NLM</a>
                  </li>
                  <li>
                    <a class="text-white"
                  href="https://www.nih.gov/">NIH</a>
                  </li>
                  <li>
                    <a class="text-white" href="https://www.hhs.gov/">HHS</a>
                  </li>
                  <li>
                    <a
                  class="text-white" href="https://www.usa.gov/">USA.gov</a>
                  </li>
                </ul>
              </nav>
            </div>
          </div>
        </div>
      </section>
    </footer>
 <!-- ========== END FOOTER ========== -->
  <!-- javascript to inject NWDS meta tags. Note: value of nwds_version is updated by "npm version" command -->
 
  <script type="text/javascript">
    var nwds_version = "1.1.9-2";

    var meta_nwds_ver = document.createElement('meta');
    meta_nwds_ver.name = 'ncbi_nwds_ver';
    meta_nwds_ver.content = nwds_version;
    document.getElementsByTagName('head')[0].appendChild(meta_nwds_ver);

    var meta_nwds = document.createElement('meta');
    meta_nwds.name = 'ncbi_nwds';
    meta_nwds.content = 'yes';
    document.getElementsByTagName('head')[0].appendChild(meta_nwds);

	var alertsUrl = "/core/alerts/alerts.js";
	if (typeof ncbiBaseUrl !== 'undefined') {
		alertsUrl = ncbiBaseUrl + alertsUrl;
	}
  </script>



  
    <!-- JavaScript -->
    <script src="/pmc/static/CACHE/js/output.0f72d6a64937.js"></script>
  
  
    <script src="https://code.jquery.com/jquery-3.5.0.min.js"
          integrity="sha256-xNzN2a4ltkB44Mc/Jz3pT4iU1cmeR0FkXs4pru/JxaQ="
          crossorigin="anonymous">
    </script>
    <script>
        var fallbackJquery = "/pmc/static/base/js/jquery-3.5.0.min.js";
        window.jQuery || document.write("<script src=" + fallbackJquery + ">\x3C/script>")
    </script>
  

  <script src="/pmc/static/CACHE/js/output.a212a9fcf845.js"></script>
<script src="/pmc/static/CACHE/js/output.7999321d1aac.js"></script>
<script src="/pmc/static/CACHE/js/output.7ca436b2ea51.js"></script>
<script src="/pmc/static/CACHE/js/output.f8422046fbe0.js"></script>
<script src="/pmc/static/CACHE/js/output.ff40c7d85ff8.js"></script>
<script src="/pmc/static/CACHE/js/output.a6a84a0ad361.js"></script>

<script type="text/javascript" src="/pmc/static/bundles/base/base.038d36e4e31104b40a19.js" ></script>

    <script type="text/javascript">
        if(typeof jQuery !=='undefined') {
            jQuery.migrateMute = true;
        }
    </script>
    <script type="text/javascript" src="https://code.jquery.com/jquery-migrate-1.4.1.js"></script>
    <script type="text/javascript" src="/core/jig/1.15.2/js/jig.nojquery.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/crb.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/jactions.min.js?_=3.18">//</script><script type="text/javascript">window.name="mainwindow";</script>

    <script type="text/javascript">var exports = {};</script>
    <script src="/pmc/static/CACHE/js/output.340a3b9cce7f.js"></script>
<script src="/pmc/static/CACHE/js/output.228f96f3298e.js"></script>
    <script type="text/javascript" src="/pmc/static/bundles/article/article.b7dd20e527283dd68f45.js" ></script>
    <script type="text/javascript">
        window.ncbi.pmc.articlePage.init({ pageURL: '/pmc/articles/PMC5858970/', citeCookieName: 'pmc-cf'});
    </script>


  
  
  <script  type="text/javascript" src="https://www.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


  
      
  

</body>
</html>
